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Introduction2 Introduction
1.1 Neurodegeneration
Neurodegeneration is dened as progressive loss of neuronal structure and func-
tion that ultimately leads to neuronal death. Neurodegeneration occurs in various
diseases aecting the central nervous system. The loss of specic populations of neu-
rons related to functional neuronal networks determines the clinical presentation of
the neurodegenerative disease. For example, degeneration of neurons located in the
frontal lobes and caudate nucleus/striatum of the basal ganglia are associated with
Huntington's disease, although the loss of neuronal function in the substantia nigra
and striatum is related to Parkinson's disease.
Because of the social and nancial impact of these diseases to modern western
societies, the development of aordable and eective therapies to prevent and protect
against neurodegenerative diseases is of great interest. However, the prospects of
adequate treatment of brain diseases are still very limited in spite of the impressive
increase of neuroscience research during the last four decades. Due to the high level
of complexity of brain function and dysfunction, the progress in development of new
treatments and safe drugs is still impeded by insucient knowledge of the causes and
the mechanisms by which neurons die in neurodegenerative disorders.
Classication of neurodegenerative disorders has been a matter of serious dis-
pute for a long time since many disorders overlap with one another in their clini-
cal representation and their neuropathological characteristics. Traditionally, diseases
of the brain were categorized based on the main clinical feature or the anatomical
distribution of the predominant lesion. According to the anatomical regions, neu-
rodegenerative disorders include roughly diseases of the cerebral cortex, the basal
ganglia, the brainstem, the cerebellum or the spinal cord (Dickson, 2003). Within
each group a further classication was made, based on particular clinical features.
The cerebral cortex diseases were subdivided into dementing (e.g. Alzheimer's dis-
ease (AD)) and non-dementing illnesses. However, dementia is not specic to AD
only. It can accompany a diversity of conditions besides neurodegenerative disorders
such as metabolic or infectious brain diseases. More recent classications tend to
be based not on anatomical dysfunctions but on common molecular defects. The
major group of molecules implicated in neurodegenerative processes includes amyloid
(Alzheimer's disease (AD), some forms of Creutzfeldt-Jacob disease); tau (Alzheimer's
disease, Frontotemporal-17 dementia, Parkinson's disease, Pick's disease, Progressive
Supranuclear Palsy), a-synuclein (Parkinson's disease, Multiple System Atrophy de-
mentia, Diuse Lewy Body dementia and some forms of AD), trinucleotide-repeat
sequence (Huntington disease, Spino-Cerebellar Atrophy, Myotonic Dystrophy) and
prions (Creutzfeldt-Jacob disease, Fatal Familial Insomnia, Gerstmann-Str aussler-
Scheinker, Kuru, Scrapie) (Dickson, 2003).
Given that regenerative capacities are rather limited in the adult central nervous
system neuronal death represents a catastrophic event during neurodegenerative pro-
cesses. Neuronal cell death can be roughly divided into necrotic and non-necrotic
types. Necrotic cell death is a fast process characterized by cell swelling that requires1.1 Neurodegeneration 3
no active contribution of the degenerative cell. In contrast, non-necrotic cell death
is tightly regulated by autonomous processes, requires the engagements of active cel-
lular processes and ultimately induces distinctive ultrastructural alterations. This
cell death type can be further divided into apoptotic and autophagic type (Clarke,
1990). The hallmark features of apoptosis include chromatin condensation, nuclear
fragmentation, margination and cytoplasmic blebbing (Clarke, 1999). Apoptosis is
the most common and well-investigated form of programmed cell death. It is impli-
cated in several neurodegenerative disorders and the main regulators include Bcl-2
and caspase families (Korsmeyer, 1999; Wellington and Hayden, 2000).
1.1.1 Alzheimer's disease
AD represents the most common cause of dementia. Behavioral abnormalities fol-
lowed by impairments in language prociency, sensory perceptions and motor skills
often occur during the progression of AD. The disease includes sporadic and familial
forms with both \early-onset" (less than 65 years of age) and \late-onset" (over 65
years of age) forms. The diagnosis is rather dicult since the clinical features of AD
overlap with the symptoms of various other neuropathological conditions. In addi-
tion, a denite conrmation of AD is achieved only by morphological and histological
examination of the brain at autopsy (Jellinger, 1998). AD pathology is characterized
by an accumulation of \senile plaques" and \neurobrillary tangles" in brain regions
involved in learning and memory processes and degeneration of basal forebrain cell
groups. Senile plaques are extracellular deposits of brils and amorphous or diuse
aggregates of amyloid -peptide (A). Amyloid precursor protein (APP) is an in-
tegral membrane protein, highly expressed throughout the body. In AD, APP is
abnormally cleaved by several secretases and this results in formation of the insol-
uble A peptides (Fig. 1.1). Neurobrillary tangles are intracellular accumulations
of hyperphosphorylated microtubule-associated protein tau. As far as we currently
know, tangle formation is for a large part the nal result of amyloid-induced nerve cell
degeneration. Another hallmark of AD is the degeneration of synapses and the death
of specic groups of neurons. In particular cholinergic and glutamatergic neurons are
aected but even those producing norepinephirine or serotonin have been observed to
degenerate (Dickson, 2003).
1.1.2 Stroke/ischemia
Cerebrovascular accident (CVA) is a clinical denition used to describe the symp-
toms of a perturbation in the cerebral blood supply. Decreased or interrupted blood
supply has several consequences. The major one is the strong reduction in glucose
and oxygen availability in the territory of the aected vascular brain areas, a phe-
nomenon designated as cerebral ischemia. Ischemia leads, within seconds or minutes,
to a cellular energy crisis, initiation of anaerobic glycolysis, disruption in the activ-
ity of cellular pumps, increase in intracellular calcium and extracellular potassium,4 Introduction
Figure 1.1: Amyloid precursor protein (APP) is an integral membrane protein, highly expressed
throughout the body. It can be cleaved by alpha, beta- and gamma-secretases. The beta- and gamma-
secretase cleavage results in the splicing product amyloid beta-peptide (A1-40 or A1-42), which
is able to aggregate due to abnormal peptide folding. Depending on the degree of aggregation, A
peptides are considered to be neurotoxic as in large quantities they induce amyloid plaque formation.
Extracellular amyloid plaques produce loss of connections between neurons and decreased neuronal
activity.
neurotransmitter release and in the end to neuronal death. The temporal prole of
an ischemic injury can be described in a series of phases (ter Horst and Korf, 1997).
The rst phase includes the initiation of the expression of immediate early genes that
transform the cells from a resting into an activated state. The second phase includes
the activation of acute phase response proteins (such as heat shock proteins) with
temporary repair functions. The third phase comprises the secretion of immediate
early gene proteins from the rst phase. The fourth phase is the most damaging since
the proteinases activated in previous phases challenge the integrity of the cell. The
fth and last phase consists of activation of repair/remodeling molecular events to
rescue the cell. Several mechanisms have been proposed to explain the pathophysi-
ology of an ischemic injury, including increased excitotoxicity, calcium overload, free
radical formation, immune response, and inhibition of protein synthesis. All these
unbalanced events are ultimately causing neurodegeneration. Some of these aspects
will be discussed in detail in the following sections.1.2 Glutamate in neurodegeneration 5
1.2 Glutamate in neurodegeneration
The neurodegenerative molecular pathways are poorly understood largely due to
the diculty in distinguishing primary from secondary events. One important player
in neurodegeneration is glutamate, the major excitatory neurotransmitter in par-
ticular in the forebrain regions. In many neurodegenerative disorders like cerebral
ischemia and AD glutamate is locally released in high quantities and promotes an
eect called excitotoxicity, which ultimately leads to programmed neuronal death
(Smith-Swintosky and Mattson, 1994).
1.2.1 Glutamate-induced excitotoxicity
The neurotoxic action of the excitatory amino acid glutamate arises from its ca-
pacity to trigger a pathophysiological chain of reactions when it acts continuously on
its receptors. L-Glutamate (L-Glu) is the major excitatory neurotransmitter in the
brain being present at approximately two thirds of central synapses (Fonnum, 1984).
Glutamate receptors are divided on the basis of their mode of action and pharmaco-
logical properties into two major subdivisions: ionotropic channel receptors (iGluR)
and metabotropic G-protein coupled receptors (mGluR). iGluRs are characterized by
their selective anity for specic agonists: N-methyl-D-aspartate (NMDA), -amino-
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainic acid (KA). Upon
binding of these ligands to the receptor, the channel opening occurs which allows the
in
ux of mainly sodium and/or calcium ions into the nerve cell. A dierential distribu-
tion and a specic pharmacological prole exists for each iGluR subtype (Monaghan
et al., 1989).
The excitotoxicity theory asserts that the physiological excitatory transmission
can be changed from a physiological into a pathological state leading to neuronal de-
struction (Whetsell and Shapira, 1993). The drastic increase in L-Glu in the synaptic
cleft during brain injury could initiate two detrimental processes. These processes
dier in time-dependency and ionic characteristics. The rst process involves acute
swelling of cell bodies and dendrites via the opening of membrane cation channels,
causing depolarization. The Na+ in
ux and passive in
ux of Cl{ ions and H2O pre-
cedes the cell volume expansion. Swelling occurs within minutes of L-Glu exposure
and is critically dependent on the extracellular concentrations of Na+ and Cl{ ions.
The second process is marked by delayed neuronal degeneration. In vitro observations
suggest that the neuronal death is closely related with the increase in Ca2+ in
ux,
mainly via NMDA receptors. NMDA receptors exhibit the highest permeability to
Ca2+ compared to AMPA or KA receptors and posses a superior capacity for induc-
ing intracellular Ca2+ in
ux and thus initiating neurodegenerative processes (Choi,
1992).6 Introduction
1.2.2 NMDA-receptors
NMDA receptors constitute a major class of Glu receptors in the mammalian
central nervous system (MacDonald et al., 1989). They are localized at the post-
synaptic membrane of excitatory synapses on almost all neurons, but are specically
enriched on pyramidal neurons in the neocortex and hippocampus. Pyramidal neurons
are particularly susceptible to neurodegeneration and are e.g. massively lost in AD
(Hynd et al., 2004). Normally speaking NMDA receptors are involved in a wide
range of cellular processes, including neuronal dierentiation, synaptic plasticity, and
long-term potentiation (LTP) (Carroll and Zukin, 2002). In addition they mediate
the neurotoxic eects of excitatory amino acids in the adult brain under pathological
conditions of overstimulation (Choi, 1994).
NMDA receptors are activated by glutamate and glycine which makes NMDA
receptors unique among other neurotransmitter receptors. NMDA receptor activity
is modulated by several modulators such as divalent cations (Ca2+, Mg2+, Zn2+),
redox substances, pH and polyamines.
NMDA receptors are ligand-gated channels and are composed of heteromultimeric
subunits: NR1 and NR2 (NR2A-D) (McBain and Mayer, 1994). Although the struc-
ture and stoichiometry of the NMDA channel is unknown, in vivo receptors contain
an obligatory NR1 and one of the NR2 subunits (Dingledine et al., 1999). The type
of NR2 subunit determines agonist anity, Mg2+, Zn2+ sensitivity, deactivation ki-
netics and channel conductance. In AD, NMDA receptors are signicantly altered:
NR1 and NR2B protein levels are signicantly reduced, while the NR2A expression is
increased in the regions involved in learning and memory processes (Mishizen-Eberz
et al., 2004). Therefore, subunit composition denes the response of the receptor to
glutamate activation, which subsequently aects neuronal function.
1.3 Neuroprotective signaling
1.3.1 TNF- signaling
Cytokines are dened as small soluble proteins secreted by a cell, which can alter
the behavior or properties of the cell itself or of another cell. Cytokines are involved
in a variety of in
ammatory and infectious conditions. They are not expressed con-
stitutively but rather transiently after an inducing stimulus. The most potent signals
for cytokine expression are other cytokines. In the end this led to the concept of a
cytokine matrix in which they can stimulate or inhibit each other (Zhu and Emer-
son, 2002). This concept accounts for the complexity of the cytokine network found
with any neurodegenerative disorder. Cytokine receptors are constitutively expressed
and their activity is modulated by ligand interaction. Cytokine receptors are cleaved
by metalloproteinase enzymes to produce soluble cytokine receptors (Williams et al.,
1996), which are able to capture soluble cytokines, and hence act as inhibitors by
competing with membrane-bound receptors.1.3 Neuroprotective signaling 7
Tumor necrosis factor-alpha (TNF-), one of the best-characterized cytokines was
discovered in the 1970s by Old and colleagues (Carswell et al., 1975; Old, 1985). TNF-
 is produced mainly by the monocyte/macrophage lineage, but T lymphocytes, neu-
trophils, mast cells, endothelial cells and neurons can express it also under particular
circumstances. TNF- is highly expressed under physical (UV, X-radiation, heat),
chemical or immunological challenges. In vivo, TNF- is considered to be the most
rapidly secreted pro-in
ammatory cytokine (Sorimachi et al., 1999) from preformed
stores. It is produced by cleavage of the membrane TNF- by TNF- converting
enzyme (TACE/ADAM17) (Cerretti et al., 1999). Membrane TNF- is a 26-kDa cell
surface transmembrane type II polypeptide. The result of the TACE cleavage consists
of a 17-kDa soluble TNF- form. TACE cleavage results in a decreased cell surface
membrane-bound receptor density. Since clustering of TNF receptors is necessary for
signaling, their overall activity is inhibited in this way. Most of the reported TNF-
-mediated biological eects are attributed to the soluble TNF- form, whereas cell
surface transmembrane TNF--mediated physiological eects are less known. The bi-
ological eects exerted by transmembrane TNF- are mediated by direct cell-to-cell
interaction (Probert et al., 1997).
In vivo TNF- coordinates the cytokine response to injury. If its production is
blocked, the expression of other cytokines, such as IL-1 and IL-6 or chemokines is
down-regulated as well (Probert et al., 1996). Under pathophysiological conditions
TNF- acts as a switch-on molecule for the immune system. Following prolonged
exposure to an excess of TNF- its in
ammatory properties are tailored towards
immunosuppressive properties (Correale and Villa, 2004).
a) TNF-R1 and TNF-R2 signaling
TNF- binds two distinct cell surface receptors: TNF-R1 and TNF-R2. TNF-R
molecular pathways, either cooperatively or individually lead to cytotoxicity as well
as dierentiation and growth regulatory activities.
TNF-R1 activation can trigger broblast growth, and endothelial cell adhesion,
while TNF-R2 signaling promotes proliferation of thymocytes and peripheral T cells
and inhibition of early haematopoiesis (MacEwan, 2002). Because of its low anity
to soluble TNF, TNF-R2 was for a long time thought to have an \accessory function"
by enhancing TNF-R1 signaling through a "ligand passing" process by which TNF-
binds to TNF-R2, dissociates and subsequently binds to TNF-R1.
Both TNF-Rs potentiate NF-B complex activation. It was reported that neuro-
protection is dependent on TNF-R1 expression in kainic acid-induced seizures model
(Gary et al., 1998) or on TNF-R2 expression in a retinal-induced ischemic model
(Fontaine et al., 2002). TNF-R2-induced neuroprotection was associated with the
PKB/Akt pathway, since inhibition of PKB/Akt signaling abolished the neuropro-
tective eect (Fontaine et al., 2002). These in vivo studies were paralleled by studies
in cultured cortical neurons where TNF- induced neuroprotection by activation of
TNF-R2 pathway. Moreover, it was suggested that activation of NF-B by TNF-R18 Introduction
and TNF-R2 displays dierential temporal kinetics: while TNF-R1 signaling led to a
transient NF-B activity, TNF-R2 signaling resulted in a persistent NF-B activation,
which turned out to be crucial for neuroprotection (Marchetti et al., 2004). In addi-
tion, the TNF-R2 gene contains the consensus elements for transcription factors, such
as nuclear factor-kappa B (NF-B) in the 5'-
anking region suggesting receptor-self
promotion (Rasmussen et al., 2001; Santee and Owen-Schaub, 1996).
b) TNF- in pathology and therapy
Several reports showed the involvement of TNF- in neurodegenerative illnesses
(Probert et al., 1996; Ghezzi and Mennini, 2001; Sriram and O'Callaghan, 2007; Perry
et al., 2001). It has been suggested that in CNS disorders, in which apoptosis is
an underlying process for neuronal death such as AD, Parkinson's disease, retinitis
pigmentosa, cerebellar degeneration and ischemic injury, TNF- is a major player.
TNF- signaling in AD. A number of studies have shown that TNF- is up-
regulated in AD (Perry et al., 2001). Furthermore, TNF promoter polymorphisms
are associated with AD genes (Ma et al., 2004). It was reported that the chromosome
1p and chromosome 12p regions are involved in late-onset AD and these two regions
harbor the TNF-R1 and TNF-R2 genes. However, only TNF-R2 exon 6 polymorphism
was found to be linked to late-onset AD in families with no apolipoprotein E-epsilon
4 (ApoE-e4) genotype (Perry et al., 2001).
In addition, it has been demonstrated that overexpression of TNF-R1 promotes
A-induced neuronal death (Li et al., 2004). Cross-breeding transgenic APP23 mice,
which are able to develop A plaques, with TNF-R1-/- mice (APP23/TNF-R1-/-) re-
sulted in a strong decrease of A plaques compared with APP23 mice. APP23/TNF-
R1-/- mice have lower expression of BACE1 and show increased learning abilities
compared to APP23 mice. The authors suggested that TNF-R1 is connected to ab-
normal A processing which could lead to A plaque formation, neuronal damage
and learning decits (He et al., 2007). Thus, anti-TNF-R1-based therapies might be
an ecient therapeutic target in treating AD (Rosenberg, 2005).
TNF signaling in ischemia. TNF- expression in the cerebrospinal 
uid (CSF)
and in postmortem brain tissue correlates with the extent of ischemic injury in humans
suering from ischemic stroke (Zaremba et al., 2001). Similarly, TNF- expression
was increased both at the protein and mRNA level in an experimental focal ischemia
model in rats (Botchkina et al., 1997). Additional evidence for the role of TNF-
signaling in models of focal cerebral ischemia was previously reported using mice
double-decient for both TNF receptors (Bruce et al., 1996). In these studies TNF-
R1 ameliorated hippocampal damage (Gary et al., 1998). In contrast, the depletion
of TNF-R2 signaling increased the cellular degeneration in retinal ischemia (Fontaine
et al., 2002). These two dierential eects of TNF-R1 suggest a distinct signaling with
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Furthermore, middle cerebral artery occlusion/focal cerebral ischemia induces a dra-
matic up-regulation of TNF receptors, with TNF-R1 appearing within 6 hr, followed
by the appearance of TNF-R2 at 24 hr after the onset of ischemia (Botchkina et al.,
1997). TNF-R1 can induce neuroprotection in some cell systems by increasing Fas-
associated death domain-like interleukin-1-beta-converting enzyme-inhibitory protein
(FLIP(L) (Taouk et al., 2007) and NF-B activation. TNF-R2 promotes neuronal
survival by activation of PKB/Akt and NF-B activation (Fontaine et al., 2002). The
TNF-R2 neuroprotective eect persisted for 8 days following the retinal ischemic in-
jury (Fontaine et al., 2002), which suggests that TNF-R2 may be a promising new
approach in preventing irreversible neuronal loss by ischemic insults.
1.3.2 PKB/Akt signaling
Protein kinase B (PKB/Akt) belongs to the serine/threonine protein kinase family
called AGC protein kinases (EC 2.7.11.1). PKB/Akt research started back in 1977,
when Staal and co-workers identied a transforming leukemia virus in mice developing
spontaneous lymphoma. This virus, termed Akt8, induced tumor formation conrm-
ing the oncogenic potential of the Akt gene (Staal et al., 1977). Together with this
discovery, the PKB/Akt molecular homology was identied as signicantly related to
protein kinase A (PKA) and C (PKC) using a PCR screening approach (Coer and
Woodgett, 1991).
The rst PKB/Akt transgenic mouse model was generated in 2000 (Jones et al.,
2000). Overall, results from transgenic PKB/Akt mice demonstrate that PKB/Akt
is an important modulator of cellular growth and cell survival and it controls the
development and progression of various tumors.
PKB/Akt isoforms. Hitherto three isoforms of PKB/Akt have been identied and
described in mice and humans (Brazil and Hemmings, 2001). Characterization and
analyses of PKB/Akt isoform mutants provided new insight into the function of the
three PKB/Akt proteins. PKB/Akt1 is expressed in all organs and tissues and plays
e.g. an essential role in the modulation of fetal growth. In the brain PKB/Akt1
was shown to mediate neuroprotection in adult mice against ischemia-induced injury
(Miao et al., 2005) by increasing endothelial nitric oxide synthase (eNOS) expression
via phosphatidylinositol 3 (PI3)-kinase pathways (Hashiguchi et al., 2004). These data
were conrmed in PKB/Akt1 ko mice. These mice display diminished PKB/Akt
phosphorylation and a reduction in eNOS (Yang et al., 2003), which could lead to
enhanced neuronal degeneration. PKB/Akt2 is predominantly found in fat tissue,
liver and skeletal muscle suggesting an involvement in glucose metabolism (Altomare
et al., 1998). The role of PKB/Akt2 in the central nervous system is not known yet.
PKB
/Akt3 is found in the brain, testis, lung, mammary gland and fat (Yang et al.,
2005). In contrast to PKB/Akt1 or PKB/Akt2 mutant mice, PKB
/Akt3 mutant
mice display normal glucose metabolism and no growth retardation. However, their
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cant decrease in both10 Introduction
cell size and cell number (Tschopp et al., 2005). Characterization of the isoforms of
PKB/Akt in double or triple knockout mice also provided more information on the
specic function of the PKB/Akt isoforms. These studies concluded that the Akt1
gene is more important than Akt3 for embryo survival but that both are required for
embryonic development (Yang et al., 2005; Tschopp et al., 2005).
PKB/Akt activation. PKB/Akt is activated by several cytokines, growth fac-
tors or neurotransmitters. PKB/Akt activation can be mediated via PI3-kinase
(Datta et al., 1999). This pathway includes membrane phospholipids, especially
phosphatidylinositol 3,4,5-triphosphate [PtIns(3,4,5)P3] that recruits PKB/Akt to
the plasma membrane where it becomes phosphorylated. In the case of PKB/Akt1,
activation is reached when threonine 308 (Thr308) and serine 473 (Ser473) are phos-
phorylated by 3-phosphoinositide-dependent protein kinase 1 (PDK1) and a still to
be identied Ser473 kinase (Yang et al., 2003).
PKB/Akt regulation. So far several mechanisms of PKB/Akt regulation have
been proposed. One hypothesis is that carboxyl-terminal modulator protein (CTMP)
keeps PKB/Akt in an unphosphorylated and inactive state by physical protein-protein
interactions (Maira et al., 2001). Another known negative regulator is protein phos-
phatase and tensin homologue deleted on chromosome 10 (PTEN) that inactivates
PKB/Akt in a PI3-kinase dependent manner. PTEN knockout mice develop a broad
range of tumors. Furthermore, they display atypical social interactions, exaggerated
responses to stressful sensory stimuli in paradigms designed to assess anxiety and
learning. Their brains are enlarged in the regions in which the PTEN gene was
deleted and this eect is associated with hypertrophy of the cell bodies and with ab-
normal growth of neuronal processes (Kwon et al., 2006). Similar pathophysiological
conditions were described for PKB/Akt overexpression in mice (Yang et al., 2003). In
addition, heat shock proteins (Hsp) also bind and regulate PKB/Akt activity. Hsp are
stress proteins that regulate protein stabilization and protect cells from several stress
circumstances. It has been reported that overexpression of Hsp27 in neurons protects
against excitotoxicity and may act as an inhibitor of neurodegeneration (Wagsta
et al., 1999). To date, Hsp27 and Hsp90 proteins have been reported to specically
bind and activate PKB/Akt leading to an inhibition of apoptosis (Rane et al., 2003).
PKB/Akt is interacting and regulated as well by scaold proteins, such as scaold
proteins in the stress-mediated MAP-kinase (SAPK) signaling: JNK interacting pro-
tein 1 (JIP1) a scaold protein for the c-jun amino-terminal kinase (JNK) pathway
in neuronal cells and plenty of Src homology 3 (POSH), a scaold protein for the
mixed-lineage kinase (MLK)-JNK pathway (Kim et al., 2002; Figueroa et al., 2003).
It has been suggested that PKB/Akt suppresses the JNK-dependent death mecha-
nism not only upstream but also downstream of MLKs, thus leading to a decrease in
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PKB/Akt substrates. PKB/Akt isoforms are able to phosphorylate several sub-
strates providing a variety of cellular responses. Glycogen synthase kinase-3 (GSK-3)
was the rst identied PKB/Akt substrate (Burgering and Coer, 1995). Impor-
tantly, PKB/Akt phosphorylates the Bcl-2/Bcl-X antagonist (BAD). BAD binds the
proteins Bcl-2 and Bcl-X at the mitochondrial membrane. Upon phosphorylation by
PKB/Akt, BAD translocates from the mitochondrial membrane and Bcl-2 is released.
Bcl-2 is then translocated from the mitochondria to the nucleus where it promotes
anti-apoptotic activities (Datta et al., 1999). Bcl-2 proteins exhibit neuroprotective
functions against various excitotoxic challenges, such as glutamate or amyloid beta
peptides. Another substrate which is activated and phosphorylated by PKB/Akt in
a PI3-kinase-dependent manner (Fulton et al., 1999) is eNOS. eNOS activation has
been shown to have neuroprotective function in various neurodegenerative conditions
(Endres et al., 2004).
Other PKB/Akt phosphorylation targets essential for neuroprotection are several
transcription factors, including cyclic AMP (cAMP)-response element binding protein
(CREB) and NF-B (Kane et al., 1999). Upon phosphorylation CREB possesses a
higher anity for its co-activator, resulting in transcriptional activation. The detailed
mechanism of how CREB and PKB/Akt both lead to cellular survival still remains
to be elucidated. Activation of NF-B is dependent on the IkB kinase (IKK) com-
plex. PKB/Akt is a direct regulator of IKK activity in a PI3-kinase-dependent man-
ner. PKB/Akt-mediated NF-B activation contributes to the suppression of apopto-
sis since NF-B activity initiates the transcription of several anti-apoptotic proteins
(Kane et al., 1999; Lawlor and Alessi, 2001).
1.3.3 NF-B signaling
NF-B is a transcription factor involved in the development and progression of
several diseases such as autoimmune disease, cancer and neurodegenerative disorders.
Depending on the cell type and its regulators NF-B complex could induces the
transcription of pro- and anti-apoptotic genes. It was rst identied in B lymphocytes
as an activator of immunoglobulin  light chain transcription (Sen and Baltimore,
1987). The NF-B complex consists of an inactive form of DNA-binding dimers and
inhibitory subunits. In neurons, the most common subunits expressed are p50, p65
(RelA) and the inhibitory subunit IB, which is composed of IB and IB (Mattson
and Meert, 2006).
NF-B activation. The NF-B complex is activated in neurons by several molecules
such as TNF-, Fas ligands, glutamate, nerve growth factor (NGF), cell adhesion
molecules and a secreted form of amyloid precursor protein (APP) or even by synaptic
transmission between neurons (Mattson et al., 2000). These stimuli activate various
cellular signaling pathways such as the protein kinase C (PKC), mitogen-activated
protein (MAP) kinase kinase kinase-1 (MEKK1) and also the PKB/Akt signaling
pathway, which all have the potential to phosphorylate IKK. This kinase consists of12 Introduction
two catalytic subunits (IKK and IKK) and a regulatory subunit (IKK
). IKK
phosphorylates the inhibitory subunit IB and induces the dissociation of IB from
the NF-B complex. Upon dissociation of IkappaB from the NF-B complex, the
p50-p65 dimer of the NF-B complex translocates from the cytosol to the nucleus
where it binds to NF-B responsive genes (Mattson and Meert, 2006).
NF-B substrates. The NF-B complex induces the expression of genes involved
in the regulation of several cellular processes, including cellular survival (Bcl-2, in-
hibitor of apoptosis proteins (IAP), TNF- or TNF-R2 genes); immune response
(TNF-, interleukins (IL)-2, IL-6 genes); ion homeostasis (subunits of NMDA recep-
tors and small conductance Ca2+ activated potassium (SK) channels). Furthermore,
NF-B can promote the transcription of the inhibitory subunit IB and in this way
regulates its own activity in a negative feedback loop (Mattson and Meert, 2006).
The NF-B complex is activated in neurons and glia cells in response to acute or
chronic neurodegenerative processes. In several neurodegenerative models for trau-
matic brain injury, stroke, epilepsy or AD an increase in NF-B activity was observed.
These data were paralleled by in vitro studies which showed an activation of NF-B in
response to glutamate-induced excitotoxicity, metabolic insults or glucose deprivation.
In neuronal cells sustained activation of NF-B was shown to induce neuroprotection
(Marchetti et al., 2004; Mattson et al., 2000). This benecial outcome was in part the
result of PI3-kinase-PKB/Akt pathway activation, increase in mitochondrial antiox-
idant Cu/Zn-SOD, Mn-SOD and the induction of anti-apoptotic proteins Bcl-2 and
Bcl-x. Furthermore, NF-B cellular survival mechanisms underlie cytokine-induced
neuroprotective pathways, including transforming growth factor-beta1 (TGF-beta1)
and TNF- (Zhu et al., 2004).
NF-B in relation to neurodegenerative conditions. Several reports showed
that in AD NF-B activity is increased in cells associated with neurodegenerative pro-
cesses such as neurons and astrocytes located in close proximity to amyloid- plaques
(Lezoualc'h and Behl, 1998; Collister and Albensi, 2005). Furthermore, NF-B ac-
tivity is increased in cholinergic neurons in the basal forebrain and in the superior
temporal lobe gyrus of AD patients (Lukiw and Bazan, 1998; Boissi ere et al., 1997).
These brain regions are known to be susceptible to neurodegeneration. In cultured
neurons amyloid- and a secreted form of APP induce an up-regulation of NF-B
activity. This NF-B activation was reported to be protective against amyloid-
toxicity in cultured neurons (Barger et al., 1995). Interestingly, in early-stage AD
pathology NF-B activity is strongly increased while in later stages NF-B activity
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1.4 Neuroprotective agents
1.4.1 Statins
Statins, 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibi-
tors, are widely used as medication for lowering cholesterol levels. Today nine phar-
maceutical compounds are available: lovastatin, mevastatin, simvastatin, pravastatin,

uvastatin, atorvastatin, rosuvastatin, pitavastatin and cerivastatin. They are classi-
ed in relation to their inhibitory properties for either the puried HMG-CoA reduc-
tase enzyme or for cellular cholesterol biosynthesis (McTaggart et al., 2001).
Statin signaling. Besides their acknowledged role on the regulation of cardiovas-
cular functions, statins are able to exert neuroprotective eects, mainly attributed
to anti-in
ammatory eects (Leung et al., 2003), stimulation of eNOS (Harris et al.,
2004; Hern andez-Perera et al., 1998) and inhibition of inducible nitric oxide synthase
(iNOS) (Vaughan and Delanty, 1999). In general, statins inhibit mevalonate synthesis
and prevent the production of several isoprenoids, including farnesylpyrophosphate
and geranylgeranylpyrophosphate that modulate small G proteins (GTPases). Thus,
statins suppress the activation of GTPases, such as Rho, Ras and Rac by preventing
their isoprenylation and thus their translocation from the inactive GDP-bound forms
located in the cytoplasm to the active GTP-bound forms in the plasma membrane
(Maltese, 1990; Seabra, 1998). Inhibition of Rho proteins by statins prevents down-
regulation of eNOS expression and activity under hypoxia conditions, leading to the
stabilization of eNOS mRNA (Laufs et al., 2000). Furthermore, Rho isoprenylation
inhibits neuronal outgrowth in hippocampal neuronal cultures (Pooler et al., 2006).
Although our understanding of statin-mediated cellular pathways increased tremen-
dously in the last decade, statin-induced neuroprotective mechanisms are still elu-
sive. In vitro studies using primary neuronal cultures described merely three possible
statin-mediated neuroprotective mechanisms. Although acute treatment with statins
did not rescue neurons from cellular death and did not prevent the rise in [Ca2+]
caused by NMDA treatment in their system, Zacco and colleagues managed to show
the neuroprotective potential of various chronic statin treatments against NMDA ex-
citotoxicity. In this case the neuroprotective eect of statins was not attributed to
direct regulation of NMDA receptor-mediated events but rather to depletion of the
cellular pool of cholesterol (Zacco et al., 2003). In an oxygen and glucose depriva-
tion (OGD)/reoxygenation-evoked neuronal death model simvastatin treatment was
reported to induce neuroprotection (Lim et al., 2006). Simvastatin mediated this ben-
ecial eect by reducing the production and toxicity of 4-hydroxy-2E-nonenal (HNE),
a major cytotoxic end product of lipid peroxidation. The statin-induced neuroprotec-
tive mechanism was not ascribed to NMDA or AMPA receptor-mediated events but
rather to modulation of NF-B activity, since HNE directly inhibits NF-B basal ac-
tivity (Lim et al., 2006). It was concluded that simvastatin treatment suppresses HNE
cytotoxicity by restoring the NF-B activity in the OGD model leading to increased14 Introduction
neuronal survival. Johnson-Anuna and colleagues reported simvastatin-mediated neu-
roprotective eects against A toxicity via increased Bcl-2 mRNA and protein levels
in primary cortical neurons (Johnson-Anuna et al., 2007).
Several in vivo studies have shown statin-mediated neuroprotective eects against
various neurodegeneration-like events. This benecial neuroprotective eect was main-
ly attributed to increased eNOS expression (Kurosaki et al., 2004), Hsp cooperation,
Bcl2 up-regulation, NF-B and PKB/Akt pathways (Lu et al., 2007). In a model for
brain injury, statins (simvastatin and atorvastatin) were shown to increase neurogen-
esis in neurogenic brain areas such as the hippocampal dentate gyrus and to reduce
neuronal loss in the non-neurogenic brain areas such as the cornu ammonis 3 (CA3)
(Lu et al., 2007). In a dierent study simvastatin enhanced neuronal survival in axo-
tomized retinal ganglion cells after optic nerve injury via the overexpression of Hsp27
and activation of PKB/Akt pathways (Kretz et al., 2006). Furthermore, statin treat-
ment increases the expression level of 26 genes (as observed in a microarray study)
in particular genes related to apoptosis (c-myc, Bcl2) (Johnson-Anuna et al., 2005)
and PKB/Akt phosphorylation (Li et al., 2006). These microarray studies were par-
alleled by in vivo chronic simvastatin administration to investigate whether statins
would provide neuroprotection in brain cells after a challenge with the Bcl-2 inhibitor
HA 14-1 or the NO donor sodium nitroprusside (SNP). Bcl-2 levels were signicantly
increased in brains of simvastatin-treated and these brains were less vulnerable to
mitochondrial dysfunction or caspase activation (Franke et al., 2007).
1.4.2 SK channels
SK channels are voltage insensitive channels and belong to the KCNN family
(potassium intermediate/small conductance calcium-activated channel, subfamily N).
In the mammalian brain, SK channels are the product of three paralogous genes,
namely KCNN1/KCa2.1/SKCa1 (SK1), KCNN2/KCa2.2/SKCa2 (SK2) and KCNN3/
KCa2.3/SKCa3/hKCa3 (SK3). Recently, a new KCNN4/ KCa3.1/SK4/IK1 channel
was discovered being highly expressed in rat microglia (reviewed by Stocker (2004)).
SK1 and SK2 channel subunits show extensive colocalization. They are mainly
found in the entorhinal cortex, the subiculum, in pyramidal cortical neurons, the
CA1 - CA3 region from the hippocampus and in the thalamus. SK3 channel subunits
have a complementary distribution, and are mainly located in the brain stem and in
monominergic neurons (Sailer et al., 2002).
Functional SK channels are composed of heteromeric subunits with constitutively
bound calmodulin (CaM). The channels are activated in response to low (< 1M)
intracellular Ca2+ that binds to CaM. It has been shown that SK channels contribute
to basal synaptic integration at least in four dierent ways. In cortical and hippocam-
pal pyramidal central neurons, SK channel activity dampens membrane excitability,
contributes to dendritic response and regulates the synaptic integration. In certain
neuronal cell types, SK channels are localized to dendritic spines where they inter-
act with NMDA receptors. There SK channel activity suppresses the amplitude of1.5 Outline of this thesis 15
evoked synaptic potentials by inhibiting NMDA receptor-dependent activation (Ngo-
Anh et al., 2005; Faber et al., 2005). In tonically ring cells, including midbrain
dopamine neurons SK channels aect pacemaking by decreasing interspike intervals
during a burst of action potentials as well as the length of the burst. In high ring-
frequency cells, including cerebellar Purkinje neurons, SK channel activity is required
for enduring basal rapid ring and SK channels act as modulators for ring pattern.
In auditory hair cells SK channels are able to convert excitatory neurotransmitter
signal into inhibitory signals (reviewed by Bond et al. (2005)). Overall, it can be con-
cluded that SK channels are important regulators of synaptic integration and neuronal
excitability in such a way that an increase in SK channel activity normally leads to
decreased excitability of the cells (reviewed by Stocker (2004)).
Hitherto, there is only limited information on the role of SK channels in aging and
neurodegenerative disorders. Changes in neuronal excitability are currently thought
to underlie learning and memory processes. Aging is often characterized by a decrease
in neuronal excitability and cognitive decits. Since SK channel activity leads to
a reduction of neuronal excitability it was hypothesized that increased SK channel
expression and activity can in part account for the cognitive impairments found in
aged individuals. In agreement with this hypothesis SK3 channel expression was
found to be up-regulated in the hippocampus of aged mice. This elevation in SK3
channel expression was shown to result in a strong decrease in neuronal excitability
and was paralleled by impaired memory and learning abilities (Blank et al., 2003).
Since SK channels can regulate neuronal excitability a role in neurodegeneration and
neuroprotection may be expected. Indeed overexpression of SK2 channels in in vitro
cultured hippocampal neurons induced neuroprotection against kainite and glutamate
excitotoxicity. Furthermore, in vivo overexpression of SK2 channels in dentate gyrus
diminished a kainate-induced CA3 lesion (Lee et al., 2003). Thus, SK channels may
prove to be important drug targets in the development of new eective therapeutic
strategies against degenerative events.
1.5 Outline of this thesis
Neurodegenerative processes lead to neuronal loss which may ultimately result
in functional impairments or even death. Thus, the understanding of the molecular
basis of neuroprotective mechanisms for developing eective therapies to prevent and
treat neurodegenerative diseases is of paramount importance. Hitherto, a number of
studies showed that TNF- is able to promote protection against glutamate-induced
excitotoxicity in cortical neurons. Until now, the molecular mechanisms underlying
these benecial eects of TNF- are largely unknown. An initial study showed that
TNF- increases neuronal survival by mobilizing the TNF-R2 pathway. TNF-R2-
associated neuroprotective eects are mediated by the activation of PKB/Akt and
subsequent sustained NF-B activation.
In the rst part of this thesis (Chapters 2, 3 and 4) the TNF--mediated pro-16 Introduction
tective mechanisms in cortical neurons are investigated in more detail. In Chapter
2 we studied the kinetics of the neuroprotective eect of TNF- treatment. Since
PTEN is a counter-regulator of PKB/Akt signaling we investigated the time course
of PKB/Akt and PTEN expression during TNF--treatment in wild-type, TNF-R1-/-
and TNF-R2-/- neurons. In particular, we checked whether PTEN activation precedes
PKB/Akt activation during long-term TNF- treatment. Finally, we identied which
PKB/Akt isoform is important in TNF--induced neuroprotective pathways.
To gain further insight into the regulation of PKB/Akt we studied the phosphory-
lation of PKB/Akt by two cAMP eector systems, PKA and Epac in cortical neurons
in Chapter 3. PKA activation was shown to dephosphorylate PKB/Akt whereas Epac
activation lead to increased PKB/Akt phosphorylation. Since both PKA and Epac
were found to be complexed to the A-kinase anchoring protein AKAP150, we hy-
pothesized that AKAP150 acts as a coordinator of PKA/Epac signaling to modulate
PKB/Akt phosphorylation.
To date, only limited data is available on potential neuroprotective downstream
targets of TNF- induced NF-B activation. SK channels are important regula-
tors of neuronal excitability and were recently identied as a downstream target for
NF-B-mediated promoter regulation. Therefore, we investigated whether increased
SK channel expression is part of the mechanism of TNF--induced cellular survival
(Chapter 4).
Chapter 5 describes the neuroprotective eect of lovastatin pretreatment on glu-
tamate-induced neuronal death in neurons. Interestingly, in primary human vascular
endothelial cells (HUVEC) lovastatin treatment was shown to increase the expression
of TNF-R2 proteins, without aecting TNF-R1 expression levels. We investigated
whether lovastatin can also induce an increase in TNF-R2 expression levels in cortical
neurons and whether activation of TNF-R2 signaling might be the mechanism that
underlies the neuroprotective eect exerted by lovastatin. Moreover, we investigated
the eect of lovastatin on PKB/Akt and NF-B phosphorylation.
In Chapter 6 we wanted to conrm the observed in vitro neuroprotective eect of
lovastatin in an in vivo mouse model. The damage of cholinergic neurons and their
cortical target areas from the magnocellular nucleus basalis (MNB) that occurs during
aging or AD could be mimicked using an NMDA-induced lesions into MNB model. In
this in vivo model we found that lovastatin has a neuroprotective eect on NMDA-
induced excitotoxic lesions. In addition, we investigated whether this neuroprotective
eect of lovastatin administration was dependent on PKB/Akt activation. Since the
degeneration of cortical cholinergic bers is associated with a cognitive decline in AD
we studied the eects of lovastatin treatment on learning and memory abilities using
dierent behavior paradigms.
It is known that glutamatergic and cholinergic systems interact functionally at the
level of the cholinergic basal forebrain. The N-methyl-D-aspartate receptor (NMDA-
R) is a multiprotein complex composed of NR1, NR2 and/or NR3 subunits. The
subunit composition of NMDA-R of cholinergic cells in the nucleus basalis has not yetReferences 17
been investigated. By means of choline acetyl-transferase and NR2B or NR2C double
staining, we investigated whether mice express both the NR2C and NR2B subunits in
nucleus basalis cholinergic cells (Chapter 7). Since we found increased acetyl choline
(ACh) in the frontal cortex and amygdala, we assessed behavioral habituation to novel
environments and objects as well as object recognition in NR2C-2B subunit exchange
mice.
Overall this thesis provides more insight into TNF- mediated neuroprotective sig-
naling. We investigated both upstream and downstream targets of TNF- pathways.
In addition, we provide more information about PKB/Akt regulation, lovastatin-
induced neuroprotective mechanisms.
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Abstract
We have previously shown that tumor necrosis factor-alpha (TNF-) protects
neurons in vivo in an retinal ischemia model. In vitro studies showed that long term
TNF- (24 h) promotes benecial eects on neuronal survival against a glutamate
insult. To elucidate the neuroprotective signaling pathways of TNF- we studied
the kinetics of this protective TNF- eect. Using a glutamate-induced excitotoxi-
city model we showed that TNF- is able to increase neuronal survival after 6-8 h
of treatment. Furthermore, phosphorylation levels of PKB/Akt and the expression
of PTEN were profoundly altered upon TNF- treatment. Since, the mammalian
brain is endowed with three PKB/Akt isoforms we investigated which PKB/Akt iso-
form is important for TNF- induced neuroprotective eect. From experiments using
TNF- expressing neurons from TNF-transgenic mice, which have constitutively ac-
tivated PKB/Akt signaling and which were transfected with specic siRNA probes
for PKB/Akt1, PKB/Akt2 and PKB
/Akt3 we concluded that PKB/Akt1 and
PKB
/Akt3 isoforms are important in TNF--mediated neuroprotective eect.2.1. Introduction 29
2.1 Introduction
TNF- is a proin
ammatory cytokine that has been associated with the pathology
of several autoimmune disorders, including rheumatoid arthritis, spondylitis, Crohn's
disease, psoriasis and asthma (Eisel et al., 2006). TNF- expression is up-regulated
in the brain of human patients with neurodegenerative disorders such as Alzheimer's
disease, Parkinson's disease (Perry et al., 2001; Nagatsu and Sawada, 2005; Comabella
et al., 2006) suggesting a potential pathogenic role of TNF- in neurodegenerative
diseases as well. These ndings were paralleled by in vivo models for neurodegener-
ation, such as the mouse model of retinal ischemia (Fontaine et al., 2002). Recent
studies showed that TNF- contributes to both neuroprotection and neurodegenera-
tion (Cheng et al., 1994; Hermann et al., 2001). Excess TNF- causes cell death of
human cortical neurons and oligodendrocytes (Chao and Hu, 1994) and together with
ceramide and NF-B can induce apoptotic neuronal cell deaths in cultured dopamin-
ergic neurons (Hunot et al., 1997). On the other hand, cortical neurons isolated from
NR2B/TNF mice, which have locally restricted TNF- activity are entirely resistant
to neuronal death induced by toxic doses of glutamate. In addition, in isolated cell
culture of puried wild-type neurons long TNF- exposure time exhibit a neuropro-
tective eect against glutamate-mediated excitotoxicity (Marchetti et al., 2004).
Until now, the molecular mechanisms underlying these benecial eects of TNF-
are largely unknown, but at least PKB/Akt and NF-KB activation are associated with
TNF--mediated neuroprotective pathways (Fontaine et al., 2002; Marchetti et al.,
2004). TNF- exerts its biological functions through the action of two main receptors,
TNF-R1 and TNF-R2 (Eisel et al., 2006). In recent studies we proposed new functions
for TNF-R2 pathway. We showed that TNF-R2 exerts neuroprotection in vivo in a
retinal ischemia model (Fontaine et al., 2002) and in vitro in a glutamate-induced
excitotoxicity model (Marchetti et al., 2004) in a PKB/Akt-dependent manner.
In the present study we investigated in more detail the kinetics of the TNF-
neuroprotective eect. We concentrated on the kinetics of PKB/Akt activation and
on the kinetics of the phosphatase and tensin homologue deleted from chromosome 10
(PTEN), the main negative regulator of PKB/Akt. In particular, we checked whether
PTEN activation precedes PKB/Akt activation during long-term TNF- treatment.
Since three isoforms of PKB/Akt have been identied and described in mice and
humans (Brazil and Hemmings, 2001) we investigated which PKB/Akt isoform is
important in TNF--induced neuroprotective pathways.
2.2 Materials and methods
Materials. Neurobasal medium, B27 supplement, L-glutamine and Penicillin/Strep-
tomycin were purchased from Invitrogen (Carlsbad, CA). LY294002 was from Cal-
biochem (San Diego, CA) and Complete mini protease inhibitor cocktail tablets from
Roche (Indianapolis, IN). TNF- was purchased from HBT (Uden, The Netherlands).30 The kinetics of neuroprotective TNF- molecular signaling
Primary antibodies used were a rabbit polyclonal antibody specic for total PKB/Akt
(9272, Cell Signaling, Danvers, MA, 1:2000 dilution), anti p-Akt (Ser473, 9271, Cell
Signaling, Danvers, MA, 1:2000 dilution), anti PKB/Akt1 (5919, Abcam, 1:2000
dilution), anti PKB/Akt2 (5920, Abcam, 1:2000 dilution), anti PKB
/Akt3 (5922,
Abcam, 1:2000 dilution) and a monoclonal mouse antibody specic for actin as in-
ternal standard (MP Biomedicals, Irvine, CA, 1:100000 dilution). The secondary
antibodies used were alkaline phosphatase (AP)-conjugated goat anti-mouse (Applied
Biosystems, Bedford, MA, 1:10000 dilution) and AP-conjugated goat anti-rabbit (Ap-
plied Biosystems, Bedford, MA, 1:10000 dilution). The chemi-luminiscence detection
kit (Nitroblock II and CDP-Star) was purchased from Applied Biosystems (Bedford,
MA). All other materials were from Sigma.
Animal experiments. All experiments were performed using C57BL/6J (Harlan,
Horst, The Netherlands), TNF-R1-/-, TNF-R2-/- and TNF- overexpressing mice
(Rothe et al., 1993; Pfeer et al., 1993; Erickson et al., 1994). The procedures con-
cerning animal care were in accordance with the regulation of the Ethical Committee
for the use of experimental animals of the University of Groningen, The Netherlands.
Mice were individually housed in standard macrolon cages and maintained on a 12 h
light/dark cycle. They received food and water ad libitum.
Cell cultures. Primary cortical neurons were isolated from embryonic brains (E15-
16) of C57BL/6J, TNF-R1-/- TNF-R2-/- and TNF- overexpressing mice. The menin-
ges was removed and the PCNs were separated by mechanical dissociation. Cortical
neurons were plated in a density of 12  104 cells/well (96 well plates) and 2  106
cells/well (6 well plates) on 2 ￿g/ml poly-D-lysine coated plates. Neurobasal medium
with B27-supplement, 0.5 mM L-glutamine, 50 units/ml Penicillin/Streptomycin and
2.5 ￿g/ml amphotericin B was used as a culture medium. After 48 h cells were treated
with 10 ￿M cytosine arabinoside for another 48 h to inhibit non-neuronal cell growth.
Subsequently, the medium was completely changed and after 6 days of in vitro culture,
cortical neurons were used for experiments. Acquisition of primary cultures was under
the regulation of the Ethical Committee for the use of experimental animals of the
University of Groningen, The Netherlands (DEC 4048).
Cortical neurons were incubated with 100 ng/ml TNF- for dierent time in-
tervals. Excitotoxicity was induced by 50 ￿M glutamate for 1 h. After treatment,
neuronal cells were either lysed (and subsequently subjected to western blot analysis)
or allowed to recover for another 24 hours, as shown in the schematic diagram 2.1(a).
Determination of cell viability. 24 h after glutamate treatment viability of the
neurons was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl-)2,5-
diphenyltetrazo-lium bromide) assay as described previously (Mosmann, 1983). 1.25
mg/ml MTT solution was added to each well of a 96 well plate. After 2-4 h of
incubation, cells were lysed by adding 120 ￿l of isopropyl-HCl solution (37% (v/v)2.2. Materials and methods 31
HCl/isopropyl alcohol: 1/166) for 15 min. The absorbance of each well was deter-
mined with an automated ELISA reader (Bio-Rad, Munich, Germany) at 595 nm
with a background correction at 620 nm.
siRNA experiments. siRNA probes targeted to PKB/Akt1 (L-040709-00),
PKB/Akt2 (L-040782-00) and PKB
/Akt3 (L-040891-00) were purchased from Dhar-
macon (Dharmacon, Inc. Lafayette, CO, USA). A scrambled siRNA probe was used
as a control in all siRNA transfection experiments. Primary cortical neurons were
transfected with siRNAs using the Amaxa nucleofector technology (Amaxa, Cologne,
Germany). Cells were cultured for 4 days after nucleofection, lysed and subsequently
analysed for protein content.
Protein analysis. Cortical neurons were washed twice with ice cold phosphate-
buered saline and subsequently lysed by the addition of 0.15 ml lysis buer (20 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton, 2.5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate and Complete mini protease inhibitor
cocktail tablet (Roche). The samples were centrifuged at 9000g for 10 min at 4 ￿ and
the supernatant boiled for 5 min in Laemmli's sample buer. Twenty ￿g of total pro-
tein was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
After transfer to a PVDF transfer membrane (Millipore Corporation, Billerica, MA)
proteins were linked with primary antibodies overnight at 4 ￿. Phosphorylation of
PKB/Akt was evaluated as the ratio of p-Akt Ser473/total Akt. Actin was used as
an internal control to correct for variations in protein content. The blots were in-
cubated with alkaline phosphatase-conjugated goat anti-mouse (Applied Biosystems,
Bedford, MA, 1:10000 dilution) or alkaline phospatase-conjugated goat anti-rabbit
(Applied Biosystems, Bedford, MA, 1:10000 dilution). Proteins were detected with
an enhanced chemoluminscence detection system according to the manufacturer's in-
structions. Integrated optical densities (IOD) were measured by the Leica DFC 320
Image Analysis System (Leica, Cambridge, UK) and densitometric analysis was evalu-
ated by the Leica Qwin program. Quantication of IOD was performed only in images
in which saturation of signal had not occurred. IOD measurements were corrected for
the background intensity.
Statistical analysis. Results shown represent mean S.E.M. Statistical analysis
was performed by Statistical Package for the Social Science (SPSS) program. One-
Sample T Test procedure tests were used to check whether the mean of a single
variable diers from the control samples, taken as the specic constant. These tests
were followed by one-way ANOVA LSD post-hoc program. p values of 0:05 were
considered to be signicant.32 The kinetics of neuroprotective TNF- molecular signaling
2.3 Results
2.3.1 Neuroprotective time window initiated by TNF- in cortical neu-
rons.
Exposure of cortical neurons to cytotoxic glutamate concentrations triggers cell
death in a dose and time dependent manner (Rogers et al., 2004). In an initial study,
24 h of TNF- treatment of primary cortical neurons was shown to induce neu-
roprotection against the glutamate-mediated excitotoxicity (Marchetti et al., 2004).
Therefore, here we investigated the TNF--mediated eects after shorter exposure
time in an in vitro excitotoxic model.
Cortical neurons were treated as shown in the schematic diagram (2.1(a)). After
6 days in culture, neurons were pre-incubated with TNF- for 1, 2, 4, 6, 8 or 24 h and
they were glutamate-challenged after each time point. The rst 4 h of TNF- pre-
incubation did not protect neurons against glutamate excitotoxicity (Glu: 36:43:2%
compared with TNF- and Glu 35:71:8% of non-treated neurons; n = 6), while 8 h
of TNF- incubation rescued neurons from the cell death (Glu: 36:43:2% compared
with TNF- and Glu: 55:78:7% of non-treated neurons; n = 6). Neuronal resistance
to apoptosis was observed, to an even greater extent after 24 h TNF- treatment (Glu:
36:4  3:2%, TNF- and Glu: 65:2  6:3% of non-treated neurons; n = 6). Exposure
of cortical neurons to TNF- after the glutamate challenge was not able to inhibit
the cellular death (data not shown). TNF- alone for 24 h had a slight toxic eect
on primary neurons (TNF-: 89:5  6:4% of non-treated neurons; n = 6).
2.3.2 TNF-R2 pathway increases PKB/Akt phosphorylation.
To gain further insight into TNF--mediated neuroprotective mechanisms, we in-
vestigated the eects of TNF- on PKB/Akt phosphorylation status since PKB/Akt
is a downstream molecule of TNF-TNFR axis. Increased PKB/Akt phosphorylation
is linked with cell survival, proliferation and metabolic functions (Lawlor and Alessi,
2001). The activation of enzyme activity of PKB/Akt is due to phosphorylation of
two sites: Thr308 and Ser473 (Lawlor and Alessi, 2001; Franke et al., 1997). Here
we evaluated the activation of PKB/Akt as a ratio of phosphorylated-Akt Ser473
(p-PKB/Akt)/total Akt.
Primary cortical neurons were treated with TNF- for a time period ranging from
2 to 24 h. In wild-type cortical neurons, in the rst 4 h of TNF- treatment, p-
PKB/Akt levels were slightly reduced (2.2(a)). After 6 h of TNF- treatment we
observed a signicant increase in PKB/Akt phosphorylation (2.2(a)).
To investigate the contribution of each TNF-Rs in TNF--mediated neuroprotec-
tive signaling we checked PKB/Akt phosphorylation in TNF-R1-/- and TNF-R2-/-
neurons. Upon 24 h of TNF- treatment the phosphorylation of PKB/Akt was
down-regulated in TNF-R2-/- neurons (as seen in Fig. 2.2(b)). However, in TNF-
R1-/- neurons PKB/Akt phosphorylation was increasing with TNF- treatment time
(Fig. 2.2(b)).2.3. Results 33
(a)
(b)
Figure 2.1: Long term TNF- treatment increases neuronal survival. (a). Cortical neurons
were treated as shown in the schematic diagram. (b). Cortical neurons were treated with TNF-
(100 ng/ml) for the indicated periods of time and subsequently challenged with glutamate (50 ￿M,
1 h). Neuronal survival was assessed 24 h following the exposure to glutamate by an MTT assay.
Values represent mean SEM of determinations made in three separate cultures. Statistical analysis
was performed by the Student-Neumann test with a 95% condence interval using the SPSS program.
p values of < 0:05 were considered to be signicant.
2.3.3 PTEN is a negative regulator of neuroprotective signalling.
Several studies showed that PI3K-PKB/Akt signaling is inhibited by PTEN (Lawlor
and Alessi, 2001; Fayard et al., 2005). Our next step, therefore, was to investigate
whether increased levels of PTEN are associated with the neuronal sensitivity towards
glutamate neurotoxicity. We observed an increase in PTEN levels in the rst 2-4 h
of TNF--treated neurons Fig. 2.3(a), while after 24 h of TNF- treatment PTEN
expression was diminished Fig. 2.3(a).
Since PKB/Akt phosphorylation is modulated dierently by TNF-Rs signaling, we
investigated whether PTEN expression is changed as well during TNF- treatment34 The kinetics of neuroprotective TNF- molecular signaling
(a) (b)
Figure 2.2: Long term TNF- treatment increases PKB/Akt phosphorylation. PKB/Akt
phosphorylation in wild-type neurons (a) and TNF-R1-/- or TNF-R2-/- neurons (b) treated with 100
ng/ml mouse TNF- for indicated periods of time. Representative immunoblots are shown below
the quantied data of PKB/Akt phosphorylation at the Ser473 site ( p473-Akt) analyzed from three
separate experiments. The bars indicate the mean S.E.M. of IOD of protein bands corresponding to
 p473-Akt as percentage of total PKB/Akt (depicted as total Akt) (Univariate Analysis of Variance
and LSD test, p < 0:05 versus non-treated neurons).
in TNF-R-/- neurons.
Western blot analysis showed that in TNF-R2-/- neurons, PTEN levels were sig-
nicantly up-regulated after 6-8 and 24 h of TNF- pre-incubation Fig. 2.3(b), while
in TNF-R1-/- neurons, PTEN expression was down-regulated starting from 2 h of
TNF- incubation (Fig. 2.3(b)) up to an even stronger down-regulation after 24 h of
TNF- treatment (Fig. 2.3(b)).
2.3.4 Neuroprotection in neurons is dependent on PKB/Akt1 and
PKB
/Akt3 expression.
In an initial study, we found that TNF--induced PKB/Akt phosphorylation pro-
moted neuroprotection against glutamate-induced neurotoxicity (Marchetti et al.,
2004; Dolga et al., 2008). Until now, three isoforms of PKB/Akt have been iden-
tied and described in mice and humans (Brazil and Hemmings, 2001). The next
step, therefore, was to investigate which PKB/Akt isoform is important for TNF--
mediated neuroprotective signaling. Using NR2B/TNF neurons that are endowed
with constitutively activated PKB/Akt (Marchetti et al., 2004) we silenced each
PKB/Akt isoform and then checked the phosphorylation of PKB/Akt. First we ascer-2.4. Discussion 35
(a) (b)
Figure 2.3: Long term TNF- treatment decreases PTEN expression. PTEN expression
in wild-type neurons (a) and TNF-R1-/- or TNF-R2-/- neurons (b) treated with 100 ng/ml mouse
TNF- for indicated periods of time. Representative immunoblots are shown below the quantied
data of PTEN expression analyzed from three separate experiments. The bars indicate the mean
S.E.M. of IOD of protein bands corresponding to  PTEN (Univariate Analysis of Variance and
LSD test, p < 0:05 versus non-treated neurons).
tained that these NR2B/TNF neurons have indeed higher levels of PKB/Akt phospho-
rylation than wild-type neurons (Fig.2.4(a)). siRNA probes targeted for PKB/Akt1,
PKB/Akt2 and PKB
/Akt3 signicantly reduced each specic isoform after 4 days
in vitro culture (Fig.2.4(b)). Here we evaluated the reduction of PKB/Akt isoforms af-
ter siRNA experiments as a ratio of PKB/Akt(1=2 or 3)/total Akt. All three PKB/Akt
isoforms were silenced approximately 40% as compared with scramble control RNA
(Fig.2.4(c)). Interstingly, silencing PKB/Akt1 and PKB
/Akt3 drastically reduced
PKB/Akt phosphorylation, while silencing PKB/Akt2 produced only a slight de-
crease in PKB/Akt phosphorylation (Fig. 2.4(d)).
2.4 Discussion
In this study we show the kinetics of the neuroprotective TNF- eect against
glutamate-induced toxicity in primary cortical neurons. We investigated in particular
the dual eect of PTEN and PKB/Akt in this neuroprotective TNF- signaling.
In a previous study we showed that long exposure (24 h) of cortical neurons to
TNF- induced increase cellular survival. Therefore, in this study we investigated the
time course of TNF--treatment necessary to initiate neuroprotection. Using MTT as-36 The kinetics of neuroprotective TNF- molecular signaling
(a)
(b)
(c) (d)
Figure 2.4: Silencing of PKB/Akt1 and PKB/Akt3 decrease PKB/Akt phosphoryla-
tion. (a). Primary cortical neurons from NR2B/TNF mice have increased PKB/Akt phospho-
rylation levels compared to wild-type neurons. (b). NR2B/TNF neurons were transfected with
specic PKB/Akt1 siRNA, PKB/Akt2 siRNA or PKB
/Akt3 siRNA or with scrambled siRNA.
After 4 days neurons were lysed and analyzed for PKB/Akt phosphorylation at the Ser473 site (
p473-Akt). Cortical neurons electroporated without siRNA served as additional controls to scramble
siRNA. Representative immunoblots (b) and the quantied data (c) of PKB/Akt1/total PKB/Akt,
PKB/Akt2/total PKB/Akt and PKB
/Akt3/total PKB/Akt are shown. Actin was used as an in-
ternal control to correct for variations in protein content. (d). The bars indicate the mean S.E.M.
of IOD of protein bands corresponding to  p473-Akt as percentage of total PKB/Akt (depicted as
total Akt) (Univariate Analysis of Variance and LSD test, p < 0:05 versus non-treated neurons).
(LSD test, n = 3, p < 0:05 versus control neurons).2.4. Discussion 37
say for determining the cellular viability, we observed that short-time exposure (2-4 h)
to TNF- did not rescue neurons from glutamate-mediated excitotoxicity. However,
longer TNF- treatment than 6-8 h promoted neuroprotection in a time dependent
manner. In our experiments 6-8 h TNF- treatment represented a switch point from
neuronal death to neuronal survival. To further dissect the molecular mechanisms
that allowed neurons to change their condition from a vulnerable to a resistant state
when they are glutamate challenged, we investigated PKB/Akt phosphorylation dur-
ing TNF- treatment. Our hypothesis that TNF- treatment may alter PKB/Akt
phosphorylation is derived from studies showing that 24 h TNF- treatment induced
strong increase in PKB/Akt phosphorylation (Marchetti et al., 2004). In neurons,
PKB/Akt activation is associated with increased neuronal protection and survival
against various noxious conditions (Lawlor and Alessi, 2001). PKB/Akt activity can
be regulated by several phosphtases, including PTEN, PHLPP or PP2A. PTEN is
considered so far the main negative regulator of PKB/Akt phosphorylation (Fayard
et al., 2005). Furthermore, an increase in PTEN expression in cortical neurons was
shown to induce neuronal death (Gary and Mattson, 2002). In our experiments, short-
term TNF- treatment (2-4 h) induced an increase in PTEN expression and a decrease
in PKB/Akt phosphorylation. However, long-term TNF- treatment (6-8 to 24 h)
resulted in a decrease in PTEN expression and an augmented PKB/Akt phosphory-
lation in a time dependent manner. The fact that high levels of PTEN coincided with
low levels of PKB/Akt phosphorylation was in accordance with the inverse relation-
ship between PTEN and PKB/Akt activation. TNF- is a ligand for both TNF-R1
and TNF-R2. A previous study from our group reported that TNF-R2 is essential for
TNF--induced neuroprotective pathways. Using TNF-R-/- neurons in this study we
investigated the relationship between TNF-receptors and PKB/Akt phosphorylation
or PTEN expression. It appeared that in TNF-R1-/- neurons, PKB/Akt was phos-
phorylated after long term TNF- treatment with visible eects after 6-8 h, while
in TNF-R2-/- PKB/Akt phosphorylation was down-regulated in a TNF--treatment
time dependent manner (Figs. 2.2 and 2.3). Overall, in wild-type neurons the in-
crease in PTEN expression or the decrease in PKB/Akt phosphorylation observed in
the rst hours of TNF- treatment could be attributed to TNF-R1 signaling, while
the later decrease in PTEN levels and increase in PKB/Akt phosphorylation are due
to TNF-R2 signaling (Figs. 2.2 and 2.3).
Several studies showed the in
uence of TNF--treatment on synaptic transmis-
sion (Beattie et al., 2002; Stellwagen et al., 2005; Stellwagen and Malenka, 2006).
Interestingly, TNF- acting on neuronal TNF-R1 receptors, but not on TNF-R2 re-
ceptors increases in 20 to 40 min surface AMPARs through a PI3 kinase-dependent
pathway (Stellwagen et al., 2005). This fast increase in excitatory synaptic transmis-
sion (AMPARs) is concomitant with endocytosis of GABA receptors that weakens
the inhibitory synaptic strength. This unique feature of TNF- action could explain
why in our experiments the rst hours of TNF--treatment were not able to induce
neuroprotection against glutamate excitotoxicity.38 The kinetics of neuroprotective TNF- molecular signaling
In neurodegenerative disorders TNF- expression levels were found elevated in
specic brain regions. In a previous study we investigated the consequences of TNF-
 increase in specic brain regions by creating a transgenic mouse line NR2B/TNF
transgenic mice with a neuron-specic promoter to guide TNF- expression. In
NR2B/TNF transgenic mice TNF- was expressed under the control of the murine
NMDAR subunit NR2B promoter. Interestingly, NR2B/TNF neurons were totally
resistant to excitotoxic eects induced by glutamate treatment. This eect was paral-
leled somehow to a lower extent by exposure of wild-type neurons to soluble TNF-.
Most important, TNF- treatment in wild-type neurons induced PKB/Akt phos-
phorylation while NR2B/TNF neurons have a constitutively high level of activated
PKB/Akt compared with wild-type neurons (Marchetti et al., 2004). Since it is
unknown which PKB/Akt isoform is engaged in TNF--mediated neuroprotective
pathways, we used NR2B/TNF neurons to silence each PKB/Akt isoform and check
the phosphorylation status of PKB/Akt. Several reports showed that TNF-R2 neu-
roprotective pathways are dependent on the activation of PKB/Akt signaling, which
is associated with increased neuronal survival (Fontaine et al., 2002; Marchetti et al.,
2004). In this study we found that silencing PKB/Akt isoforms in NR2B/TNF neu-
rons only PKB/Akt1 and PKB
/Akt3 are important in PKB/Akt phosphorylation.
These ndings demonstrate the important role of PKB/Akt1 and PKB
/Akt3 in
neuroprotection and associate these isoforms with TNF-R2 pathways.
Taken together, our studies suggest potential for therapeutic manipulation of
TNF- signaling in the treatment of neurodegenerative disorders.
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Abstract
In diverse neuronal processes ranging from neuronal survival to synaptic plastic-
ity cyclic adenosine monophosphate (cAMP)-dependent signaling is tightly connected
with the protein kinase B (PKB)/Akt pathway but the precise nature of this con-
nection remains unknown. In the current study we investigated the eect of two
mainstream pathways initiated by cAMP, cAMP-dependent protein kinase (PKA)
and exchange proteins directly activated by cAMP (Epac1 and Epac2) on PKB/Akt
phosphorylation in primary cortical neurons and HT-4 cells. We demonstrate that
PKA activation leads to a reduction of PKB/Akt phosphorylation, whereas activation
of Epac has the opposite eect. This eect of Epac on PKB/Akt phosphorylation
was mediated by Rap activation. The increase in PKB/Akt phosphorylation after
Epac activation could be blocked by pretreatment with Epac2 siRNA and, to a some-
what smaller extent, by Epac1 siRNA. PKA, PKB/Akt and Epac were all shown
to establish complexes with neuronal A-kinase anchoring protein 150 (AKAP150).
Interestingly, activation of Epac increased phosphorylation of PKB/Akt complexed
to AKAP150. From experiments using PKA-binding decient AKAP150 and pep-
tides disrupting PKA anchoring to AKAPs, we conclude that AKAP150 acts as a key
regulator in the two cAMP pathways to control PKB/Akt phosphorylation.3.1. Introduction 43
3.1 Introduction
Cyclic adenosine monophosphate (cAMP) is one of the most common and ver-
satile intracellular signaling compounds and has been implicated in the downstream
transfer of molecular messages upon stimulation by a large number of hormones, neu-
rotransmitters, prostaglandins and odorants. It functions as a universal and highly
modulated second messenger for events underlying a wide variety of cellular processes
such as central metabolic events, cardiac and smooth muscle contraction, secretory
processes, ion channel conductance, learning and memory, cell growth and dierenti-
ation, apoptosis and in
ammatory responses (Beavo and Brunton, 2002). Although
originally cAMP-dependent protein kinase (PKA) was thought to be the major if not
the sole eector of cAMP, meanwhile other targets have been identied, in particular,
exchange factors directly activated by cAMP (Epac) proteins. To date, there are
two variants of Epac known, Epac1 and Epac2, and both were initially characterized
as exchange factors for the small GTPases Rap1 and Rap2 (Bos, 2006). Epac1 is
ubiquitously distributed with predominant expression in the thyroid, kidney, ovary,
skeletal muscle, and specic brain regions, whereas Epac2 is mainly expressed in the
brain and adrenal gland (de Rooij et al., 1998; Kawasaki et al., 1998). The available
information on the functional role of Epac in neurons is still rather limited. It was
shown that Epac enhances neurotransmitter release in glutamatergic synapses of the
rat brain calyx of Held (Sakaba and Neher, 2003) and in the craysh neuromuscular
junction (Zhong and Zucker, 2005). In dorsal root ganglion neurons, Epac mediates
the translocation and activation of protein kinase C (PKC) leading to the establish-
ment of in
ammatory pain (Hucho et al., 2005) and in cerebellar granule cells Epac
can modulate neuronal excitability (Ster et al., 2007).
Since PKA and Epac are co-expressed in many tissues, an increase in intracellular
cAMP levels can lead to the activation of both cAMP targets, thus specicity and co-
ordination of cAMP signaling is urgently required. Members of the A-kinase anchoring
protein (AKAP) family were shown to play a pivotal role in the intracellular targeting
and compartmentalization of cAMP signaling pathways (Task en and Aandahl, 2004;
Wong and Scott, 2004). AKAPs represent a group of more than 50 identied function-
ally related proteins. Although they share few primary structure similarities, they all
have the ability to bind the PKA regulatory subunit (Herberg et al., 2000). Besides a
binding site for PKA many AKAPs contain distinct binding sites for other signaling
enzymes such as phosphatases (Colledge and Scott, 1999), phosphodiesterases (Dodge
et al., 2001) and other protein kinases such as PKC (Klauck et al., 1996; Nauert et al.,
1997; Takahashi et al., 1999).
Intriguingly, recent studies identied a signal transduction complex formed by
muscle AKAP (mAKAP) at the nuclear envelope of striated myocytes, which con-
tains both PKA and Epac1 (Dodge-Kafka et al., 2005). Upon association with both
PKA and Epac1, mAKAP serves as a coordinator of two cAMP eector pathways to
regulate cellular processes. Hitherto, mAKAP is the only AKAP reported to associate
with both PKA and Epac1. However, both PKA anchored to neuronal AKAP79/15044 AKAP150-PKA-Epac2 complex
and Rap GTPases have been shown to be involved in AMPA receptor tracking dur-
ing synaptic plasticity (Snyder et al., 2005; Zhu et al., 2002). Thus, AKAP79/150
might also serve to integrate cAMP signals to coordinate distinct signaling properties
in neuronal cells.
Elevation of cAMP was shown to in
uence neuronal survival and axonal outgrowth
via multiple signaling cascades including protein kinase B (PKB)/Akt signaling (Cui
and So, 2004). PKB/Akt activated in response to elevated cAMP has also been re-
ported to be of importance for learning and memory (Lin et al., 2001). Since the alter-
ation of PKB/Akt activity is associated with several diseases, including Alzheimer's
disease (Grin et al., 2005), novel insights into the molecular mechanisms of the
regulation of PKB/Akt signaling are essential for successfully developing new ther-
apeutics. So far, the precise mechanism of how PKA and Epac regulate PKB/Akt
activity in neurons remained unknown.
Therefore, we investigated herein the molecular mechanisms by which PKA and
Epac aect the PKB/Akt signaling in primary cortical neurons and HT-4 cells, in
particular we focused on the role of AKAP150 in this neuronal response.
3.2 Materials and Methods
Cell cultures and toxin treatment. Primary cortical neurons were isolated from
embryonic brains (E15-16) of C57BL/6J mice (Harlan, Horst, The Netherlands). The
meninges were removed and the cells were separated by mechanical dissociation. Cor-
tical neurons were plated in a density of 2  106 cells/well on 2 ￿g/ml poly-D-lysine
(PDL, Sigma-Aldrich, St. Louis, MO, USA) coated 6 well plates. Neurobasal medium
with B27-supplement (Invitrogen, Carlsbad, CA, USA), 0.5 mM glutamine (Sigma-
Aldrich, St. Louis, MO, USA), 50 units/ml penicillin/streptomycin (Invitrogen) and
2.5 ￿g/ml amphotericin B (Sigma-Aldrich) was used as a culture medium. After 48
h cells were treated with 10 ￿M cytosine arabinoside (Sigma-Aldrich) for another
48 h to inhibit non-neuronal cell growth. Subsequently, the medium was completely
exchanged and, after 6 days of in vitro culture, primary cortical neurons were used
for experiments. Clostridium dicile Toxin B-1470 (strain 82) was purchased from
tgcBiomics (Mainz, Germany) and applied on neurons for 3 h, at a concentration of
300 pg/ml (Schmidt et al., 1998; Reineke et al., 2007).
Acquisition of primary cultures was under the regulation of the Ethical Committee
for the use of experimental animals of the University of Groningen, The Netherlands
(DEC 4048). The mouse hippocampal-derived HT-4 cell line was grown in RPMI
1640 (Invitrogen) optimal medium containing 10% (v/v) fetal calf serum (Invitrogen)
and 50 units/ml penicillin/streptomycin. HEK293FT cells were cultured in D-MEM
(Invitrogen) full medium containing 10% (v/v) fetal calf serum, 50 units/ml peni-
cillin/streptomycin, 1% (v/v) non essential amino acids (Invitrogen) and 4 ￿g/ml
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Drug treatment. Cells were incubated for the indicated time period with 50 ￿M
forskolin, 50 ￿M H89, 50 ￿M cell-permeable Ht31 (InCELLectﬁ AKAP St-Ht31 in-
hibitor peptide (Promega, Madison, WI, USA)), 50 ￿M of the cell permeable Ht31
inactive control peptide (InCELLectﬁ St-Ht31P (Promega)), 5 or 20 ￿M stearated
superAKAP-IS (kindly provided by B. Penke, University of Szeged, Hungary), 1,
5 or 20 ￿M 5,6 dichlorobenzi-midazole-riboside-3',5'-cyclic monophosphoro-thioate
Sp-isomer (Sp-5,6-DCl-cBIMPS), or 5, 10, 50 or 100 ￿M 8-(4-chlorophenylthio)-2'-
O-methyl cyclic AMP (8-pCPT-2Me-cAMP (BioLog, Lifescience Institute, Bremen,
Germany)). The nal concentration of dimethyl sulfoxide in all experiments was
less than 0.5% (v/v). Dimethyl sulfoxide solvent itself had no eect on PKB/Akt
phosphorylation (data not shown).
Protein analysis. Primary cortical neurons or HT-4 cells, which were grown in a
6 well plate, were washed twice with ice cold phosphate-buered saline (PBS) and
subsequently lysed by the addition of 0.15 ml lysis buer 20 mM Tris, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton, 2.5 mM sodium pyrophosphate, 1 mM
sodium orthovanadate and complete mini protease inhibitor cocktail tablet (Roche
Diagnostics, Basel, Switzerland). The samples were centrifuged at 9000g for 10 min
at 4 ￿ and the supernatant boiled for 5 min in Laemmli's sample buer. Twenty ￿g
of total protein was separated by 10% SDS-polyacrylamide gel electrophoresis. After
transfer to a PVDF transfer membrane (Millipore Corporation, Billerica, MA, USA)
proteins were linked with primary antibodies overnight at 4 ￿. Primary antibodies
used were a rabbit polyclonal antibody specic for total PKB/Akt (9272, Cell Signal-
ing, Danvers, MA, USA, 1:2000 dilution), p-Akt (Ser473, 9271, Cell Signaling, 1:2000
dilution), C-terminal AKAP150 C20 (sc-6445, Santa Cruz, CA, USA, 1:2000 dilu-
tion) N-terminal AKAP150 antibody N-19 (sc-6446, Santa Cruz, CA, USA, 1:1000
dilution), Epac1 (1:10000 dilution for Western blot), Epac2 (1:10000 Western blot),
PKA RII (610625, BD Biosciences, Franklin Lakes, NJ, USA, 1:3000 dilution),
PKB/Akt1 (5919, Abcam, Cambridge, UK, 1:2000 dilution), PKB/Akt2 (5920,
Abcam, 1:2000 dilution), PKB
/Akt3 (5922, Abcam, 1:2000 dilution) and a mono-
clonal mouse antibody specic for actin as internal standard (MP Biomedicals, Irvine,
CA, USA, 1:100000 dilution). Phosphorylation of PKB/Akt was evaluated as the ra-
tio of p-Akt Ser473/ total Akt. Actin was used as an internal control to correct for
variations in protein content. The blots were incubated with alkaline phosphatase-
conjugated goat anti-mouse (Applied Biosystems, Bedford, MA, USA, 1:10000 dilu-
tion) or alkaline phosphatase-conjugated goat anti-rabbit (Applied Biosystems, Bed-
ford, MA, USA, 1:10000 dilution). Proteins were detected with an enhanced chemolu-
miniscence detection system (Nitroblock II and CDP-Star, Applied Biosystems, Bed-
ford, MA, USA) according to the manufacturer's instructions (Applied Biosystems,
Bedford, MA, USA). Integrated optical densities (IOD) were measured by the Leica
DFC 320 Image Analysis System (Leica, Cambridge, UK) and densitometric analysis
was evaluated by the Leica Qwin program. Quantication of IOD was performed only46 AKAP150-PKA-Epac2 complex
in images in which saturation of the signal had not occurred. IOD measurements were
corrected for background intensity.
Rap activation assay. GTP-loading of Rap1 and Rap2 was performed by glu-
tathione S-transferase fusion of the Rap1 and Rap2-binding domain of RalGDS (GST-
RalDGS). Cells were grown to 70% con
uence, then incubated in minimal serum
medium (1% (v/v)) for 24 h. Cells were incubated with 50 ￿M forskolin or 50 ￿M
8-pCPT-2Me-cAMP for 10 min. Activation of Rap was terminated by washing twice
with cold PBS. Cells were lysed with 10% (v/v) glycerin, 1% (v/v) Nonidet-P40, 50
mM Tris-HCl (pH 7.5), 200 mM NaCl, 2 mM MgCl2, 0.2 mM -glycerolphosphate,
1 mM phenylmethylsulfonyl 
uoride and complete mini protease inhibitor cocktail
tablet (Roche Diagnostics). Following a short centrifugation at 3000g for 5 min, the
supernatants were incubated with 15 ￿g of GST-RalGDS at 4 ￿ for 2 h with gentle
agitation. The beads were washed 3 times with lysis buer and then treated with
30 ￿l of SDS-sample buer. 20 l of protein sample was separated by 10% (v/v)
SDS-polyacrylamide gel electrophoresis and probed with specic Rap1 (Santa Cruz,
1:5000 dilution) and Rap2 (Santa Cruz, 1:5000 dilution) antibodies.
Confocal microscopy. Cortical neurons were grown on PDL-coated coverslips for
6 days. Subsequently, they were xated with 4% paraformaldehyde in PBS (pH
7.4) at 4 ￿. Neurons were permeabilized with 0.2% TritonX-100/PBS and blocked
with 10% (v/v) normal donkey serum (NDS) and 2% (v/v) bovine serum albumin
(BSA) in PBS for one hour at room temperature. Slices were incubated overnight
at 4 ￿ with antibodies raised against total PKB/Akt (1:1000 dilution), C-terminal
AKAP150 (1:750 dilution), Epac1 (1:750 dilution), Epac2 (1:750 dilution) or PKA
(1:750 dilution). The next day, cells were incubated with secondary antibodies (Alexa
488, 555 and 633, Invitrogen, 1:500 dilution). For mounting we used PreLong Gold
(Invitrogen). The confocal images were analyzed with a Leica TCS SP2 confocal
microscope using an Ar/ArKr laser (488 nm) or a HeNe laser (543 and 633 nm). To
avoid overlap in emission spectra we used sequential scanning by frame.
Immunoprecipitation. Lysed cell homogenates containing 20 mM Tris, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton, 2.5 mM sodium pyrophosphate,
1 mM sodium orthovanadate and complete mini protease inhibitor cocktail tablet
(Roche) were used for AKAP150, Epac1, Epac2, PKA, PKB/Akt and uncoupled IgG
immunoprecipitation. Per sample 100 ￿l of Dynabeads protein A (Dynal Biotech,
Oslo, Norway) was washed twice with Na-phosphate buer (0.1 M, pH 8.1). Ten
￿g of antibody was incubated with the beads for 10 min. Afterwards, the beads
were washed three times with Na-phosphate buer (0.1 M, pH 8.1) and twice with
triethanolamine (0.2 M). IgGs were crosslinked with dimethyl pimelimidate (20 mM
in 0.2 M trietholamine) for 30 min. The beads were washed for 15 min with Tris
(50 mM, pH 7.5) and three times with PBS. Unbound IgG was removed by washing3.2. Materials and Methods 47
twice for 30 min with Na-citrate (0.1 M, pH 2-3). 500 ￿g of protein sample was
incubated for 1 h with the beads. Bound proteins were eluted with Na-citrate (0.1
M, pH 2-3). pH of the eluted sample was equilibrated by 0.5 M Na-phosphate buer
with pH 8.1. All the steps of the immunoprecipitation procedure were performed at
room temperature. The immunoprecipitated sample was stored at  80 ￿ until use
for protein analysis.
siRNA experiments. siRNA probes targeted to either Epac1 or Epac2 were pur-
chased from Dharmacon (Dharmacon, Inc. Lafayette, CO, USA). The target se-
quences for the mouse-specic Epac1 siRNAs mixture were as follows: sense: GA-
ACGUAUCUCCUCAGACCUU (D-057800-01), sense: CGUGGUACAUUAUCUG-
GAAUU (D-057800-02), sense: GGUCAAUUCUGCCGGUGAUUU (D-057800-03),
sense: CGACACCACAGGUUGGAAAAUU (D-057800-04) and for the Epac2 siRNA
mixture: sense: GUACGGCAAAUUAAAUGUGAUU (D-057784-01), sense: CAAGU-
UAGCUCUAGUGAAACUU (D-057784-02), sense: ACGACGAGCUCCUUCAUAU-
UU (D-057784-03), sense: GGAU-GCCGCUGAAGCUAAUUU (D-057784-04). A
scrambled siRNA probe was used as a control in all siRNA transfection experiments.
Primary cortical neurons were transfected with siRNAs using the Amaxa nucleofec-
tor technology (Amaxa, Cologne, Germany). Cells were cultured for 4 days after
nucleofection, treated, lysed and subsequently analyzed for protein content.
HT-4 cell lines expressing wild-type AKAP150 or AKAP150PKA. For
the generation of HT-4 cell lines expressing wild-type AKAP150 or AKAP150PKA,
the lentiviral expression system from Invitrogen was used. In short, AKAP150 or
AKAP150PKA (706-729) cDNA was cloned into the destination vector pLenti6/
UBC/V5DEST. HEK293FT cells were transfected with the destination vector and
an optimized mixture of the three packaging plasmids, pLP1, pLP2, and pLP/VSVG
using calcium precipitation. Viral particles were harvested 40 h post-transfection and
added to HT-4 cells for infection. Blasticidin was used for the selection of infected
cells according to the manufacturer's recommendations.
Statistical analysis. Results shown represent mean S.E.M. Statistical analysis
was performed by Statistical Package for the Social Science (SPSS) program. The
One-Sample T-Test was used to check whether the mean of a single variable diers
from their appropriate control samples. These tests were followed by Univariate
Analysis of Variance and one-way ANOVA LSD post-hoc program. P values of < 0:05
were considered to be signicant.48 AKAP150-PKA-Epac2 complex
3.3 Results
3.3.1 Opposing eects of PKA and Epac on PKB/Akt phosphorylation
in primary cortical neurons.
PKB/Akt is activated through phosphorylation of the Ser473 and Thr308 sites
(Lawlor and Alessi, 2001; Franke et al., 1997). In this study we focussed on phos-
phorylation of the Ser473 site but preliminary data showed that phosphorylation at
the Thr308 site is regulated in a similar way (data not shown). Initially, we exam-
ined the temporal kinetics of the adenylate cyclase activator, forskolin, on PKB/Akt
phosphorylation. Forskolin reduced PKB/Akt phosphorylation at the Ser473 site in
a time-dependent manner (Fig. 3.1(a)). Since 10 min of forskolin treatment already
resulted in a strong decrease of PKB/Akt phosphorylation, this time-point was taken
to investigate the concentration-dependent eect of the specic PKA activator Sp-
5,6-DCl-cBIMPS on PKB/Akt phosphorylation. Sp-5,6-DCl-cBIMPS treatment for
10 min resulted in decreased PKB/Akt phosphorylation similar to forskolin treatment
(Fig. 3.1(b)). In contrast, inhibition of PKA by H89, increased PKB/Akt phospho-
rylation in a time-dependent manner (Fig. 3.1(c)).
To investigate the eect of Epac activation on PKB/Akt phosphorylation, we rst
checked for the endogenous expression of Epac1 and Epac2 in primary cortical neu-
rons. Both Epac1 and Epac2 were found to be expressed in primary cortical neurons
(Fig. 3.2(a)). Treatment with forskolin or 8-pCPT-2Me-cAMP led to increased GTP-
loading of Rap1 and Rap2, the main downstream eectors of Epac (Fig. 3.2(b) and
(c)). Interestingly, PKB/Akt phosphorylation was increased by 8-pCPT-2Me-cAMP
in a time- and concentration- dependent manner (Fig. 3.2(d) and (e)). Under the
same experimental conditions, the highest concentration of 8-pCPT-2Me-cAMP used
(100 ￿M) did not induce phosphorylation of the PKA specic eector CREB (data
not shown). To validate whether Rap activation is an intermediate step in Epac-
induced PKB/Akt phosphorylation we treated neurons with toxin B-1470, which is
known to inactivate the main Epac eector Rap (Schmidt et al., 1998). 8-pCPT-2Me-
cAMP-induced PKB/Akt phosphorylation was completely blocked by toxin B-1470
treatment (Fig. 3.2(f)). Toxin B-1470 treatment reduced PKB/Akt phosphorylation
even under unstimulated conditions (Fig. 3.2(f)).
The role of Epac1 and Epac2 in Epac-induced phosphorylation of PKB/Akt was
studied using specic siRNA probes. Epac1 and Epac2 siRNA probes reduced Epac1
and Epac2 expression by 42.1% and 53.2%, respectively, when compared to control
samples. Scrambled siRNA did not signicantly aect Epac1 and Epac2 expression
(Fig. 3.3(a) and (b)). Pretreatment with Epac1 partially attenuated the 8-pCPT-
2Me-cAMP-induced increase in PKB/Akt phosphorylation, whereas pretreatment
with Epac2 siRNA completely blocked the eect of 8-pCPT-2Me-cAMP on PKB/Akt
phosphorylation (Fig. 3.3(c)).
3.3.2 Epac and PKB/Akt are complexed to AKAP150.
Using confocal microscopy we assessed the subcellular localization of AKAP150,3.3. Results 49
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Figure 3.1: PKA activation negatively regulates PKB/Akt phosphorylation in cortical
neurons. Forskolin (a) and H89 (c) were applied for the indicated time periods on cortical neurons.
(b) A specic PKA activator Sp-5,6-DCl-cBIMPS (BIMPS) was applied in dierent concentrations
for 10 min. Representative immunoblots are shown below the quantied data of PKB/Akt phos-
phorylation at the Ser473 site ( p473-Akt) analyzed from three separate experiments. The bars
indicate the mean S.E.M. of IOD of protein bands corresponding to  p473-Akt as percentage of
total PKB/Akt (depicted as total Akt) (Univariate Analysis of Variance and LSD test, p < 0:05
versus non-treated neurons).50 AKAP150-PKA-Epac2 complex
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Figure 3.2: Epac activator 8-pCPT-2Me-cAMP increases PKB/Akt phosphorylation
in cortical neurons. (a) Representative immunoblots of Epac1 and Epac2 expression in cortical
neurons. (b) & (c). Neurons were treated with forskolin or 100 ￿M 8-pCPT-2Me-cAMP for Rap1
(b) and Rap2 (c) pull-down assays. Untreated cells served as controls. GTP-bound Rap1 ( GTP-
Rap1) and GTP-bound Rap2 ( GTP-Rap2) pulled down by a GST immunoprecipitation and total
Rap1/Rap2 were detected by Western blot. (d) & (e). 8-pCPT-2Me-cAMP was applied for the
indicated concentrations (d) and time periods (e) on cortical neurons and PKB/Akt phosphorylation
assessed. (f) Neurons were treated with Toxin B-1470 for 3 h. Where indicated, this treatment was
followed by an incubation of 100 ￿M 8-pCPT-2Me-cAMP for 10 min. Representative immunoblots
are shown below the quantied data analyzed from at least three separate experiments (mean –SEM,
LSD test, p < 0:05 versus indicated neurons).3.3. Results 51
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Figure 3.3: Silencing of Epac1 and Epac2 decreases PKB/Akt phosphorylation. Primary
cortical neurons were transfected with specic Epac1 siRNA (a), Epac2 siRNA (b) or with scrambled
siRNA. After 4 days, where indicated, neurons were treated with 100 ￿M 8-pCPT-2Me-cAMP for
10 min. (c) Cortical lysates were analyzed for PKB/Akt phosphorylation at the Ser473 site (
p473-Akt). Cortical neurons electroporated without siRNA served as additional controls to scramble
siRNA (LSD test, n = 3, p < 0:05 versus indicated neurons).
PKA, PKB/Akt, Epac1 and Epac2 in primary cortical neurons (Fig. 3.4). Be-
sides PKA, AKAP150 appeared to be co-localized with PKB/Akt, Epac1 and Epac2
(Fig. 3.4). Interestingly, AKAP150 immunoreactivity showed more overlap with
Epac2 than Epac1. Co-immunoprecipitation studies conrmed that PKA, PKB/Akt
and Epac2 indeed bind to AKAP150, whereas Epac1 could not be detected (Fig. 3.5(a)).
Moreover, we found all three mammalian isoforms of PKB/Akt: PKB/Akt1,
PKB/Akt2 and PKB
/Akt3 (Fayard et al., 2005) to be complexed to AKAP150
(Fig. 3.5(a)). Experiments with control-IgG resulted in no detectable bands for
AKAP150, PKA, PKB/Akt or Epac2 proteins (data not shown).
Next, we assessed whether Epac activation led to phosphorylation of PKB/Akt
bound to AKAP150. Cortical neurons were treated with 8-pCPT-2Me-cAMP, fol-
lowed by immunoprecipitation of AKAP150-bound PKB/Akt with an antibody di-
rected against AKAP150. Activation of Epac by 8-pCPT-2Me-cAMP increased phos-
phorylation of PKB/Akt bound to AKAP150 already at early time points (Fig. 3.5(b)).52 AKAP150-PKA-Epac2 complex
Figure 3.4: AKAP150 co-localizes with PKA, PKB/Akt and Epac1 and Epac2 in cul-
tured cortical neurons. Cultured cortical neurons were xated, permeabilized and stained with
anti-AKAP150 antibody coupled to Alexa 633, anti-PKA, anti-Epac1/2 antibodies coupled to Alexa
488 and anti-PKB/Akt antibody coupled to Alexa 555 as indicated in the respective panels. Images
were collected from stained neurons by confocal microscopy and merged in the respective color image.
In the colocalization panels, the overlap between AKAP150 and PKA, PKB/Akt, Epac1 and Epac2
is shown. Scale bar, 10 ￿m.
3.3.3 AKAP150 balances PKA and Epac activation to regulate PKB/Akt
phosphorylation.
To investigate the role of AKAP150 in the regulation of PKB/Akt phosphoryla-
tion in more detail, we generated HT-4 cells overexpressing wild-type AKAP150 or3.3. Results 53
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Figure 3.5: PKA, Epac2 and PKB/Akt bind AKAP150. (a) Co-immunoprecipitation studies
were performed using antibodies directed against PKB/Akt and AKAP150, respectively. Pulled down
fractions (IP) were tested in Western blot (WB) using antibodies for the detection of AKAP150,
PKA, total PKB/Akt (presented as total Akt), PKB/Akt1, PKB/Akt2, PKB
/Akt3, Epac1 and
Epac2. As a negative control we used uncoupled rabbit IgG antibody. The rst row represents 10-20
￿g of total input from primary cortical neurons lysates as a positive control. Interrupted membranes
are due to dierences in exposure time to detect the protein of interest. (b) The AKAP150 complex
was precipitated from untreated control neurons and neurons treated with 100 ￿M 8-pCPT-2Me-
cAMP for the indicated time periods. Afterwards PKB/Akt phosphorylation was detected by Western
blot. Representative immunoblots are shown below the quantied data of p473-Akt expression. The
bar graphs represent the ratio between IOD of p473-Akt versus AKAP150 expression (LSD test,
n = 3, p < 0:05 versus non-treated neurons).
AKAP150 lacking the PKA-binding domain (AKAP150PKA). Although endoge-
nous AKAP150 could not be detected in unmodied HT-4 cells, AKAP150 could
be detected in HT-4 cells overexpressing AKAP150 or AKAP150PKA, using an
AKAP150 antibody directed against the N-terminal part of the protein (Fig. 3.6(a)).
The nding that AKAP150PKA is not detectable with an C-terminal AKAP150
antibody conrms that this mutated protein lacks the PKA binding site, since this
binding site is located at the C-terminal end of the protein (Fig. 3.6(a)). Deletion of
the PKA binding site in AKAP150PKA was supported by co-immunoprecipitation
experiments. AKAP150 was bound to PKA in HT-4 cells transfected with wild-
type AKAP150, but PKA binding was signicantly reduced in HT-4 cells expressing
AKAP150PKA (Fig. 3.6(a)).
HT-4 cells also expressed Epac1 and Epac2 (Fig. 3.6(b)). Similar to our ndings
in primary cortical neurons (Fig. 3.2(c)), forskolin and 8-pCPT-2Me-cAMP treatment54 AKAP150-PKA-Epac2 complex
led to Rap1 activation in HT-4 cells (Fig. 3.6(c)). Importantly, HT-4 cells transfected
with AKAP150PKA showed signicantly higher basal Rap1 activation than HT-4
cells expressing wild-type AKAP150 (Fig. 3.6(d)). These ndings were paralleled by
enhanced basal PKB/Akt phosphorylation in HT-4 cells expressing AKAP150PKA
compared to phosphorylation levels in HT-4 cells overexpressing wild-type AKAP150
(Fig. 3.6(e)). Interestingly, overexpression of wild-type AKAP150 in HT-4 cells al-
ready led to increased PKB/Akt phosphorylation, when compared to PKB/Akt phos-
phorylation levels in unmodied HT-4 cells (Fig. 3.6(e)).
Further evidence for a coordinative function of AKAP150 in PKB/Akt signaling
came from studies with cortical neurons that were treated with cell-permeable Ht31,
a peptide known to disrupt the binding of PKA to AKAPs (Vijayaraghavan et al.,
1997). Similar to PKA inhibition by H89, treatment of the cells with Ht31 signi-
cantly increased PKB/Akt phosphorylation (Fig. 3.7(a)), whereas its control peptide
did not alter this neuronal response (Fig. 3.7(b)). Since AKAP150 was found to be
mainly bound to PKA regulatory subunit RII (Hausken et al., 1996), we also treated
neurons with cell permeable superAKAP-IS. Whereas Ht31 has the potential to dis-
rupt RII but also some PKA-RI anchoring (Herberg et al., 2000), superAKAP-IS is
a peptide that is 10000-fold more selective for the RII isoform relative to RI (Gold
et al., 2006). SuperAKAP-IS treatment also led to a signicant increase in PKB/Akt
phosphorylation (Fig. 3.7(c)). Finally, treatment of cortical neurons with Ht31 led to
increased activation of the Epac eector Rap1 when compared to untreated neurons
(Fig. 3.7(d)). This suggests that inhibition of PKA-binding to AKAP150 redirects
cAMP signaling in cortical neurons to Epac-mediated Rap1 activation.
To investigates whether inhibition of PKA to AKAPs indeed promotes Epac-
induced phosphorylation of PKB/Akt bound to AKAP150, cortical neurons were
treated with superAKAP-IS, followed by immunoprecipitation of the AKAP150 com-
plex with an antibody directed against AKAP150. As expected, treatment with
superAKAP-IS reduced the amount of PKA bound to AKAP150 in comparison to
untreated neurons (Fig. 3.8). Most importantly, disrupting PKA binding to AKAP150
increased the amount of Epac2 bound to AKAP150 and enhanced PKB/Akt phos-
phorylation bound to AKAP150 (Fig. 3.8).
3.4 Discussion
cAMP is a ubiquitous mediator of intracellular signaling events. For many years,
it was thought to act principally through stimulation of PKA. However, the discovery
of Epac proteins as additional cAMP eectors dramatically altered this cAMP-PKA
dogma and opened up new opportunities to further dissect the divergent roles that
cAMP exerts. It is now generally assumed that AKAPs play a central role in in-
tracellular targeting and compartmentalization of diverse cAMP-dependent signaling
events (Task en and Aandahl, 2004; Wong and Scott, 2004).
Recent studies indicated that cAMP-dependent signaling is closely interwoven3.4. Discussion 55
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Figure 3.6: AKAP150 coordinates PKA/Epac signaling in neuronal HT-4 cells. (a)
AKAP150 protein expression was checked in unmodied HT-4 cells and HT-4 cells overexpressing
wild-type AKAP150 or AKAP150PKA using antibodies against the C-terminal or N-terminal end
of the protein. Co-immunoprecipitation studies were performed using the N-terminal AKAP150
antibody. (b) Expression of Epac1 and Epac2 in HT-4 cells. (c) HT-4 cells treated with forskolin
or 100 ￿M 8-pCPT-2Me-cAMP were used for a Rap1 pull-down assay. Untreated cells served as
controls. GTP-bound Rap1 ( GTP-Rap1) pulled down by a GST immunoprecipitation and total
Rap1 were detected by Western blot. (d) Rap1 expression analyzed from unmodied HT-4 cells
and HT-4 cells overexpressing wild-type AKAP150 or AKAP150PKA (T test, n=3, p < 0:05
versus HT-4 cells overexpressing wild-type AKAP150). Representative immunoblots are shown at
the lower part of the quantied data. (e) Quantication and representative immunoblots of PKB/Akt
phosphorylation in unmodied HT-4 cells and HT-4 cells overexpressing wild-type AKAP150 or
AKAP150PKA (T test, n = 3, p < 0.01 versus unmodied HT-4 cells).56 AKAP150-PKA-Epac2 complex
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Figure 3.7: Disrupting PKA binding to AKAPs increases PKB/Akt phosphorylation.
(a) Cortical neurons were incubated with Ht31 for the indicated time periods. Representative im-
munoblots are shown below the quantied data of PKB/Akt phosphorylation at the Ser475 site (
p473-Akt) analyzed from three separate experiments (LSD test, p < 0:05 versus non-treated neu-
rons). (b) Cortical neurons were incubated with Ht31 control peptide for the indicated time periods.
Representative immunoblots are shown below the quantied data of PKB/Akt phosphorylation at
the Ser475 site ( p473-Akt) analyzed from three separate experiments (T test, p < 0:05 versus
non-treated neurons). (c) Cortical neurons were incubated with 5 or 20 ￿M of superAKAP-IS for
10 minutes. Representative immunoblots are shown below the quantied data of PKB/Akt phospho-
rylation at the Ser475 site ( p473-Akt) (LSD test, n = 3, p < 0:05 versus non-treated neurons).
(d) Non-treated neurons or Ht31-treated cortical neurons were analyzed for Rap1 activation. GTP-
bound Rap1 ( GTP-Rap1) and total Rap1 were detected by Western blot (LSD test, n=3, p < 0:05
versus non-treated neurons).3.4. Discussion 57
with the phosphatidylinositol 3-kinase (PI3K)/PKB/Akt pathway (Cui and So, 2004).
PKB/Akt is of tremendous importance for several neuronal key signaling events, in-
cluding cell dierentiation, proliferation and survival (Kim et al., 2004). We reported
before that PKB/Akt is able to activate NF-B and therefore to induce anti-apoptotic
signals in primary cortical neurons (Marchetti et al., 2004; Dolga et al., 2008) and
that in neuronal tissue PKB/Akt is instrumental in neuroprotective signaling upon
ischemia/reperfusion (Fontaine et al., 2002). Neuronal survival and axonal regenera-
tion mediated by PI3K-dependent PKB/Akt signaling were shown to be induced by
elevated cAMP levels (Cui and So, 2004). Interestingly, PI3K-dependent PKB/Akt
signaling activated in response to elevated cAMP is also required for the expression
of long term potentiation (LTP) in the hippocampal CA1 region (Lin et al., 2001;
Sanna et al., 2002), and has been even implicated in memory consolidation in fear
conditioning (Sweatt, 2001). In contrast, the classical counter regulator of PKB/Akt
signaling, the phosphatase PTEN, seems to be important for the induction of long
term depression (Wang et al., 2006). Most of the observed eects are thought to
be mediated by PKA; however, a role of Epac can in some cases not be excluded.
For example, glutamatergic NMDA receptor functions are modulated in a cAMP and
PI3K-dependent manner through PKB/Akt in cerebellar granule cells. Based on the
ndings that four dierent PKA inhibitors did not aect cAMP-dependent NMDA
receptor functions, Epac has been implicated to play a role in this scenario (Llansola
et al., 2004; S anchez-P erez et al., 2006). Furthermore, an upregulation of cAMP sig-
naling pathways in parallel to increased activation of PKB/Akt (Grin et al., 2005)
has also been associated with the pathophysiology of Alzheimer's disease (Mart nez
et al., 1999). Interestingly, it was also reported that the expression levels of both
Epac1 and Epac2 are altered in brain regions that are predominantly aected in
Alzheimer's disease (McPhee et al., 2005). Thus, several lines of evidence point to
concerted mechanisms in neuronal cellular actions, involving cAMP-driven eector
proteins and PKB/Akt signaling but at present the precise role that PKA and Epac
play in these processes remains unclear.
Here we report for the rst time the role of the two cAMP-regulated eector pro-
teins PKA and Epac on PKB/Akt phosphorylation in cortical neurons and hippocam-
pal neuron derived HT-4 cells. An interconnectivity of these two cAMP-dependent
eector proteins and PKB/Akt signaling has been reported before in non-neuronal
cells (Mei et al., 2002). We demonstrate that the signaling properties of PKB/Akt
are profoundly altered in a reciprocal fashion upon activation of PKA and Epac, re-
spectively. After treatment of the cells with the adenylate cyclase activator, forskolin,
and the specic PKA activator, Sp-5,6-DCl-cBIMPS, we found a strong inhibition
of PKB/Akt phosphorylation, whereas inhibition of PKA yielded the opposite ef-
fect. Interestingly, activation of Epac mimicked the eect of PKA inhibition on the
PKB/Akt response, an eect being paralleled by activation of Rap proteins. Forskolin
is expected to activate both PKA and Epac, and therefore such a scenario is expected
to result in a rather neutral eect on PKB/Akt phosphorylation. The results pre-58 AKAP150-PKA-Epac2 complex
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Figure 3.8: SuperAKAP-IS increases the phosphorylation of PKB/Akt bound to
AKAP150. The AKAP150 complex was precipitated with the C-terminal AKAP150 antibody from
homogenates of non-treated control neurons and neurons treated with 20 ￿M superAKAP-IS for
10 min. Afterwards AKAP150, PKB/Akt, p473-Akt and PKA were detected by Western blotting.
(a) Representative immunoblots. Interrupted membranes are due to dierences in exposure time
to detect the protein of interest. (b) Quantication of AKAP150, PKA, p473-Akt/Akt expression
in untreated- and superAKAP-IS-treated neurons. Precipitation with control IgG did not show any
bands (LSD test, n = 2, p < 0:05 versus indicated neurons).
sented, however, point strongly to an inhibitory eect of forskolin via PKA activation
towards PKB/Akt activation in cortical neurons and HT-4 cells. The molecular mech-
anisms underlying the distinct eects of PKA and Epac on PKB/Akt phosphorylation
are currently under investigation.
Signicant support for a coordinative role of AKAPs in the integration of the two
distinct cAMP eector pathways, PKA and Epac, came from studies in neonatal rat
cardiomyocytes. A cAMP-responsive multiprotein complex, maintained by mAKAP
including PKA and Epac1, was recently identied and reported to be functional in
sensing and transmitting local cAMP 
uctuations (Dodge-Kafka et al., 2005). To
date, only mAKAP was reported to associate with both PKA and Epac. However,
AKAP150 might also represent a suitable candidate to coordinate distinct cAMP-
driven signaling routes in neuronal cells. AKAP150 was found to be widely expressed
throughout the brain especially in those brain areas that are known to be involved in
learning and memory (Ostroveanu et al., 2007). We and others recently found sup-
port for an important role of this anchoring kinase in learning and memory (Moita
et al. (2002); Nijholt et al. (2007); Nijholt et al. (2008)). This multi-enzyme signaling3.4. Discussion 59
complex was also reported to coordinate changes in synaptic structure and receptor
signaling functions underlying synaptic plasticity (Dell'Acqua et al., 2006). It was
shown that synaptic anchoring of PKA through association with AKAP150 is impor-
tant in the regulation of AMPA receptor surface expression and synaptic plasticity
(Snyder et al., 2005). Similarly Rap GTPases also have been shown to be involved
in AMPA receptor tracking during synaptic plasticity (Zhu et al. (2002); Zhu et al.
(2005)).
The main conclusion from the present study is that neuronal AKAP150 specically
interacts with PKA, PKB/Akt and Epac. As such, we dene a novel cAMP-responsive
multiprotein complex in neuronal cells, maintained by AKAP150 that includes PKA
and Epac, and that nally determines the neuronal PKB/Akt response. Several lines
of evidence support this notion. First, the eect of PKA inhibition on Epac-mediated
Rap activation and PKB/Akt phosphorylation were mimicked upon expression of the
PKA-binding decient AKAP150 mutant and by the AKAP inhibitory peptides Ht31
and superAKAP-IS. Under conditions where PKA is not able to bind AKAP150,
Epac2 binding to AKAP150 is enhanced and Rap activated. This may lead to the
observed increase in phosphorylation of PKB/Akt bound to AKAP150. Second, the
association of both PKA and Epac to AKAP150 clearly indicates that the two cAMP-
dependent signaling pathways are physically linked to the AKAP150 complex. Finally,
the immunoprecipitation studies clearly showed that PKB/Akt bound to AKAP150
is rapidly phosphorylated upon Epac activation.
Interestingly, co-immunoprecipitation experiments showed that Epac2 is bound to
AKAP150, whereas Epac1 could not be detected. Similar, the results from the confo-
cal colocalization studies also pointed towards a stronger overlap between AKAP150
and Epac2. Pretreatment with Epac2 siRNA also completely blocked the Epac-
induced PKB/Akt phosphorylation, whereas the eect of Epac1 siRNA pretreatment
was weaker. Thus, it is tempting to attribute neuronal PKB/Akt activation mainly to
Epac2. Indeed, as shown herein Epac driven phosphorylation of PKB/Akt was dimin-
ished upon silencing of Epac2. However, silencing of Epac1 also blocked Epac-induced
PKB/Akt phosphorylation. Therefore, a role of Epac1 in Epac-induced PKB/Akt
phosphorylation cannot be completely ruled out. The low detection level of Epac1
in the co-immunoprecipitation and confocal experiments may merely be the eect of
lower Epac1 antibody anity. Until now, at least to our knowledge, Epac2 has been
specically attributed to the regulation of insulin secretion in pancreatic -cells (Bos,
2006). Association of mAKAP with Epac1 modulates neonatal rat cardiomyocyte
responses upon inhibition of extracellular signal-regulated kinase signaling (Dodge-
Kafka et al., 2005). The data reported herein indicate that association of AKAP150
with Epac2 modulates neuronal responses upon stimulation of PKB/Akt signaling.60 AKAP150-PKA-Epac2 complex
3.5 Conclusion
We report here on a novel molecular link between neuronal AKAP150, PKA,
PKB/Akt and Epac, and provide evidence that these two cAMP-dependent eectors
exert a reciprocal eect on neuronal PKB/Akt signaling. By modulation of PKB/Akt
signaling, known to regulate many early and late neuronal functions, ranging from cell
dierentiation, proliferation, and survival to an essential role in learning and memory
processes (Brazil et al., 2004), cAMP-regulated and AKAP150-coordinated PKA and
Epac most likely control essential neuronal functions.
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Abstract
Previous studies have shown that TNF- induces neuroprotection against exci-
totoxic damage in primary cortical neurons via sustained NF-B activation. The
transcription factor NF-B can regulate the expression of small conductance calcium-
activated potassium (SK) channels. These channels reduce neuronal excitability and
as such may yield neuroprotection against neuronal overstimulation. In the present
study we investigated whether TNF--mediated neuroprotective signaling is induc-
ing changes in the expression of SK channels. Interestingly, the expression of SK2
channel was up-regulated by TNF- treatment in a time-dependent manner whereas
the expression of SK1 and SK3 channels was not altered. Furthermore, activation of
SK channels by NS309 or CyPPA induced neuroprotection against a glutamate chal-
lenge and inhibition of SK channels with apamin reverted the neuroprotective eect
elicited by TNF-. The increase in SK2 channel expression after TNF- treatment
was shown to be NF-B-dependent since the NF-B inhibitor BAY11-7082 blocked
the TNF--induced increase in SK2 channel expression. We conclude that treatment
of primary cortical neurons with TNF- leads to increased SK2 channel expression
which renders neurons more resistant to excitotoxic cell death.4.1. Introduction 67
4.1 Introduction
TNF- is a proin
ammatory cytokine involved in a wide range of cellular re-
sponses including in
ammation, cellular dierentiation and apoptosis. TNF- per
se can be synthesized and released in the brain by several types of cells, including
astrocytes, microglia and neurons. TNF- was shown to be upregulated in a num-
ber of neurodegenerative disorders including Alzheimer's disease, stroke and multiple
sclerosis. It exerts its biological functions through the stimulation of two receptors,
TNF-R1 and TNF-R2. Both TNF-R1 and TNF-R2 induce activation of the NF-B
pathway (Marchetti et al., 2004; Eisel et al., 2006). However, the activation kinetics of
NF-B stimulation reveals characteristic dierences: while activation of the TNF-R1
pathway leads to a transient NF-B stimulation (rst 20-40 min during 24 h TNF-
treatment), TNF-R2 signaling promotes persistent and long lasting NF-B activation
(persisting even after 24 h of TNF- treatment) (Marchetti et al., 2004).
Several studies showed that TNF- is able to promote neuroprotection against
glutamate-induced excitotoxicity in cortical neurons (Cheng et al., 1994; Marchetti
et al., 2004; Barger et al., 1995). Until now, the molecular mechanisms underlying
the neuroprotective eects of TNF- against glutamate-induced excitotoxicity are
largely unknown but at least PKB/Akt activation and subsequent sustained NF-B
activation were shown to play a major role (Marchetti et al., 2004).
In a recent study, small conductance Ca2+ activated potassium (SK) channels were
identied as one of the downstream targets of NF-B mediated promoter regulation
(Kye et al., 2007). SK channels are important regulators of neuronal excitability.
These channels are voltage insensitive, but open in response to low (< 1 ￿M) intra-
cellular Ca2+ levels. In many central nervous system neurons, SK channel activity
dampens excitability by contributing to the afterhyperpolarization, aecting inter-
spike intervals during a burst of action potentials as well as the length of the burst
(reviewed by Stocker (2004)). In the mammalian brain, SK channels are the product
of three paralogous genes, namely SK1, SK2 and SK3 genes. SK1 and SK2 chan-
nel subunits show extensive colocalization. They are mainly found in the entorhinal
cortex, the subiculum, in pyramidal cortical neurons, the CA1 - CA3 region from
the hippocampus and in the thalamus. SK3 channel subunits have a complementary
distribution, and are mainly located in the brain stem and in monoaminergic neurons
(Sailer et al. (2002); Sailer et al. (2004)). In certain neuronal cell types, SK channels
are present at dendritic spines where they co-localise with NMDA receptors. There,
SK channel activity suppresses the amplitude of evoked synaptic potentials by in-
hibiting NMDA receptor-dependent activation (Faber et al., 2005; Lin et al., 2008;
Ngo-Anh et al., 2005). Thus, enhancing SK channel expression during an excitotoxic
insult could be protective due to hyperpolarization and diminished excitability. In an
initial study Lee and colleagues (Lee et al., 2003) showed indeed that overexpression
of SK channels can prevent kainic acid and glutamate-induced excitotoxicity.
In the present study we have tested the hypothesis whether increased SK2 chan-
nel expression is part of the mechanism of TNF- mediated neuroprotection against68 TNF--induced neuroprotection is mediated by SK2 channels
glutamate-induced excitotoxity in cortical neurons.
4.2 Materials and methods
Materials. Neurobasal medium and B27 supplement were purchased from Invit-
rogen (Carlsbad, CA, USA). Complete mini protease inhibitor cocktail tablets were
from Roche (Indianapolis, IN) and mouse TNF- was purchased from HBT (Uden,
The Netherlands). Cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-
yl]-amine (CyPPA) was bought from Specs (Delft, Netherlands). Primary antibod-
ies used to detect SK channels were rabbit anti-SK1, rabbit anti-SK2 (both kindly
provided by H-G. Knaus (Sailer et al., 2004)), and anti-SK3 (APC-025; Alomone
Laboratories, Jerusalem, Israel). For the detection of actin a monoclonal mouse
antibody from MP Biomedicals (691001; Irvine, CA, USA) was used. Alkaline phos-
phatase (AP)-conjugated goat anti-mouse (Applied Biosystems, Bedford, MA, USA)
and AP-conjugated goat anti-rabbit (Applied Biosystems, Bedford, MA, USA) were
used as secondary antibodies. The chemi-luminiscence detection kit (Nitroblock II
and CDP-Star) was purchased from Applied Biosystems (Bedford, MA, USA). Im-
munohistochemical studies were performed using SK2 (LifeSpan Biosciences, Seattle,
WA, USA), NR2B antibodies (BD Transduction Laboratories, Franklin Lakes, NJ,
USA) and Alexa antibodies (Invitrogen, Carlsbad, CA, USA). All other materials
were from Sigma.
Animal experiments. All experiments were performed using C57BL/6J mice (Har-
lan, Horst, The Netherlands). All procedures were in accordance with the regulation
of the Ethical Committee for the use of experimental animals of the University of
Groningen, The Netherlands (Licence number DEC 4048). Mice were housed in stan-
dard macrolon cages and maintained on a 12 h light/dark cycle. They received food
and water ad libitum.
Primary cortical neuron culture. Primary cortical neurons were prepared from
embryonic brains (E15-16) of C57BL/6J mice. The meninges were removed and the
cortical neurons were separated by mechanical dissociation. Cells were plated in a
density of 12104 cells/well (96 well plates) and 2106 cells/well (6 well plates) on
poly-D-lysine pre-coated plates. Neurobasal medium with B27-supplement, 0.5 mM
glutamine, 1% penicillin/ streptomycin and 2.5 ￿g/ml amphotericin B was used as a
culture medium. After 48 h neurons were treated with 10 ￿M cytosine arabinoside
for another 48 h to inhibit non-neuronal cell growth. Subsequently, the medium was
completely exchanged and after 6 days of in vitro culture, the neurons were used for
experiments.
Neurons were incubated for the indicated periods of time with 100 ng/ml mouse
TNF-. Some cortical neurons were incubated with NF-B inhibitor BAY11-70824.2. Materials and methods 69
(10 ￿M). Where indicated, neurons were pre-incubated with NS309 (6,7-dichloro-1H-
indole-2,3-dione 3-oxime) 50 ￿M or CyPPA (with indicated concentrations) for 30 min.
Apamin was used where indicated in a concentration of 20 ￿M. Pilot experiments using
dierent concentrations of apamin showed that, at a concentration of 10 ￿M, apamin
already partially blocked the TNF-mediated neuroprotective eect but the eect was
even stronger when a concentration of 20 ￿M was used. 50 ￿M apamin had a similar
eect as 20 ￿M apamin. The nal concentration of DMSO in all experiments was less
than 0.5% (v/v). In this concentration DMSO had no eect on glutamate-induced
cell death. Excitotoxicity was induced by 1 h treatment with glutamate (50 ￿M).
After treatment, the medium was completely removed and fresh media was added to
the cells.
Confocal microscopy. Cortical neurons were grown on PDL-coated coverslips for
6 days. Neurons were either incubated or not with 100 ng/ml TNF- for 6 h. Sub-
sequently, they were xated with ice-cold methanol for 10 min at 20 ￿. Neurons
were permeabilized with 0.05% TritonX-100 in phosphate-buered saline (PBS) and
blocked with 10% (v/v) normal donkey serum and 2% (v/v) bovine serum albumin
(BSA) in PBS (pH 7.4) for 30 min at room temperature (RT). Slices were incubated
overnight at 4 ￿ with antibodies raised against SK2 (LifeSpan Biosciences, Seat-
tle, WA, USA, 1:500 dilution) and NR2B (BD Transduction Laboratories, Franklin
Lakes, NJ, USA, 1:500 dilution). The next day, cells were incubated with secondary
antibodies (Alexa 488, 555 and 633, Invitrogen, Carlsbad, CA, USA, 1:500 dilution).
For mounting we used PreLong Gold (Invitrogen, Carlsbad, CA, USA). The confocal
images were analysed with a Leica TCS SP2 confocal microscope using an Ar/ArKr
laser (488 nm) or a HeNe laser (543 and 633 nm). To avoid overlap in emission spectra
we used sequential scanning between frames.
Determination of cell viability. 24 h after glutamate treatment neuronal vi-
ability was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl-)2,5-
diphenyltetrazolium bromide) assay as described previously (Mosmann, 1983). 1.25
mg/ml MTT solution was added to each well of a 96 well plate. After 2-4 h of incuba-
tion, cells were lysed by adding 120 ￿l of isopropyl-HCl solution (37% HCl/isopropyl
alcohol: 1/166) for 15 min. The absorbance of each well was determined with an
automated ELISA reader (Bio-Rad, Munich, Germany) at 595 nm with a background
correction at 620 nm.
Protein analysis. Primary cortical neurons from C57BL/6J mice were washed
twice with ice cold PBS after indicated periods of time of TNF- incubation and
subsequently lysed by the addition of 0.15 ml lysis buer (20 mM Tris, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% (v/v) TritonX, 2.5 mM sodium pyrophosphate, 1 mM
sodium orthovanadate and complete mini protease inhibitor cocktail tablet (Roche,
Indianapolis, IN, USA)). The samples were centrifuged at 9000 g for 10 min at 4 ￿70 TNF--induced neuroprotection is mediated by SK2 channels
and the supernatants boiled for 5 min in Laemmli's sample buer. Twenty ￿g of
total protein was separated by 10% SDS-polyacrylamide gel electrophoresis. After
transfer to a PVDF transfer membrane (Millipore Corporation, Billerica, MA, USA)
proteins were linked with primary antibodies overnight at 4 ￿. Subsequently, the blots
were incubated with AP-conjugated secondary antibodies (1:10000). Proteins were
detected with an ECL detection system according to the manufacturer's instructions
(Applied Biosystems, Bedford, MA, USA). Actin (1:100000 antibody dilution) was
used as an internal control to correct for variations in protein content.
Integrated optical densities (IOD) were measured with the Leica DFC 320 Image
Analysis System (Leica, Cambridge, UK) and densitometric analysis was performed
using the Leica Qwin program. Quantication of IOD was done only with images in
which saturation of the signal had not occurred. IOD measurements were corrected
for background intensity.
Statistical analysis. Each experiment was performed with at least two dierent
batches of neurons and MTT and Western blot were repeated at least twice for each
batch. Results are represented as mean SEM. Statistical analysis was performed
by the Student-Neumann test with a 95% condence interval followed by one-way
ANOVA post-hoc LSD and Dunnett test using the SPSS program. p values of < 0:05
were considered to be signicant.
4.3 Results
4.3.1 TNF- protects neurons against glutamate-induced excitotoxicity.
To assess the time-dependent eect of TNF- pretreatment on cortical neuronal
cultures challenged with glutamate, we exposed cortical neurons to mouse TNF- (100
ng/ml) for 2, 4, 6, 8 or 24 h. After TNF- incubation, cortical neurons were challenged
with glutamate (50 ￿M, for 1 h). Neuronal viability was determined 24 h following
glutamate exposure by the colorimetric MTT assay. Preincubation of neurons with
TNF- for up to 6 h had no signicant protective eect against glutamate-induced
excitotoxicity (Fig. 4.1). The number of surviving neurons gradually increased when
the TNF- pre-treatment lasted between 6-24 h. Treatment with TNF- (100 ng/ml)
alone for 24 h did not change neuronal viability (Fig. 4.1). TNF- treatment after
the glutamate challenge did not protect cortical neurons against glutamate-induced
toxicity (data not shown).
4.3.2 TNF- increases SK2 channel expression.
Activation of SK channels in cortical neurons has been shown to suppress hyperex-
citability (Pedarzani et al., 2001), which could be a mechanism to enhance neuronal
survival in conditions of overstimulation. Therefore, we determined whether TNF-
treatment leads to a change in expression of the three SK channels SK1, 2 or 3. Similar
to a previous study in mouse brain (Sailer et al., 2004), we found that anti-SK1(12 29)4.3. Results 71
Figure 4.1: TNF--mediated neuroprotection against glutamate-induced excitotoxicity.
Cortical neurons were treated with TNF- (100 ng/ml) for the indicated periods of time and subse-
quently challenged with glutamate (50 ￿M, 1 h). Neuronal survival was assessed 24 h following the
exposure to glutamate by an MTT assay. Values represent mean SEM of determinations made in
three separate cultures. Statistical analysis was performed by the Student-Neumann test with a 95%
condence interval using the SPSS program. p values of < 0:05 were considered to be signicant.
antibody detects three separate bands with mocleular weights of 65;58 and 43 kDa.
The anti-SK2(538 555) antibody detects a band with an apparent Mr value of 64 kDa
and the anti-SK3(504 522) antibody recognises a protein running at the height of 75
kDa. Glutamate treatment of neurons did not aect SK channel expression (data not
shown) and treatment of cortical neurons with TNF- (100 ng/ml) for 2, 4, 6, 8 and
24 h had no eect on the expression of SK1 and SK3 channels (Fig. 4.2). However,
SK2 channel expression increased signicantly when neurons were treated with TNF-
 for 6, 8, and 24 h. Shorter incubation of TNF- showed no eect on SK2 channel
expression when compared to untreated neurons.
These data were extended by confocal studies showing increased SK2 channel
immunoreactivity in TNF- (100 ng/ml) treated cortical neurons in comparison to
untreated neurons (Fig. 4.3(a)). In addition, SK2 channel expression was also aug-
mented in dendrites where they appeared to be co-localised with NR2B subunits
(Fig. 4.3(b)).
4.3.3 SK channel activation leads to neuronal survival.
To investigate whether increased SK2 channel activity can be neuroprotective,
cortical neurons were treated for 30 min. with dierent concentrations of NS309,
an activator of SK and intermediate conductance Ca2+-activated K+ (IK) channels
(Strbaek et al., 2004), followed by addition of glutamate (50 ￿M) to the medium for72 TNF--induced neuroprotection is mediated by SK2 channels
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(c)
Figure 4.2: Exposure to TNF- increases SK2 channel expression in cortical neurons.
Neurons were treated with murine TNF- (100 ng/ml) for indicated periods of time. (a) Blots and
bar graphs show the quantication of the 65 kDa SK1 band. Accordingly, integrated optical densities
for the other two SK1 bands at 58 and 43 kDa showed no changes in response to the indicated TNF-
 incubation times. (b) Quantication and representative immunoblot for SK2 with apparent Mr of
64 kDa after exposure to TNF- for indicated periods of time. (c) Quantication and representative
immunoblot for SK3. Results shown represent mean SEM from three independent experiments.
Statistical analysis was performed by the Student-Neumann test with a 95% condence interval
followed by one-way ANOVA post-hoc LSD and Dunnett test using the SPSS program. p values of
< 0:05 were considered to be signicant.
1 h. NS309 strongly reduced glutamate-induced neuronal death in a concentration-
dependent manner (Fig. 4.4(a)). Since NS309 does not distinguish between the SK
subtypes and also activates the related IK channels, we repeated this experiment with
CyPPA, a compound which is selective for stimulating SK2 and SK3 (Hougaard et al.,
2007). Treatment with CyPPA also led to increased neuronal survival upon glutamate4.3. Results 73
Figure 4.3: TNF- treatment increases SK2 channel immunoreactivity. (a) Untreated
cortical neurons and neurons treated with TNF- for 6h were xated, permeabilized and stained
with anti-SK2 antibody coupled to Alexa 555. Boxed area represents the localization of panel (b)
TNF-  treated neurons were stained with anti-SK2 antibody coupled to Alexa 555 and anti-NR2B
antibody coupled to Alexa 488 as indicated in the respective panels. Images were collected from
stained neurons by confocal microscopy and merged in the respective color image.
treatment in a concentration-dependent manner although to a somewhat lower extent
than NS309. Higher CyPPA concentrations than 50 ￿M, however, induced neuronal
death (Fig. 4.4(b)).
To conrm the involvement of SK channels in TNF--induced neuroprotection,
we analyzed the viability of cortical neurons that were treated with 100 ng/ml mouse
TNF- for 24 h and challenged with glutamate (50 ￿M, for 1 h) in the presence or
absence of an inhibitor of SK channel activity (Fig. 4.4(c)). As inhibitor we used
apamin, an 18-amino-acid bee-venom toxin with a high selectivity for SK channels.
Application of apamin (20 ￿M) alone had no signicant eect on cell survival. The
detrimental eect of glutamate on cell survival was also not changed by apamin treat-
ment. Glutamate-induced neuronal death was partially reverted by preincubation of
TNF-, whereas suppression of SK channel activity by apamin (20 ￿M) prevented
the TNF- induced neuroprotective eect (Fig. 4.4(c)).74 TNF--induced neuroprotection is mediated by SK2 channels
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Figure 4.4: SK channel activation induces neuroprotection. (a) Cortical neurons were
incubated with the SK channel activator, NS309 (50 ￿M) for 30 min. Then, where indicated,
neurons where challenged with glutamate (50 ￿M) for 1 h. After the glutamate challenge media
were completely replaced by fresh media After additional 24 h the viability of cells was veried by
an MTT assay. (b) CyPPA (25 ￿M and 50 ￿M), a positive modulator of SK channels with a high
selectivity for SK3 and SK2, was applied alone or in combination with glutamate for 1h. (c) Cortical
neurons were treated with TNF- for 24 h. Neurons were challenged with glutamate (50 ￿M) for
1 h. Where indicated, neurons were preincubated with the SK channel blocker apamin for 30 min.
Statistical analysis was performed by the Student-Neumann test with a 95% condence interval. *p
values of < 0:05 versus glutamate-treated neurons were considered to be signicant.
4.3.4 Inhibition of NF-B attenuates TNF- induced upregulation of SK2
channel expression.
The activation kinetics of the transcription factor NF-B in response to TNF-
treatment in neurons was shown by several groups (Marchetti et al., 2004; Wang et al.,
2005) (reviewed by Kaltschmidt et al. (1999)). It has been reported that long-term
(24 h) exposure of neurons to TNF- promotes persistent and long lasting NF-B4.4. Discussion 75
Figure 4.5: NF-B inhibition prevents TNF--induced increase in SK2 channel expres-
sion. Neurons were co-incubated with TNF- (100 ng/ml) and BAY11-7082 (10 ￿M) for indicated
periods of time. Quantication and a representative immunoblot for SK2 channel protein with
apparent Mr values detected at 64 kDa are presented. Results shown represent mean SEM. Statis-
tical analysis was performed by the Student-Neumann test with a 95% condence interval followed
by one-way ANOVA post-hoc LSD and Dunnett test using the SPSS program. *p values of < 0:05
were considered to be signicant.
activation, which is associated with increased protection against glutamate-induced
neurotoxicity (Marchetti et al., 2004). Since SK2 channel expression is regulated by
NF-B (Kye et al., 2007), we determined whether the observed increase in SK2 chan-
nel expression after TNF- incubation was NF-B dependent. SK2 protein expression
was evaluated by Western blot analyses in TNF- treated neurons in the presence
or absence of BAY11-7082, an inhibitor of NF-B activity. SK2 levels in cortical
neurons were not increased by application of TNF- (100 ng/ml) when BAY11-7082
(10 ￿M) was co-applied (Fig. 4.5). BAY11-7082 treatment alone did not aect SK2
channel expression. These ndings suggest that inhibition of NF-B prevented the
TNF--induced increase in SK2 channel expression (Fig. 4.5).
4.4 Discussion
In the present study we have demonstrated that an NF-B-dependent increase in
SK2 channel expression in cortical neurons contributes to the neuroprotective eect
of TNF- against glutamate-induced excitotoxicity. TNF- has been implicated as
contributing to both neuroprotection and neurodegeneration, depending on the tissue
and experimental paradigm and conditions (Chao and Hu, 1994; Cheng et al., 1994;
Hermann et al., 2001; Marchetti et al., 2004; Zou and Crews, 2005). In our in vitro76 TNF--induced neuroprotection is mediated by SK2 channels
model of glutamate-induced cell death of primary cortical neurons, TNF- was shown
to have neuroprotective properties. Although the involvement of TNF-R2, PKB/Akt
and NF-B was already suggested (Dolga et al., 2008; Fontaine et al., 2002; Marchetti
et al., 2004), only limited data are available on potential neuroprotective downstream
targets of NF-B.
In our study, the time-dependent neuroprotective eect of TNF- against a glu-
tamate challenge was paralleled by a selective increase in SK2 channels, whereas the
expression of SK1 and SK3 channels remained unaected. The specic SK chan-
nel blocker apamin blocked the neuroprotective eect of TNF- against glutamate-
induced excitotoxicity. SK channels have dierent anities for apamin with SK2
proteins being the most sensitive, SK3 intermediate and SK1 being the least sensitive
to apamin (Finlayson et al., 2001; Strbaek et al., 2004). Given the nding that in
cortical neurons SK1 and SK2 channels are more abundant than SK3 channels (Sailer
et al. (2002); Sailer et al. (2004) and SK2 channels are more sensitive to apamin than
SK1 channels (D'hoedt et al., 2004), reduction of the TNF- mediated neuroprotec-
tion by apamin could be mainly attributed to the inhibition of SK2 channels.
The neuroprotective function of SK channels becomes evident by the nding
that the SK channel activators, NS309 and CyPPA, elicited neuroprotection against
glutamate-induced excitotoxicity in primary cortical neurons. NS309 facilitates Ca2+-
dependent activation of IK and SK channels, being most potent on IK and 1020 times
less active on the SK subtypes (Strbaek et al., 2004). CyPPA is a selective posi-
tive modulator of SK3 and SK2 channels, which does not aect SK1 or IK channels
(Hougaard et al., 2007). Although we can not exclude the involvement of SK3 chan-
nel activity in the neuroprotective eect elicited by CyPPA, the distribution prole
of SK2 and SK3 in cortical neurons (Sailer et al., 2002) suggests a major role of SK2
in the CyPPA-induced neuroprotective eect. The neuroprotective eect of CyPPA
was similar to the neuroprotective eect of TNF- whereas the eect of NS309 was
much larger. This result may be explained by the possible neuroprotective eect of
IK channel activation in NS309-treated neurons.
Based on our results we can only speculate on how increased SK2 channel ex-
pression can contribute to the neuroprotective eect elicited by TNF-. However
an SK2-mediated decrease in neuronal excitability is likely to be part of the mech-
anism. Indeed, the neuroprotective potential of SK2 has also been observed in an
earlier study showing that overexpression of SK2 channels in cultured hippocampal
neurons increases cellular survival against a kainic acid challenge by blunting the
kainic acid-induced increase in excitability (Lee et al., 2003). We and others showed
a colocalization of SK2 channels with NMDA receptor subunits in dendritic spines
(Faber et al., 2005; Lin et al., 2008; Ngo-Anh et al., 2005). Glutamate treatment
of neurons triggers ionotropic glutamate (e.g. NMDA, AMPA) receptor dependent
activation which leads to excessive Ca2+ in
ux into the cell. SK2 channels can be
activated by this Ca2+ in
ux. It was shown that the repolarizing eect of SK2 chan-
nel activity can oppose the depolarizing eect of AMPA receptor activity, favoringAcknowledgements 77
Mg2+ reblocking of NMDA receptors and thus reducing the Ca2+ transient (Faber
et al., 2005; Lin et al., 2008; Ngo-Anh et al., 2005). In this way SK2 channels may
decrease glutamate-induced excitotoxicity. We hypothesize that increased SK2 chan-
nels expression/activity may lead to decreased susceptibility to glutamate-induced
excitotoxicity via its coupling with NMDA receptors.
Our data correspond well with the results from Houzen and colleagues
(Houzen et al., 1997) who reported that the neuroprotective eect of TNF- against
NMDA-induced toxicity can be attributed to an increase in outward potassium current
(A-current) density in rat cortical neurons. The A-current is shown to be involved in
the regulation of the neuronal ring rates in such a way that an increase in A-current
density reduces cell excitability (Houzen et al., 1997). In addition, 4-aminopyridine
(4-AP), a blocker of the potassium current, which can also inhibit the activation
of all SK channel subtypes, reverted the observed TNF--mediated neuroprotection
(Houzen et al., 1997). The increase in A-current density was inhibited by cyclo-
heximide, a blocker of gene translation. Therefore, it was concluded that the eect
of TNF- might be mediated by de novo synthesis of channel protein itself and/or
modulating proteins associated with the channel activities.
The observed increase in SK2 expression after TNF- treatment is most likely
mediated by NF-B because BAY11-7082, a specic inhibitor of NF-B, blocked the
TNF- mediated increase in SK2 channel levels. NF-B might interact with two NF-
B binding sites, which were recently reported as regulatory parts of the murine SK2
promoter (Kye et al., 2007).
Altogether, the TNF-/NF-B pathway may recruit several downstream targets
in order to produce neuroprotective eects (Mattson, 2005) and the present study
identied SK2 as a central and novel candidate.
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Abstract
Statins are widely used as medication to lower cholesterol levels in human pa-
tients. In addition, it was recently reported that they can also reduce the incidence
of stroke and progression of Alzheimer disease when prophylactically administered.
To date there is only limited information available on how statins exert this ben-
ecial eect. Therefore, we investigated the neuroprotective eect of lovastatin in
primary cortical neurons. We found that lovastatin protects cortical neurons in a
concentration-dependent manner against glutamate-mediated excitotoxicity. Inter-
estingly, lovastatin with or without glutamate and/or tumor necrosis factor-alpha
(TNF-) increased TNF receptor 2 (TNF-R2) expression in cortical neurons. It was
previously shown that activation of TNF-R2 signaling, which includes phosphoryla-
tion of protein kinase B (PKB)/Akt and activation of nuclear factor-kappa B (NF-B),
protects neurons against ischemic or excitotoxic insults.
To investigate if the lovastatin-induced neuroprotection is mediated by TNF-R2
signaling, primary cortical neurons were isolated from TNF-R1-/- or TNF-R2-/- mice.
We could show that lovastatin is neuroprotective in TNF-R1-/- neurons, while protec-
tion is completely absent in TNF-R2-/- neurons. Furthermore, lovastatin-mediated
neuroprotection led to an increase in PKB/Akt and NF-B phosphorylation, whereas
inhibition of PKB/Akt activation entirely abolished lovastatin-induced neuroprotec-
tion.
Thus, lovastatin induced neuroprotection against glutamate-excitotoxicity via ac-
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5.1 Introduction
Hitherto, nine statins are available as pharmaceutical agents: lovastatin, mev-
astatin, simvastatin, pravastatin, 
uvastatin, atorvastatin, rosuvastatin, pitavastatin
and cerivastatin. Statins are commonly used as cholesterol lowering drugs (Endo,
1992). They inhibit 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reduc-
tase, a key-regulating enzyme in cholesterol biosynthesis. Besides this well-known
eect on cholesterol synthesis, statins exert several cholesterol-independent eects,
including anti-thrombotic (Kunieda et al., 2003) and anti-in
ammatory eects (Le-
ung et al., 2003), stimulation of endothelial nitric oxide synthase (eNOS) (Harris et al.,
2004; Hern andez-Perera et al., 1998) and inhibition of inducible nitric oxide synthase
(iNOS) (Vaughan and Delanty, 1999). They are also able to inhibit small G protein
activation, such as activation of Rho, Ras and Rac by preventing their isoprenyla-
tion and thus their translocation from the inactive GDP-bound forms located in the
cytoplasm to the active GTP-bound forms in the plasma membrane (Maltese, 1990;
Seabra, 1998). Interestingly, clinical studies showed that statins slow the progression
of mild-to-moderate Alzheimer's disease (AD) in patients treated with these drugs as
prophylactic agents (Sparks et al., 2006). These data were paralleled by the nding
that statins markedly attenuate amyloid beta deposition in the PSAPP transgenic
mouse model of Alzheimer's amyloidosis (Petanceska et al., 2002).
During Alzheimer's disease pathology, several pro-in
ammatory cytokines are
highly expressed in the brain (Perry et al., 2001). TNF- initiates signaling cascades
by binding to its receptors: TNF-R1 and TNF-R2 (Eisel et al., 2006; MacEwan,
2002a,b; Wajant et al., 2003). Although TNF receptors are barely detectable under
basal conditions, we reported recently that the expression level of both TNF receptors
is drastically increased after retinal ischemia/reperfusion injury (Fontaine et al., 2002).
While TNF-R1 expression is modulated by post-translational shedding (Madge et al.,
1999), TNF-R2 expression is mainly regulated by transcriptional processes (Hehlgans
et al., 2001). We showed that in retinal-induced ischemia the TNF-R1-stimulated
pathway promotes neuronal degeneration whereas activation of TNF-R2 signaling
leads to neuronal survival (Fontaine et al., 2002). TNF-R2-associated neuroprotec-
tive eects are mediated by the activation of PKB/Akt (Fontaine et al., 2002) and
phosphorylation of NF-B (Marchetti et al., 2004).
In an initial experiment we found that lovastatin had a neuroprotective eect in a
glutamate-induced excitotoxicity model using primary cortical neurons. Glutamate-
mediated excitotoxicity is a major apoptosis-inducing event that occurs under several
pathological conditions including Alzheimer's disease (Hynd et al., 2004). Interest-
ingly, in primary human endothelial cells (HUVEC) lovastatin treatment was shown
to increase the expression of TNF-R2 proteins, without aecting TNF-R1 expres-
sion levels (N ubel et al., 2005). Therefore, we investigated whether lovastatin can
also induce an increase in TNF-R2 expression levels in primary cortical neurons and
whether activation of TNF-R2 signaling might be a mechanism that underlies the
neuroprotective eect exerted by lovastatin.84 Lovastatin induces neuroprotection through TNF-R2 signaling
5.2 Materials and methods
Materials. Neurobasal medium and B27 supplement were purchased from Invit-
rogen (Carlsbad, CA). LY294002 and lovastatin were bought from Calbiochem (San
Diego, CA). Mouse TNF- was purchased from HBT (Uden, The Netherlands). Pri-
mary antibodies used were a rabbit polyclonal antibody specic for PKB/Akt (9272,
Cell Signaling, Danvers, MA, 1:2 000 dilution), anti-p-Akt (Ser473, 9271, Cell Sig-
naling, 1:2 000 dilution), mouse monoclonal anti-TNF-R1 (8436, Santa Cruz Biotech-
nology, Santa Cruz, CA, 1:500 dilution), rabbit polyclonal anti-TNF-R2 (3727, Cell
Signaling, 1:2000 dilution), mouse monoclonal anti-p-p65 (Ser536, 3036, Cell Signal-
ing, 1:2 000 dilution), rabbit polyclonal anti-p65 (sc-372, Santa Cruz Biotechnology,
Santa Cruz, CA, 1:2 000 dilution) and a monoclonal mouse antibody specic for
actin (MP Biomedicals, Irvine, CA, 1:100 000 dilution). The neutralizing rat anti
mouse TNF- antibody V1q was provided by Werner Falk and was used at a nal
dilution of 2 ￿g/ml. The secondary antibodies used were alkaline phosphatase (AP)-
conjugated goat anti-mouse (Applied Biosystems, Bedford, MA, 1:10 000 dilution)
and AP-conjugated goat anti-rabbit (Applied Biosystems, 1:10 000 dilution). The
chemi-luminiscence detection kit (Nitroblock II and CDP-Star) was purchased from
Applied Biosystems. Complete mini protease inhibitor cocktail tablets were purchased
from Roche-Diagnostics (Indianapolis, IN). All other materials were from Sigma.
Animal experiments. All experiments were performed using C57BL/6J (Harlan,
Horst, The Netherlands), TNF-R1-/- or TNF-R2-/- mice (Erickson et al., 1994; Pf-
eer et al., 1993; Rothe et al., 1993b). TNF-R1-/- or TNF-R2-/- mice were kept in
a C57BL/6J background for more then ten generations. All procedures were in ac-
cordance with the regulation of the Ethical Committee for the use of experimental
animals of the University of Groningen, The Netherlands (Licence number DEC 4048).
Mice were housed in standard macrolon cages and maintained on a 12 h light/dark
cycle. They received food and water ad libitum.
Primary cortical neuronal culture. Primary cortical neurons were prepared
from embryonic brains (E15-16) of C57BL/6J, TNF-R1-/- or TNF-R2-/- mice. The
meninges were removed and cortical neurons were separated by mechanical dissocia-
tion. Cells were plated in a density of 12 104 cells/well (96 well plates) and 2106
cells/well (6 well plates) on poly-D-lysine pre-coated plates. Neurobasal medium with
B27-supplement, 0.5 mM glutamine, 1% penicillin / streptomycin and 2.5 ￿g/ml am-
photericin B was used as a culture medium. After 48 h cortical neurons were treated
with 10 ￿M cytosine arabinoside for another 48 h to inhibit non-neuronal cell growth.
Subsequently, the medium was completely exchanged and after 6 days of in vitro
culture, the neuronal cultures were used for experiments.
Neurons were incubated over a period of 24 h with dierent concentrations of
lovastatin and/or 100 ng/ml TNF-. Lovastatin was dissolved in DMSO to a stock5.2. Materials and methods 85
concentration of 10 mM and stored at  20 ￿ until used. The nal concentra-
tion of DMSO in all experiments was less than 0.5% (v/v). At this concentration
DMSO had no eect on the survival of neuronal cultures. Incubation with PI3K
inhibitor LY294002 was performed at a standard concentration of 25 ￿M and the NF-
B inhibitor BAY11-7082 was applied at 10 ￿M. Standard neurotoxic challenges were
performed by incubating neuronal cultures for 1 h with 50 or 100 ￿M of glutamate.
After treatment, medium was completely removed and fresh medium was added to
the cells.
Determination of cell viability. 24 h after the glutamate treatment neuronal
cell viability was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl-
)2,5-diphenyl-tetrazolium bromide) assay as described previously (Mosmann, 1983).
1.25 mg/ml MTT solution was added to each well of a 96 well plate. After 2-4 h
of incubation, the cells were lysed by adding 120 ￿l of isopropyl-HCl solution (37%
HCl/isopropyl alcohol: 1/166) for 15 min. The absorbance of each well was deter-
mined with an automated ELISA reader (Bio-Rad, Munich, Germany) at 595 nm
with a background correction at 620 nm.
Nuclear fractionation. Cortical neurons treated in the absence and presence of
lovastatin (10 ￿M) and/or mouse TNF- (100 ng/ml) for 24 h were challenged by
100 ￿M glutamate for 1 h. After the glutamate treatment neurons were washed twice
with ice cold phosphate-buered saline (PBS), lysed in lysis buer (10 mM HEPES,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05 % NP40 and complete mini protease
inhibitor cocktail tablet (pH 7.9)) and centrifuged at 2000g for 10 min at 4 ￿. The
pellet was re-suspended in 5 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, 26% glycerol (v/v) (pH 7.9) and 300 mM NaCl. The samples were homogenized
and centrifuged at 24000g for 20 min at 4 ￿. The supernatant, which includes the
nuclear fraction was aliquoted and stored before use at 70 ￿.
Protein analysis. Primary cortical neurons from C57BL/6J, TNF-R1-/- and TNF-
R2-/- mice, which were grown in a 6 well plate, were washed twice with ice cold
phosphate-buered saline (PBS) and subsequently lysed by the addition of 0.15 ml
lysis buer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton,
2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate and complete mini pro-
tease inhibitor cocktail). Samples were centrifuged at 9000g for 10 min at 4 ￿ and
the supernatants boiled for 5 min in a Laemmli sample buer. Protein samples (20
￿g total) were separated by 10% SDS-polyacrylamide gel electrophoresis and trans-
ferred to a PVDF transfer membrane (Millipore Corporation, Billerica, MA) using a
semi-dry blotting device (BioRad, Munich, Germany). Proteins were incubated with
primary antibodies overnight at 4 ￿, washed and subsequently the membranes were
incubated with AP-conjugated secondary antibodies. Proteins were detected using
the ECL detection system (Applied Biosystems) according to the manufacturer's in-86 Lovastatin induces neuroprotection through TNF-R2 signaling
structions. Actin was used as an internal control to correct for variations in protein
content.
Integrated optical densities (IOD) were measured using the Leica DFC 320 Image
Analysis System (Leica, Cambridge, UK) and densitometric analysis was evaluated
using the Leica Qwin program. IOD measurements were corrected for the background
intensity. Levels of phosphorylated PKB/Akt were calculated as a ratio of Ser473 p-
Akt versus total Akt. IOD values of non-treated controls were set as 100%.
Statistical analysis. Results shown are represented as SEM. Independent exper-
iments were repeated at least three times. All statistical analyses were performed
using the Student-Neumann test with a 95% condence interval followed by one-way
ANOVA post-hoc LSD and Dunnett test using the SPSS program. p values of < 0:05
were considered to be signicant.
5.3 Results
5.3.1 Lovastatin mediated neuroprotection against glutamate excitotoxi-
city.
Glutamate-induced excitotoxicity in cortical neurons is well established as a model
mimicking the molecular pathways of neurodegeneration in Alzheimer's disease or of
the cerebral ischemic cell death (Marchetti et al., 2004; Hynd et al., 2004). We exam-
ined the eect of lovastatin on the viability of neurons after a glutamate challenge.
Neurons were pre-treated for 24 h with dierent concentrations (0.1 ￿M, 1 ￿M, 10
￿M, 100 ￿M) of lovastatin. Afterwards they were exposed to 50 ￿M glutamate for 1
h. At these concentrations glutamate alone induced cell death in approximately 60%
of the neurons. Interestingly, lovastatin signicantly decreased cell death elicited by
glutamate. This neuroprotective eect could be detected even at concentrations as
low as 0.1 ￿M (Fig. 5.1). Large but submaximal eects were observed at a concen-
tration of 10 ￿M (Fig. 5.1). Therefore, this concentration was used for the following
experiments.
5.3.2 Lovastatin alone or in combination with TNF- or glutamate in-
duced the up-regulation of TNF-R2 but not of TNF-R1 in cortical neu-
rons.
In HUVEC cells lovastatin induces the up-regulation of TNF-R2 expression, with-
out aecting the TNF-R1 expression levels (N ubel et al., 2005). Activation of TNF-R2
signaling leads to increased cell survival against glutamate-induced excitotoxicity in
neurons (Marchetti et al., 2004). Since lovastatin also has a neuroprotective eect in
primary cortical neurons, we investigated whether lovastatin is able to alter TNF-R2
protein levels in neurons. Interestingly, lovastatin increased the expression of TNF-
R2 protein (Fig. 5.2(b), lane 2). Furthermore, the combination of 10 ￿M lovastatin
with 100 ￿M glutamate resulted in a two fold increase in the expression of TNF-R25.3. Results 87
Figure 5.1: Lovastatin mediates neuroprotection in a concentration-dependent manner.
Primary cortical neurons were pre-treated with the indicated lovastatin concentrations for 24 h and
subsequently treated with 50 ￿M glutamate for 1 h. Using an MTT assay neuronal viability was
assessed 24 h later. Each bar represents the mean of 12 absorbance values from a single exper-
iment. Experiments were repeated at least 3 times. Statistical analysis was performed using the
Student-Neumann test with a 95% condence interval followed by one-way ANOVA post-hoc LSD
and Dunnett test using the SPSS program. Results shown are represented as SEM. *p values of
< 0:05 versus glutamate-treated neurons were considered to be signicant.
as compared to non-treated neurons (Fig. 5.2(b), lane 3). Combining lovastatin with
100 ng/ml mouse TNF- treatment for 24 h also led to increased TNF-R2 protein
levels, while in combination with glutamate, TNF-R2 protein expression was even
further up-regulated (3-fold higher than non-treated neurons). Lovastatin alone or
in combination with TNF- and/or glutamate did not aect the expression of TNF-
R1 (Fig. 5.2(a)). TNF- together with glutamate increased the expression levels of
both TNF-Rs, but this up-regulation was much lower than the combined treatment
with lovastatin, glutamate and TNF- (Fig. 5.2).
The involvement of TNF-R2 in lovastatin-mediated neuroprotection was conrmed
in neurons isolated from TNF-R1-/- or TNF-R2-/- mouse embryo brains (Fig. 5.3(b)
and (c)). Although these data cannot exclude an indirect eect due to the absence of
one of the receptors, the nding that the selective up-regulation of TNF-R2 induces
neuroprotection and that the selectivity of TNF-R2 signaling in neuroprotection was
shown previously (Marchetti et al., 2004) by the treatment of wild-type neurons with
TNF-R2 specic agonistic antibodies, makes this possibility highly unlikely. These
neurons were treated with lovastatin (10 ￿M) or with lovastatin and TNF- for 24 h.
After the drug incubation, neurons were stimulated with glutamate (100 ￿M) for 1 h.
In TNF-R1-/- neurons, lovastatin was able to rescue neurons from glutamate-mediated
excitotoxicity, with or without TNF- treatment (Fig. 5.3(b)). The neuroprotective88 Lovastatin induces neuroprotection through TNF-R2 signaling
eect of treatment with lovastatin alone may be explained by activation of TNF-R2
signaling by endogenous TNF- levels. However, in TNF-R2-/- neurons lovastatin
with or without TNF- treatment did not protect neurons against glutamate-induced
excitotoxicity (Fig. 5.3(c)).
5.3.3 The neuroprotective eect of lovastatin is PKB/Akt and TNF-
dependent.
Previous studies of cellular survival pathways indicated that the activation of
PKB/Akt by PI3K is one of the key steps involved in the induction of transcription
factors involved in anti-apoptotic gene transcription (Marchetti et al., 2004; Gustin
et al., 2004; Song et al., 2005). We have recently shown that TNF--induced neu-
roprotection against glutamate excitotoxicity in primary cortical neurons (Marchetti
et al., 2004) is dependent on TNF-R2 activation and that this eect is associated
with PI3K-dependent PKB/Akt phosphorylation (Fontaine et al., 2002) and NF-B
activation (Marchetti et al., 2004).
To check if the neuroprotective eect of lovastatin is also mediated by the PI3K
pathway, cortical neurons were pre-treated with a PI3K inhibitor (LY294002) and
then challenged with glutamate (Fig. 5.3). The neuroprotective eect elicited by
pre-incubation with lovastatin with or without TNF- was completely reverted by
LY294002 treatment (Figs. 5.3(a) and (b)).
To investigate whether TNF- was involved in the neuroprotective eect induced
by lovastatin treatment we used TNF- neutralising antibodies. Lovastatin-mediated
neuroprotection was partially reverted when TNF- neutralizing antibodies were in-
cubated together with lovastatin for 24 h (Fig. 5.3(a), lane 5).
PKB/Akt becomes activated by phosphorylation at two dierent sites Thr308 and
Ser473. Activation of PKB/Akt was evaluated as a ratio of phosphorylated-Akt-Ser473
(phospho-Akt)/ total PKB/Akt. We chose the serine site to determine the PKB/Akt
activation, as this site is primarily linked to the PI3K pathway (Franke et al., 1997;
Lawlor and Alessi, 2001). Analysis of PKB/Akt activation in wild-type neurons pre-
treated with lovastatin revealed an increase in PKB/Akt phosphorylation (Fig. 5.4(a),
lane 10). However, lovastatin-treated neurons subjected to a glutamate challenge
showed a 2-fold enhanced PKB/Akt phosphorylation compared to non-treated neu-
rons (Fig. 5.4(a), lane 2). Co-incubation of TNF- with lovastatin led to a similar
activation of PKB/Akt (Fig. 5.4(a), lane 4). Glutamate alone did not signicantly
alter PKB/Akt phosphorylation (Fig. 5.4(a), lane 11). However combining TNF-
 with glutamate treatment did lead to an increase in PKB/Akt phosphorylation
(Fig. 5.4(a), lane 6). The ability of LY294002 to reverse lovastatin-mediated neu-
roprotection (Figs. 5.3(a) and (b)) and to suppress PKB/Akt phosphorylation after
lovastatin treatment (Fig. 5.4(a)) suggested that PKB/Akt activation is involved in
the neuroprotective mechanism of lovastatin.
In TNF-R1-/- neurons lovastatin treatment alone did not signicantly alter the
basal levels of PKB/Akt phosphorylation (Fig. 5.4(b), lane 2). When lovastatin-5.3. Results 89
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Figure 5.2: Lovastatin increases TNF-R2 protein levels, without aecting TNF-R1.
Primary cortical neurons were pre-treated with 10 ￿M lovastatin alone or with lovastatin and 100
ng/ml mouse TNF-. Afterwards the cortical neurons were challenged with 100 ￿M glutamate for 1
h. Where indicated, neurons were pre-incubated with for 24 hours with 10 ￿M of the NF-B inhibitor
BAY11-7082. Immediately after the glutamate challenge, all neurons were lysed. Representative
immunoblots are shown at the lower part of the quantied IOD of the (a) TNF-R1 and (b) TNF-
R2 protein expression resulted from dierent experiments (n = 3, *p < 0:05 versus non-treated
neurons).90 Lovastatin induces neuroprotection through TNF-R2 signaling
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Figure 5.3: Lovastatin mediates neuroprotection in C57BL/6J, TNF-R1-/-, but not in
TNF-R2-/- neurons. Primary cortical neurons from (a) C57BL/6J (wild-type), (b) TNF-R1-/-
and (c) TNF-R2-/- mice were pre-incubated with 10 ￿M lovastatin and/or 100 ng/ml mouse TNF-
for 24 h. After the drug incubation, neurons were challenged with glutamate. Where indicated,
neurons were also pre-incubated with 25 ￿M of the PI3K inhibitor LY294002. Neuronal viability
was checked 24 h later after the glutamate challenge using an MTT assay. *p values of < 0:05
versus glutamate-treated neurons were considered to be signicant.
treated TNF-R1-/- neurons were challenged with glutamate PKB/Akt phosphoryla-
tion was strongly increased (Fig. 5.4(b), lane 3). Lovastatin in combination with
TNF- led to a slightly stronger PKB/Akt phosphorylation in glutamate-challenged
TNF-R1-/- neurons (Fig. 5.4(b), lane 4). Augmented PKB/Akt phosphorylation was
also detected in TNF-R1-/- neurons treated with TNF- and glutamate (Fig. 5.4(b),
lane 5). Furthermore, LY294002 was able to revert the neuroprotection mediated by5.3. Results 91
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Figure 5.4: Lovastatin induces PKB/Akt activation in glutamate-challenged C57BL/6J
and TNF-R1-/- neurons. Primary cortical neurons were incubated with 10 ￿M lovastatin and/or
100 ng/ml mouse TNF- for 24 h and subsequently challenged with 100 ￿M glutamate for 1 h.
Where indicated, neurons were also pre-incubated with 25 ￿M of the PI3K inhibitor LY294002.
Immediately after the glutamate challenge all neurons were lysed and the protein lysates analyzed
in a western blot. Phosphorylation of PKB/Akt was monitored using an anti-phospho PKB/Akt
antibody (phosphorylated-AktSer473). Total cellular PKB/Akt served as loading control. Relative
optical densiometric values of phosphorylated PKB/Akt from (a) C57BL/6J, (b) TNF-R1-/- and (c)
TNF-R2-/- neurons are shown in the upper panels. Data is presented as percentage of each respective
ratio between optical density value of phospho-Akt band intensity and optical density value of the
matched Akt band intensity. *p values of < 0:05 versus non-treated neurons were considered to be
signicant.
lovastatin in TNF-R1-/- neurons (Fig. 5.3(b)).
In TNF-R2-/- neurons PKB/Akt was not activated upon lovastatin treatment92 Lovastatin induces neuroprotection through TNF-R2 signaling
alone or in combination either with glutamate or TNF- (Fig. 5.4(c)). Combining
TNF- with glutamate treatment decreased the basal PKB/Akt phosphorylation level
(Fig. 5.4(c), lane 5).
5.3.4 Lovastatin increased TNF-R2-induced NF-B activation.
Several studies have shown that both TNF-R1 and TNF-R2 signaling activate the
canonical NF-B pathway (Wajant et al., 2003; Marchetti et al., 2004). However,
the activation kinetics of NF-B stimulation reveals characteristic dierences: while
activation of the TNF-R1 pathway leads to a transient NF-B stimulation (rst 20-40
min during 24 h TNF- treatment), TNF-R2 signaling promotes persistent and long
lasting NF-B activation (even persisting after 24 h of TNF- treatment) (Marchetti
et al., 2004). Furthermore, TNF-R2-induced NF-B activation is dependent on PI3K-
PKB/Akt stimulation, whereas TNF-R1-mediated NF-B activation is not (Marchetti
et al., 2004).
It was previously shown that the phosphorylated p65 subunit from nuclear frac-
tion can be used as an indication for NF-B activation (Wang et al., 2005). In our
experiments, lovastatin altered basal NF-B phosphorylation (Fig. 5.5, lane 2). In
combination with glutamate it induced an even stronger phosphorylation of NF-B
(Fig. 5.5, lane 3). Co-incubation of lovastatin with TNF- resulted in highest levels
of p65 phosphorylation when neurons were also challenged with glutamate. (Fig. 5.5,
lane 4).
As expected, the suppression of NF-B phosphorylation by a specic inhibitor,
BAY11-7082, reverted the lovastatin-mediated neuroprotective eect (data not shown).
Interestingly, inhibition of NF-B activation by BAY11-7082 prevented the up-regu-
lation of TNF-R2 protein normally observed after lovastatin and glutamate treatment
(Fig. 5.2)(b)).
5.4 Discussion
In this study, we show that pre-treatment with lovastatin can protect cultured
cortical neurons against glutamate-induced excitotoxicity. Glutamate-mediated exci-
totoxicity is a major apoptosis-inducing event that occurs under several pathological
conditions including Alzheimer's disease and cerebral ischemia (Marchetti et al., 2004;
Hynd et al., 2004; Harkany et al., 2000; Mattson, 2004). Hitherto, only few studies
reported neuroprotective mechanisms of statins against a glutamate challenge (Zacco
et al., 2003; Lim et al., 2006). These studies described the eect of acute and chronic
simvastatin treatment on glutamate-induced neuronal damage. Acute treatment with
simvastatin inhibited the production and cytotoxicity of the nal product of lipid per-
oxidation, 4-hydroxynonenal (HNE). Chronic treatment with simvastatin results in
neuroprotection against glutamate-induced excitotoxicity by depletion of the cellular
cholesterol pool (Zacco et al., 2003). Here we show, that lovastatin resistance against
glutamate-induced excitotoxicity is elicited by activation of TNF-R2 signaling, which5.4. Discussion 93
Figure 5.5: Lovastatin treatment induces NF-B activation. Cortical neurons were treated
with 10 ￿M lovastatin and/or with 100 ng/ml mouse TNF- for 24 h and, where indicated, subse-
quently challenged with 100 ￿M glutamate for 1 h. Protein lysates from the nuclear fractions were
analyzed in a western blot. Phosphorylation of NF-B was monitored by detection using an anti-
phospho p65 antibody (phosphorylated p65 Ser536). *p values of < 0:05 versus non-treated neurons
were considered to be signicant.
includes signaling via PI3K-PKB/Akt and activation of NF-B. However, from our
study we can not exclude that these lovastatin-induced neuroprotective mechanisms
are dependent on cholesterol depletion or inhibition of HNE.
The PKB/Akt pathway is known to be essential for several physiological pro-
cesses, including insulin signaling, cell dierentiation and cell survival (Lawlor and
Alessi, 2001). Simvastatin-induced PKB/Akt translocation promotes activation of
PKB/Akt by phosphorylation at Ser473, in endothelial cells (Kureishi et al., 2000),
but not in smooth muscle cells (Skaletz-Rorowski et al., 2003). Our data showed
that in cortical neurons, lovastatin treatment alone was able to activate PKB/Akt at
Ser473. This activation was further increased when neurons were pre-incubated with a
combination of lovastatin and TNF- and afterwards stimulated with glutamate. In
TNF-R1-/- neurons lovastatin also increased PKB/Akt activation when the neurons
were stimulated with glutamate, whereas in TNF-R2-/- neurons lovastatin did not
alter the basal PKB/Akt phosphorylation. The ability of LY294002, an inhibitor of
PKB/Akt, to suppress the PKB/Akt phosphorylation and lovastatin-induced neuro-
protection, conrmed the importance of PKB/Akt activation in lovastatin-mediated
neuroprotection. Furthermore, LY294002 was able to inhibit the up-regulation of
TNF-R2 expression in lovastatin and glutamate-challenged neurons. Together these
data suggest that lovastatin-mediated neuroprotection is dependent on the activation
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In HUVEC cells, lovastatin is able to specically up-regulate the expression of
TNF-R2, but not of TNF-R1 (N ubel et al., 2005). Here, we showed that lovastatin
together with glutamate was also able to selectively increase TNF-R2 protein levels
without aecting the expression of TNF-R1 in cortical neurons. Sequence analyses of
the 5' non-coding region of the two TNF--receptors indicated that the TNF-R1 gene
is a non-inducible gene (Rothe et al., 1993a). However, under several circumstances,
such as a retinal ischemia its expression is strongly, but transiently and locally, up-
regulated (Fontaine et al., 2002). While TNF-R1 expression is mainly regulated by
post-translational processes, TNF-R2 is believed to be controlled by transcriptional
factors such as NF-B (Rasmussen et al., 2001; Santee and Owen-Schaub, 1996).
NF-B is also a key regulator in apoptotic and anti-apoptotic signal transduction
cascades. It is considered to play an important role in neuroprotection (Mattson
and Camandola, 2001). As an example, the cellular inhibitors of apoptosis proteins
(cIAPs), well-known NF-B-target gene(s) upregulated by TNF-, have been recently
identied as facilitators in regulating apoptosis sensitivity within neurons (Yang et al.,
2005). Its pleiotropic eects are mostly attributed to a large variety of upstream
stimuli and its eects are dependent on the specic cell type (Gustin et al., 2004). Al-
though in astrocytes or in tumor cells activation of NF-B leads to apoptotic events,
NF-B can promote either cell death or cell survival in cortical neurons (Marchetti
et al., 2004; Mattson and Camandola, 2001; Grilli et al., 1996). Several studies have
shown that a long lasting TNF- treatment resulted in neuroprotection against gluta-
mate excitotoxicity or oxidative injury (Cheng et al., 1994; Barger et al., 1995; Bruce
et al., 1996) in a NF-B-dependent manner (Marchetti et al., 2004). This persistent
NF-B activation was induced by TNF-R2 signaling (Marchetti et al., 2004). Several
studies carried out in vivo and in dierent cell lines revealed the ability of statins
to modulate NF-B activity (Gnad et al., 2001; N ubel et al., 2004; Sironi et al.,
2006). They can suppress NF-B activity by the inhibition of small GTPases of the
Rho family (Maltese, 1990; Seabra, 1998). In contrast, Lim and colleagues demon-
strated that acute treatment with simvastatin inhibits the lipid peroxidation product
HNE, which results in NF-B activation (Lim et al., 2006). In our study, we ob-
served that lovastatin treatment increased NF-B phosphorylation by the activation
of PKB/Akt. Furthermore, BAY11-7082, an NF-B inhibitor was able to inhibit the
up-regulation of TNF-R2 expression in glutamate-challenged neurons pre-incubated
with lovastatin. Thus, lovastatin-induced NF-B activation was involved in the up-
regulation of TNF-R2 protein. Treatment of glutamate challenged cortical neurons
with lovastatin and a TNF- neutralizing antibody (V1q) (Echternacher et al., 1990)
resulted in a substantially reduced neuroprotective eect as compared to lovastatin
treatment alone. This eect suggests that endogenous TNF- and here most likely
the membrane bound form of TNF- in an auto- or juxtatropic way may be involved
in stimulating TNF-R2 upon lovastatin treatment and that this eect plays an im-
portant role in lovastatin mediated neuroprotection. A similar eect of endogenous
and protective TNF- expression has been observed and described in an earlier studyAcknowledgements 95
(Marchetti et al., 2004).
The present study describes a novel neuroprotective mechanism of statins. Lovas-
tatin was shown to exert a neuroprotective eect via the activation of the TNF-R2
signaling pathway. TNF-R2 activation increased PI3K-PKB/Akt and NF-B phos-
phorylation and activation. Interestingly, NF-B activation in turn led to increased
TNF-R2 expression suggesting a positive feedback loop between lovastatin-induced
NF-B activation and TNF-R2-mediated neuroprotective signaling. Taken together
these ndings add to the known eects of lovastatin another signaling pathway po-
tentially explaining some of the neuroprotective eects that statins have shown in
several clinical studies on Alzheimer's disease, stroke and even in Multiple Sclerosis
(Sparks et al., 2006; Sacks et al., 1996; Vollmer and Singh, 2004).
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Abstract
Besides a benecial cardiovascular eect, it was recently suggested that statins
can also have neuroprotective eects. In a previous study we provided evidence that
lovastatin treatment abates excitotoxic cell death in primary cortical neurons. Here,
we investigated the neuroprotective eect of lovastatin in an in vivo mouse model.
We found that administration of lovastatin (20 mg/kg) signicantly protects cholin-
ergic neurons and their cortical projections against N-methyl-D-aspartate (NMDA,
60 nmol) induced cell death in the magnocellular nucleus basalis (MNB). Further-
more, lovastatin-mediated neuroprotection was shown to be dependent on protein
kinase B (PKB)/Akt signaling since inhibition of PKB/Akt with LY294002 blocked
the lovastatin-induced neuroprotective eect. The loss of cholinergic neurons after
the MNB lesion resulted in memory impairment as tested in a passive avoidance
paradigm. This was reverted by pre- lesion lovastatin treatment. It is concluded that
treatment with lovastatin may provide resistance against neuronal injury in excito-
toxic conditions associated with neurodegenerative diseases.6.1. Introduction 103
6.1 Introduction
Statins or 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase in-
hibitors are commonly used as pharmaceutical compounds to lower cholesterol levels.
Besides the benecial cardiovascular eects statins exert pleiotropic actions in the
central nervous system and were suggested to have neuroprotective properties. For
example, in a model for brain injury statins (simvastatin and atorvastatin) were shown
to increase neurogenesis in the hippocampal dentate gyrus and to reduce neuronal loss
in the cornu ammonis 3 (Lu et al., 2007). Simvastatin enhanced neuronal survival
in axotomized retinal ganglion cells after optic nerve injury via the overexpression of
heat shock protein 27 (Kretz et al., 2006).
In a previous study we showed that lovastatin mediates neuroprotective eects
against glutamate-induced excitotoxicity in cultured primary cortical neurons (Dolga
et al., 2008). The neuroprotective eect of lovastatin against glutamate-induced ex-
citotoxicity was, at least partly, mediated by the activation of tumor necrosis factor-
receptor 2 (TNF-R2) signaling pathways, which include protein kinase B (PKB)/Akt
phosphorylation and NF-B activation (Dolga et al., 2008; Marchetti et al., 2004).
A well-established model to study excitotoxic brain damage in vivo was originally
developed in rats (Dunnett et al., 1987; Luiten et al., 1995, 1987; Stuiver et al., 1996)
and consists of the injection of a neurotoxic dose of the glutamate analog NMDA into
the magnocellular nucleus basalis (MNB). Subsequently the neuronal damage is quan-
tied. The basal forebrain cholinergic neurons and their projections to the cerebral
cortex are susceptible to experimental conditions generally associated with cerebral
ischemia and Alzheimer's disease (AD), including exposure to glutamate, NMDA or
amyloid beta peptides (Luiten et al., 1987; Harkany et al., 1999). Therefore, NMDA-
induced lesion of the MNB is an eective in vivo method to study neurodegenerative
mechanisms associated with NMDA receptor overstimulation (Luiten et al., 1987)
and to assess the ecacy of potential therapeutic treatments that may interfere with
neurodegenerative processes.
Interestingly, damage to cholinergic MNB neurons and to their cortical target areas
is associated with a decline in memory function during aging and in AD and is in fact
the basis of the acetylcholinesterase inhibition therapy in AD (Bartus et al., 1982). In
the rat model NMDA-induced excitotoxicity in the MNB also led to cognitive decits
(Van der Zee et al., 1994). Hitherto the eects of statins on behavior remain rather
unexplored. A few studies, however, showed that statins improve the spatial learning
and memory decits after hypoxic-ischemic or traumatic brain injuries (simvastatin
and atorvastatin) in rats (Lu et al., 2007; Balduini et al., 2003) and increase learning
and attention (lovastatin) in a mouse model of neurobromatosis type I (Li et al.,
2005). Simvastatin treatment reversed learning and memory decits in a mouse model
for AD (Tg2576 mice). However, simvastatin enhanced also learning and memory
performance in the non-transgenic mice, independent of the levels of amyloid beta
protein in the brain (Li et al., 2006).
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protective potential of lovastatin against excitotoxic brain damage in vivo. Since our
previous in vitro studies provided evidence for a role of PKB/Akt in the neuroprotec-
tive eect of lovastatin, we also investigated whether PKB/Akt activation is essential
in the protective mechanism of lovastatin against NMDA-induced excitotoxicity in
vivo. To extend the eects of lovastatin in our mouse model we tested memory per-
formance of untreated and lovastatin-treated mice with and without NMDA-induced
lesion.
6.2 Materials and methods
Animals and treatments. Experiments were carried out on male C57BL/6J mice
(12 weeks, 25-30 g, Harlan, Horst, The Netherlands). The animals were individually
housed and received a standard laboratory diet and tap water ad libitum with a 12/12
h dark-light cycle. All procedures were approved by the Ethical Committee for the
use of experimental animals of the University of Groningen, The Netherlands (DEC
4681B).
Nucleus basalis lesion. Animals were anesthetized with avertin (tri-bromo-ethanol)
and their heads positioned in a Kopf stereotactic frame adapted to mouse brain co-
ordinates (Kopf Instruments model 900, Tujunga, CA, USA). Unilateral lesions were
achieved by a slow (0.1 ￿l/min) injection of 0.4 ￿l and a total of 60 nmol NMDA
(Sigma, St. Louis, MO, USA solved in phosphate buered saline, PBS pH=7.4) into
the MNB (0.6 mm posterior to bregma, 1.8 mm lateral to the sagital suture, 4.6 mm
and 4.4 mm ventral to the dura mater (Franklin and Paxinos, 1997) in two steps of 0.2
￿l each with an interval of 5 min. Injections were performed with a Hamilton microsy-
ringe (Hamilton, Bonaduz, Switzerland) in an infusion pump (TSE, Bad Homburg,
Germany). Control lesions (0.4 ￿l PBS) were made in the contralateral MNB of each
animal in a manner identical to the NMDA infusion procedure. Thereafter, mice were
returned to their home cages and allowed to recover.
Neuroprotective action of lovastatin (experiment I). In the rst experiment
we investigated the neuroprotective action of lovastatin against neurotoxic damage
induced by a unilateral injection of 60 nmol NMDA in the MBN. In pilot experiments
60 nmol NMDA was shown to induce approximately 50% reduction in cholinergic
neurons and projection bers which was similar to the results found in rat studies in
our laboratory (Luiten et al., 1987).
Experiment I comprised the following four groups: (1) mice received 20 mg/kg
monosodium salt lovastatin (Calbiochem, San Diego, CA, USA) i.p. for 5 consecutive
days. Afterwards 60 nmol NMDA dissolved in PBS was injected in one hemisphere
and PBS in the contralateral hemisphere. The PBS injected site served as an internal
control. The lovastatin dose is based on the results of earlier pharmacokinetic studies
(Cheng et al., 2002), (2) mice were injected with saline i.p. for 5 consecutive days6.2. Materials and methods 105
followed by an unilateral 60 nmol NMDA lesion and PBS infusion contralateral (n =
7), (3) mice received lovastatin and NMDA injections as in group 1) but the PKB/Akt
inhibitor LY294002 (100 ￿M, Calbiochem, San Diego, CA, USA) was infused into
the MNB together with NMDA. (4) mice were treated as in group 2) but received
LY294002 together with NMDA into the MNB. All animals were sacriced 7 days
after the surgical procedure (Fig. 6.1(a)).
Behavioral assessment (experiment II). To study the behavioral consequences
of lovastatin treatment and MNB lesions, four groups of animals were formed: (1)
mice injected with saline i.p. for 5 consecutive days; (2) mice injected with 20 mg/kg
lovastatin i.p. for 5 consecutive days; (3) mice receiving saline for 5 days i.p. followed
by bilateral 60 nmol NMDA lesions on the next day; (4) mice receiving lovastatin
for 5 days i.p. prior to bilateral 60 nmol NMDA lesions. 8 { 10 days after the
last i.p injection, mice were tested in spontaneous alternation and passive avoidance
paradigms (Fig. 6.1(b)).
Behavioral testing.
Spontaneous alternation task. Short-term spatial memory performance (working
memory) was assessed by recording spontaneous alternation behavior in a Y-maze
paradigm. The Y maze consisted of three tubular and transparent plexiglass arms
forming the Y. All three arms were 5 cm in diameter, 27.5 cm long, and at a 120￿
angle from each other. The experimental room contained visual cues, which served
as distal spatial cues.
The mouse (na ve to the maze) was placed into the centre of the Y maze and
allowed to explore the maze freely during an 8-min session. The series of arm entries
was recorded visually. Arm entry was considered to be completed when all four paws of
the animal had entered the arm. Alternation was dened as successive entries into the
three arms on overlapping triplet sets. The alternation percentage was calculated as
the ratio of actual to possible alternations (dened as the total number of arm entries
minus two). Since this behavior is not reinforced it is considered \spontaneous". The
exploratory activity was assessed by counting the total number of arm entries.
Passive avoidance paradigm. For this test we used a two-compartment (one-way)
step-through device. During the training trial, mice were placed in an illuminated
compartment, which was separated from the dark compartment by a door. Mice
were allowed to explore the light compartment for one minute before the door to
the dark compartment was opened. The latency to step into the dark compartment
was recorded (pre-shock latency). Upon entry into the dark compartment the door
was closed and a mild foot shock (0.3 mA for 2 sec) was delivered through the grid

oor. 30 sec after shock application the mice were returned to their home cages.
Memory retention was checked 24 h later. The mice were placed in the illuminated
compartment for 20 sec and after opening of the door the latency to step into the
dark compartment was recorded (post-shock latency) up to a maximum of 8 min.106 Lovastatin mediates in vivo neuroprotection via PKB/Akt signaling
Tissue processing and ChAT histochemistry. Fixation of the brains was car-
ried out under deep sodium pentobarbital anaesthesia by transcardial perfusion with
200 ml xative composed of 4% paraformaldehyde in 0.1 M phosphate buer (PB,
pH 7.4), which was preceded by a short prerinse (50 ml) with ice-cold physiological
salt solution. Brains were post-xed for 24 h in the same xative, cryoprotected by 3
days immersion in 30% sucrose in 0.1 M PB at 4 ￿. Thereafter, 20 ￿m coronal sec-
tions were cut on a Leica cryostat microtome and collected in 0.01 M PBS containing
0.1% sodium azide (Sigma, St. Louis, MO, USA). Free 
oating sections were pre-
incubated overnight at room temperature in 5% normal rabbit serum (NRS, Zymed,
San Francisco, CA, USA) with 0.2% Triton-X. The following day, sections were incu-
bated with goat anti choline-acetyltransferase (ChAT) primary antibody (Millipore,
Billerica, MA, USA) diluted 1:500 in PBS for 2 { 4 days at 4 ￿. Then, sections
were exposed to biotinylated rabbit anti-goat IgG (Vector, Brunschwig Chemie, Am-
sterdam, The Netherlands) diluted 1:500 in PBS followed by an incubation step for
2 h with Vectastain Elite ABC kit, according to the manufacturer's protocol (Vec-
tor, Brunschwig Chemie, Amsterdam, The Netherlands). For visualization, Sigma
Fast 3,3'-diaminobenzidine tablets (Sigma, St. Louis, MO, USA) were used as chro-
mogen with ammonium nickel sulphate (BDH Chemicals Ltd., UK) enhancement.
The specicity of immunostaining was conrmed in stainings where incubation with
the primary antibody was omitted (data not shown).
Quantitative image analysis. ChAT ber density was measured in layer V of
the posterior somatosensory cortex according to a standardized protocol using an
Image Analysis System (Leica Quantimet, Cambridge, UK) with a Leica DFC 350FK
camera. The images were analysed with Leica Qwin Image Analyse software. Surface
area density of cortical ChAT positive bers was measured in parietal cortical sections
(0.6 mm posterior to bregma (Paxinos and Watson, 1998)), the cortical area that
receives a strong cholinergic projection from the lesioned MNB region (Gaykema
et al., 1990). After background subtraction and grey-scale threshold determination,
the surface area of the skeletonized ChAT immunoreactive (ir) bers ([the area covered
by ChAT-ir bers]/[total sampling area]) was computed in each parietal region using
a 470 nm band pass lter. The relative value of ChAT bers was calculated as the
percentage dierence between the surface area density of the lesioned hemisphere and
the contralateral sham-operated control hemisphere.
6.3 Results
6.3.1 Lovastatin treatment protects against NMDA-induced lesions in
MNB.
The sensitivity of cholinergic neurons to excitotoxicity can be quantied by the
loss of the cholinergic cortical innervation that originates from the MNB (Gaykema
et al., 1989) visualized with the cholinergic marker choline-acetyltransferase (ChAT,6.3. Results 107
(a)
(b)
Figure 6.1: Schematic outline of the experimental setup. Mice were injected for 5 con-
secutive days with saline or lovastatin (20 mg/kg of body weight) for 5 consecutive days prior to
unilateral NMDA lesions (60 nmol) into the magnocellular nucleus basalis. (a) Eight days after the
last i.p injection mice were transcardial perfused (for histochemical analysis) and their brains were
xated with paraformaldehyde. (b) Memory performance was assessed using spontaneous alternation
and one-way step-through passive avoidance paradigms. These tests were performed eight days after
the drug delivery.
EC3.2.1.6) (Harkany et al., 2000). Histochemical detection of ChAT-ir projection
bers revealed a dense ber network in the layer V of the somatosensory cortex with
a smooth appearance and a layer specic homogenous staining pattern. The cholin-
ergic ber density decreased after NMDA infusion proportional to the loss of the
number of neurons in MNB (Harkany et al., 2000). Characteristic morphological pat-
terns of neuronal degeneration such as the appearance of shrunken or rounded somatic
proles without emanating dendrites, and fragmented cholinergic bers ascertained
the excitotoxic eect of NMDA-induced lesions (Figs. 6.2(a) and (b)). Quantication
of ChAT positive projection bers revealed a signicant loss of cholinergic inner-
vation in the NMDA-lesion hemisphere compared to the sham-injected hemisphere
of 35:33  5:77%. Pre-lesion administration of lovastatin signicantly attenuated the
NMDA-induced ber reduction in the parietal cortex (11:254:2%, p < 0:05 Univari-
ate ANOVA), which means a neuroprotective eect of lovastatin to 60 nmol NMDA
toxicity of 70,90% in adult mice (Fig. 6.2(c))108 Lovastatin mediates in vivo neuroprotection via PKB/Akt signaling
6.3.2 Lovastatin-mediated neuroprotection is dependent on PKB/Akt ac-
tivation.
Our previous in vitro data already revealed an essential role of PKB/Akt pathways
in lovastatin-induced protection in primary cortical neurons exposed to glutamate
excitotoxicity (Dolga et al., 2008). To further elucidate the lovastatin-mediated neu-
roprotective pathways in vivo we included in our experiments LY294002 as a specic
inhibitor of PKB/Akt signalling. The concentration used (100 ￿M) was based on
previous in vivo studies, where 100 ￿M LY294002 delivered in rat brain by a single
injection of 0.5 ￿l abolished PKB/Akt phosphorylation (Cheng et al., 2002). Lovas-
tatin or saline was administered for 5 consecutive days prior to a combined NMDA
and LY294002 infusion into MNB.
Quantitative analysis of the cholinergic ber loss indicated no eect of the LY294002
treatment alone in the NMDA lesion model (35:335:77% for NMDA plus LY294002
vs. 38:67  3:33% for NMDA alone). In the lovastatin treated animals the ChAT-
positive ber loss in the NMDA plus LY294002 group (31:6  5:41%) showed signif-
icantly more ber loss than the NMDA lesioned cases which were not treated with
LY294002 (11:254:2%; p < 0:05). The lovastatin treated NMDA+LY294002 values
were not statistically dierent from the saline-pretreated NMDA nor the saline pre-
treated NMDA+LY294002 animals. It can thus be concluded that the neuroprotective
lovastatin eect is almost completely blocked by PKB/Akt inhibition (Fig. 6.2(c)).
6.3.3 NMDA-induced lesions do not alter spatial short-term memory in
a spontaneous alternation task.
Four experimental groups of mice (saline i.p.; lovastatin i.p.; saline i.p. and MNB
lesion; lovastatin i.p. and MNB lesion) were tested for spontaneous alternation be-
havior and locomotor activity. The spontaneous alternation test in a Y maze is a
task based on the natural tendency of rodents to alternate in their choices of arm
visits (Dudchenko, 2004). Spontaneous alternation behavior is generally regarded as
a measure of spatial working memory (Dudchenko, 2004; Senechal et al., 2008).
Alternation rates of the mice with MNB lesion showed no signicant dierence
in a two-way ANOVA when compared with the non-lesioned animals. Moreover,
lovastatin treatment in NMDA-induced lesioned mice did not signicantly increase
spontaneous alternation rates compared to the saline-treated animals (see Fig. 6.3(a)).
Furthermore, we did not nd a dierence in the number of arm entries between any
of the groups, which suggested that the exploratory activity was neither aected by
lovastatin treatment nor by MNB lesions (Fig. 6.3(b)).
6.3.4 Lovastatin decreased lesion-induced memory decits.
Neuronal projections from MNB directly modulate neocortical information process-
ing. The passive avoidance task is a learning task which depends, in part, on proper
neocortical information processing. In rats NMDA-induced lesions in MNB were
indeed reported to result in memory impairments in a passive avoidance paradigm6.3. Results 109
(a)
(b)
(c)
Figure 6.2: Lovastatin protects cholinergic bers against NMDA-induced lesions. (a)
ChAT-ir neuronal perikarya and proximal ber branches in the MBN following NMDA or PBS infu-
sion. Depicted representative region of intact cholinergic neurons (1, 2) after sham lesions in MNB
whereas in (3, 4) it is shown the loss of proximal ber branches emanating from ChAT-ir perikarya.
Noteworthy is the loss of cholinergic neurons as a consequence of NMDA toxicity. Arrows show
ChAT-ir stained cholinergic processes. (b) Distribution of ChAT-positive projection bers in the
posterior somatosensory cortex following NMDA or PBS infusion in the mouse MNB. (1) Depicted
representative region of sham-operated control. Noteworthy is the loss of cholinergic projections as
a consequence of (2) NMDA infusion. (3) Pre-lesion lovastatin administration (20 mg/kg) signi-
cantly attenuated the NMDA-induced damage whereas (4, 5) inhibition of PKB/Akt with LY294002
failed to rescue cholinergic projections in (5) lovastatin-treated mice. Horizontal bars in (1) rep-
resent layer V of the somatosensory cortex where the quantitative measurements were performed.
(c) Quantitative measurements of cholinergic ber densities in layer V of the somatosensory cortex.
Whereas NMDA infusion into MNB induced a massive loss of ChAT ber loss, lovastatin treatment
signicantly antagonized this NMDA detrimental eect. However, inhibition of PKB/Akt pathway
with LY294002 did not rescue cholinergic ber projections in saline- or lovastatin-treated mice. **p
< 0:01, *p < 0:05 NMDA vs. all other groups examined (Univariate analysis of variance), n = 5 7
per group. Data represent means S.E.M.110 Lovastatin mediates in vivo neuroprotection via PKB/Akt signaling
(a) (b)
Figure 6.3: NMDA-induced lesions do not cause changes in working memory. (a). In
the spontaneous alternation task there is no dierence in alternation rate between the four groups.
Note, however that the pool of lovastatin-treated groups had a signicantly higher alternation rate
when compared to the pooled two saline-treated groups (p = 0:045, two-way ANOVA). (b). There
was no signicant dierence in the number of arm entries. *p < 0:05, n = 6   7 per group. Data
are expressed as means S.E.M.
(Harkany et al., 1999; Van der Zee et al., 1994). Therefore, we used this behavioral
paradigm to investigate whether preserved cortical cholinergic function in lovastatin-
treated mice is able to revert the cognitive decits induced by NMDA lesions into
MNB.
Altered retention mechanisms and acquisition were investigated at 8 days post-
surgery or 8 days after the last intra-peritoneal injection in the passive avoidance
paradigm. Pre-shock latencies did not exhibit signicant dierences among the exper-
imental groups. NMDA infusion into the MNB resulted in a signicant impairment of
passive avoidance learning. This was indicated by shorter post-shock latencies in the
retention trial 24 h after delivery of the foot-shock in the saline-treated NMDA lesion
group (4:5  0:75 min) in comparison to the saline-treated group (8 min). However,
lovastatin pretreatment in NMDA lesioned mice signicantly increased the postshock
latency time compared to NMDA lesioned animals (6:5  0:8 min vs. 4:5  0:75 min;
p < 0:05 Univariate analysis of variance) indicative of an improved memory perfor-
mance in this test condition. Lovastatin treatment alone had no eect on memory
performance.
6.4 Discussion
In the present study we show that administration of lovastatin protects cholinergic
neurons and their cortical projections against excitotoxic damage in vivo. Decline of6.4. Discussion 111
(a) (b)
Figure 6.4: Lovastatin pretreatment decreased the NMDA lesion-induced memory
decits. (a) Lovastatin treatment or NMDA infusion in the mouse MNB did not change pre-
shock latencies in the passive avoidance test. (a) Lovastatin administration by itself did not elicit
any signicant changes in the post-shock latencies, as compared with the latencies of saline-injected
mice. In contrast, NMDA infusion (60 nmol) into the MNB signicantly impaired memory reten-
tion as shown by the reduced post-shock latencies. However, lovastatin pretreatment (20 mg/kg)
attenuated this NMDA-induced memory decit. *p < 0:05 NMDA vs. all other groups examined
(Univariate analysis of variance), n = 6   7 per group. Data are expressed as means S.E.M.
ChAT positive neurons in the basal forebrain nucleus and their projection bers in
the parietal cortex as a result of excitotoxic stimuli is a well-established technique
to test bioactive substances in vivo (Dunnett et al., 1987; Luiten et al., 1987). For
the rst time this method was applied in mice and we could demonstrate a similar
eect of the NMDA lesion as compared with the well-established rat model (Luiten
et al., 1995; Stuiver et al., 1996; Harkany et al., 2000). The advantage of this in
vivo model is the precisely quantiable neuronal lesion eect on cholinergic ber loss.
Moreover, because of the strictly unilateral projections of the MNB, the contralateral
sham hemisphere can serve as a control within each individual case. Five days of
lovastatin treatment induced a strong neuroprotection against NMDA excitotoxicity.
In a recent in vitro study, we have shown that lovastatin mediates the specic
up-regulation of TNF-R2 in cultured neurons but not that of TNF-R1 (Dolga et al.,
2008). Interestingly, this TNF-R2 up-regulation in combination with TNF signaling
led to a strong neuroprotection. In several studies we have shown that neuroprotec-
tion initiated by activation of TNF-R2 is mediated by PKB/Akt (Marchetti et al.,
2004; Fontaine et al., 2002). In vitro this PKB/Akt pathway was also shown to un-
derlie lovastatin-mediated protection against glutamate-induced excitotoxicity (Dolga
et al., 2008). To investigate if this is also the case in the in vivo situation, we used
the inhibitor of PI3 kinase, LY294002, to block the activation of PKB/Akt. In the
presently used experimental setup we show that this LY294002 treatment resulted
in a strong reduction of lovastatin-mediated neuroprotection in vivo. The neuropro-112 Lovastatin mediates in vivo neuroprotection via PKB/Akt signaling
tective eect of PKB/Akt activation was also reported before in in vivo models for
brain injury. In a middle cerebral artery occlusion model (Pignataro et al., 2008;
Prinz et al., 2008) PKB/Akt activation was found to be essential for neuroprotective
signaling since neuroprotection after postconditioning was inhibited in the presence of
PKB/Akt inhibitor LY294002. Our ndings corroborate recently reported microar-
ray and RT-PCR studies that identied several altered genes in statin-treated mice.
Lovastatin treatment increased the expression levels of 26 genes, particularly genes
related to apoptosis (c-myc, Bcl2) (Johnson-Anuna et al., 2005) and PKB/Akt phos-
phorylation (Li et al., 2006). Bcl2 proteins exhibit neuroprotective functions against
various excitotoxic insults, such as glutamate or amyloid beta peptides. Bcl2 gene
expression is of particular interest in this respect since this major anti-apoptotic gene
is under direct PKB/Akt regulation (Pugazhenthi et al., 2000).
In order to assess whether the cholinergic neurons rescued by lovastatin treatment
are able to counteract the behavioral decits observed in NMDA-induced lesion mice
we subjected the animals to a spontaneous alternation task and a passive avoidance
memory test. To test the selectivity of the MNB lesion to cortical functions we used
the spontaneous alternation paradigm for working memory, since this test is com-
monly associated with hippocampus and pre-frontal-related memory. We found no
signicant dierence in alternation rates between NMDA-lesioned animals compared
with non-lesioned control mice. This suggests that brain regions as the hippocampus
are not aected by NMDA-induced lesions of MNB, which is in line with the known
projection patterns of the MNB and medial septum complex (Luiten et al., 1987;
Gaykema et al., 1989) and was conrmed by our anatomical data. Here, pre-lesion
administration of lovastatin signicantly attenuated the memory retention decit in-
duced by the NMDA lesion of the MNB. The passive avoidance paradigm is one of the
test conditions of choice for the behavioral assessment of the integrity of the neocorti-
cal system. Thus, the neuroprotective eect of lovastatin on NMDA-induced damage
to the MNB and its neocortical innervation are in line with the improved memory re-
tention in lovastatin treated mice. In summary, our behavioral data indicate impaired
behavioral performance associated with damage to the MNB that specically aects
neocortical denervation and its memory functions while leaving particular hippocam-
pal innervation and its learning functions unaected. Whereas lovastatin treatment
reverted the memory decits produced by NMDA lesions as observed in the passive
avoidance paradigm, lovastatin treatment itself had a modest albeit signicant ef-
fect on improving hippocampal memory and prefrontal cortex function irrespective of
damage to cholinergic neocortical innervation.
It is unlikely that behavioral alteration of lovastatin-treated animals can be at-
tributed to direct drug eect since statins are rapidly cleared from the brain within
6 hours after drug administration (Johnson-Anuna et al., 2005). We performed all
behavioral testing 7 days after the last lovastatin administration. However, the exact
underlying mechanisms of how statins can aect the brain remain to be elucidated
(Wolozin, 2004). Statins such as lovastatin are able to cross the blood brain bar-Acknowledgements 113
rier and reach the cerebral cortex within one hour after drug administration but are
signicantly reduced 6 hours later after a single drug application. It is not clear
whether the eects of statins as found in the present study can be directly associated
with cholesterol dependent processes in brain tissue. Brain cholesterol analyses in
several studies showed con
icting results. Long-term treatment of simvastatin for 3
months did not change the total cholesterol levels in the brain although the plasma
total cholesterol levels were strongly reduced (Li et al., 2006). Other studies report
reduced brain cholesterol levels in young C57BL/6J mice treated for 3 weeks with
simvastatin and pravastatin, but such a decline of cholesterol concentrations was not
observed in the brains of mice treated with lovastatin (Johnson-Anuna et al., 2005).
In conclusion our data provide evidence for a neuroprotective role of lovastatin
against NMDA-induced lesions of the MNB. Importantly, this benecial eect was
shown to be dependent on activation of the PKB/Akt pathway. Furthermore, lovas-
tatin administration was able to attenuate impaired memory functions that can be
associated with cholinergic cortical denervation that result from the damaged nucleus
basalis-cortical projection pathway.
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Abstract
It is known that glutamatergic and cholinergic systems interact functionally at the
level of the cholinergic basal forebrain. The N-methyl-D-aspartate receptor (NMDA-
R) is a multiprotein complex composed of NR1, NR2 and/or NR3 subunits. The
subunit composition of NMDA-R of cholinergic cells in the nucleus basalis has not
yet been investigated. Here, by means of choline acetyl-transferase and NR2B or
NR2C double staining, we demonstrate that mice express both the NR2C and NR2B
subunits in nucleus basalis cholinergic cells. We generated NR2C-2B mutant mice in
which an insertion of NR2B cDNA into the gene locus of the NR2C gene replaced
NR2C by NR2B expression throughout the brain. This NR2C-2B mutant was used
to examine whether a subunit exchange in cholinergic neurons would aect acetyl-
choline (ACh) content in several brain structures. We found increased ACh levels in
the frontal cortex and amygdala in the brains of NR2C-2B mutant mice. Brain ACh
has been implicated in neuroplasticity, novelty-induced arousal and encoding of novel
stimuli. We therefore assessed behavioral habituation to novel environments and ob-
jects as well as object recognition in NR2C-2B subunit exchange mice. The behavioral
analysis did not indicate any gross behavioral alteration in the mutant mice compared
with the wild-type mice. Our results show that the NR2C by NR2B subunit exchange
in mice aects ACh content in two target areas of the nucleus basalis.7.1. Introduction 119
7.1 Introduction
N-methyl-D-aspartate receptors (NMDA-Rs) have been implicated in neuroplas-
ticity and memory processes (Morris et al., 2003). Native NMDA-Rs are composed of
an NR1 and at least of one of four NR2 (A-D) and/or NR3 subunits. These subunits
are encoded by separate genes, which show distinct developmental, brain regional,
cellular and subcellular expression patterns (Das et al., 1998; Hollmann and Heine-
mann, 1994). The functional characteristics of the NMDA-R are determined by their
subunit composition (Dingledine et al., 1999). We generated mice in which the coding
sequence of the NR2C gene was replaced by the one of the NR2B gene, whereas the
regulatory sequences of the NR2C gene were kept functional (Schlett et al., 2004).
These mice express the NR2B subunit instead of the NR2C subunit throughout the
brain. Consequently, the NR2C protein was absent in cerebellar slices of adult mu-
tant mice, whereas their level of the NR2B protein was increased. Compared with
NMDA-Rs bearing the NR2C subunit, those featuring the NR2B subunit have several
distinct properties, e.g. a higher Ca2+ conductance, higher Mg2+ sensitivity, higher
excitory postsynaptic potentials (EPSPs) and coupling to distinct second messenger
systems (Nakanishi and Masu, 1994). Consequently, in cerebellar slices, the amplitude
of NMDA currents was increased in NR2C-2B subunit exchange mice. We also found
aberrations in cerebellar morphology together with motor decits on an accelerating
rotarod in these mice (Schlett et al., 2004).
The cholinergic basal forebrain innervates various limbic and cortical areas and
plays an important role in cognitive functions (Sarter and Bruno, 2000). The infu-
sion of NMDA into the basal forebrain induces cortical acetylcholine (ACh) release
(Fournier et al., 2004), and NMDA-R in the basal forebrain contributes to the release
of ACh after behavioral stimulation (Fadel et al., 2001). The NMDA-R subunit com-
position of cholinergic cells in the nucleus basalis has not been investigated so far,
neither in rats nor in mice. Therefore, we examined whether the NR2B or NR2C
subunits are expressed in these cells.
NMDA-R antagonists given systemically have been shown to impair behavioral
habituation to an open eld (Dai and Carey, 1994) and object memory (Baker and
Kim, 2002; Packard and Teather, 1997). Decits in object memory have been re-
ported after the infusions of NMDA-R antagonists into the perirhinal cortex (Abe
and Iwasaki, 2001) and hippocampus (Baker and Kim, 2002). The overexpression
of the NR2B subunit in the forebrain improved object memory after long retention
intervals up to 3 days (Tang et al., 1999). We therefore examined whether spatial
and object recognition is likewise improved in NR2C-2B mice.
Brain ACh has been implicated in behavioral habituation to novel environments
(Schildein et al., 2000) and object recognition (Abe and Iwasaki, 2001). The exposure
of rats to spatial novelty increased the extracellular levels of hippocampal ACh. This
increase was positively correlated with the amount of exploratory behavior exerted
(Thiel et al., 1998). ACh receptor (ACh-R) activation enhances NMDA-mediated
responses (Sabatino et al., 1999). Interactions between cholinergic and NMDA recep-120 NR2C-2B subunit exchange alters brain acetylcholine
tors also occur during neural plasticity (Broide and Leslie, 1999; G othert and Fink,
1989). Parallel to NMDA antagonism, interventions into cholinergic systems in
uence
spatial learning (Whishaw and Tomie, 1987). Therefore, we determined whether the
NR2C-2B subunit exchange has aected ACh concentrations in dierent brain regions
of NR2C-2B mice in order to relate changes in ACh content to possible changes in
behavioral habituation to novel environments and object recognition. Because the
exploration of novel environments and objects correlates with emotionality (Pawlak
and Schwarting, 2002) and because NMDA-R subunits have been implicated in exper-
imental anxiety (Dere et al., 2003b), we investigated whether the NR2C-2B subunit
exchange has an eect on elevated plus-maze behavior.
7.2 Materials and methods
Animals. The generation of the NR2C-2B subunit exchange mice and the veri-
cation of successful subunit exchange by in situ hybridization and Western blotting
methods as well as electrophysiological and anatomical examinations of the NR2C-2B
mice are described elsewhere (Schlett et al., 2004). Male NR2C-2B substitution mice
(n = 10) and wild-type littermates (n = 9) (2 months old) (obtained from the animal
breeding division of the Institute for Cellular Biology and Immunology, University of
Stuttgart, Germany) with a C57BL/6 genetic background were used for behavioral
and biochemical tests. One week prior to behavioral experimentation, the mice were
single-housed in standard Makrolon cages and had continuous access to food (10H10;
Nohrlin, Bad Salzu
en, Germany) and tap water. The acclimatization period to the
housing conditions during the experiment was 1 week, and during this time, the an-
imals were handled daily. They were maintained on a 12-h light/dark cycle, with
lights switched on at 07:00 h and were tested during the light phase between 09:00
h and 16:00 h. The order of behavioral testing was (a) open eld, (b) object explo-
ration and (c) elevated plus maze. All experiments were performed according to the
guidelines of the German Animal Protection Law and were approved by the North
Rhine-Westphalia state authority.
Immunocytochemistry. We examined whether the wild-type mice express the
NR2C or NR2B protein in cholinergic neurons of the nucleus basalis, by means of
double in situ hybridization using 
uorescence-labeled probes against choline acetyl
transferase (ChAT) and NR2B, or NR2C, respectively. Furthermore, a possible co-
expression of the NR2B protein along with ChAT in nucleus basalis neurons was
determined for NR2C-2B subunit exchange mice.
Cloning mouse ChAT. Mouse ChAT cDNA was cloned from tissue RNA by RT-
PCR using random hexamer primers. The PCR steps included 5 min at 95 ￿, fol-
lowed by 35 cycles: 30 seconds, 95 ￿; 30 seconds, 60 ￿; 60 seconds, 72 ￿ and
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-GCCTGGTATGCCTGGATGGTC-3' and 5' -TGGAGGGCCACCTGGATGAAG-
3'. PCR products were puried and cloned into Escherichia coli (Invitrogen, Karl-
sruhe, Germany, TOPO10 cloning system) using the manufacturer's protocol.
Labeling of RNA probes. The digoxygenin-labeled RNA probes for murine ChAT
(pAD1) were synthesized by using 2 ￿g of linearized template cDNA, 2 ￿l of T7 or Sp6
polymerase (1 U/￿l, Maxiscript Sp6/T7 kit, Ambion, Cambridgeshire, UK), 0.7 ￿l of
UTP 0.7 mM, 1 ￿l each ATP, GTP and CTP (1 mM each), 1 ￿l of digoxygenin-11-
UTP 0.3 mM (Roche Diagnostics, Rotkreuz, Switzerland), 2 ￿l of 10 transcription
buer (Maxiscript Sp6/T7 kit, Ambion) and 1 ￿l of RNAse Inhibitor (1 U/￿l, Roche
Diagnostics). Diethyl pyrocarbonate (DEPC)-treated H2O (DEPC, Sigma, Munich,
Germany) was added to a nal volume of 20 ￿l.
The biotin-labeled RNA probes for murine NR2B (pMK4; Klein et al. (1998))
and NR2C (pMK5; Pieri et al. (1999)) were synthesized by using 2 ￿g of linearized
template cDNA, 2 ￿l of T3, Sp6 or T7 polymerase (1 U/￿l), 5 ￿l of Biotin-nucleotide
mix (Perkin-Elmer, Rodgau - J ugesheim, Germany), 2 ￿l of 10 transcription buer,
1 ￿l of RNAse Inhibitor (1 U/￿l) in a total volume of 20 ￿l and incubated for 2 h at
37 ￿. The RNA probes were puried by LiCl/ethanol precipitation. The pellet was
dried and resuspended in 50 ￿l of RNAse-free H2O and stored at  80 ￿ until use.
In situ hybridization. The animals were killed by cervical dislocation (Sethy and
Francis, 1988), their brains were quickly removed and 12-￿m sections of wild-type
C57BL/6J or NR2B-2C brain mice were cut using a cryostat (Leica, Solms, Germany).
Sections were mounted on poly-L-lysine-treated slides (Polysine Slides, OmniLabo,
Artselaar, Belgium) and stored at  80 ￿ before use. Sections were warmed to room
temperature and xated in 4% paraformaldehyde/phosphate-buered saline (PBS),
at 4 ￿, for 30 min, washed in PBS for 1 min, incubated in HCl (0.6%) for 10 min, in
Triton (PBS, 1% Triton-X-100) for 2 min. Sections were washed twice in PBS for 30
seconds and incubated in 50% formamide and 5SSC for 15 min.
The digoxygenin- or biotin-labeled RNA probes (250- 400 ng/ml) were denaturated
in hybridization solution, at 65 ￿, for 5 min and subsequently chilled on ice for 5 min.
The hybridization mix contains 0.2 ￿g/￿l of yeast tRNA (Roche Diagnostics), 10%
dextransulfate, 2SSC, 0.2 ￿g/￿l of herring sperm DNA (Sigma) and 50% formamide.
One hundred microliters of denatured digoxygenin or biotin-labeled RNA probe in
hybridization solution was applied to each section, and the hybridization was carried
out at 55 ￿, for 18{24 h.
Sections were washed twice in 0:1SSC, at 60 ￿, for 30 min. each time. Sections
were treated with blocking solution [Tris-HCl 100 mM, pH 7.5, NaCl 150 mM, 0.3%
Triton-X100, 1% blocking solution (Roche Diagnostics)]. One hundred microliters of
anti-digoxygenin-AP (1 : 500, Roche Diagnostics) and streptavidin-horseradish per-
oxidase (1 : 500) diluted in blocking solution (Roche Diagnostics) were applied to
sections and incubated at 37 ￿, for 1 h, in a moist chamber. Sections were washed122 NR2C-2B subunit exchange alters brain acetylcholine
for three times with Tris-HCl 100 mM, pH 7.5, NaCl 150 mM and Tween-20 (0.5%),
for 5 min.
To detect biotin-labeled probes, we applied the 
uorophore tyramide (TSA Plus

uorescence systems, Perkin-Elmer) to slides for 15 min at room temperature. The de-
tection of digoxygenin-labeled probes was performed by O/N incubation at 4 ￿ with
a Cy3-conjugated donkey anti-sheep IgG (Jackson, West Grove, PA, USA). Sections
were washed for three times in Tris-HCl 100 mM, pH 7.5, NaCl 150 mM for 5 min
and mounted in antifading solution (Slow-fade light plus Dapi kit, Molecular Probes,
Karlsruhe, Germany). In situ hybridized sections were nally analyzed using an LSM
510 Zeiss laser scanning microscope.
Neurochemical analysis: brain ACh levels. In addition to the investigation of
whether the wild-types express the NR2C or NR2B protein in cholinergic neurons of
the nucleus basalis, we also determined the ACh content in the frontal cortex and
amygdala, the two target areas of the cholinergic projections of the nucleus basalis,
2 weeks after the end of behavioral testing in both genotypes. We further measured
ACh levels in the hippocampus, which receives cholinergic input from the medial
septum/vertical limb of the diagonal band, and in the striatum, where ACh is de-
rived from intrinsic striatal neurons. The animals were killed by cervical dislocation
(Sethy and Francis, 1988), and their brains were quickly removed and placed in an
ice-cold brain matrix. Coronal sections were made following landmarks on the base
of the brain, and the frontal cortex, dorsal and ventral striatum, hippocampus and
amygdala were dissected out bilaterally onto an iced platform. Thereafter, the brain
tissue was weighed, homogenized in ice-cold 0.05 N perchloric acid containing ethyl-
homocholine as an internal standard, centrifuged, ltered and kept at  70 ￿ until
being analyzed. The brain tissue samples were analyzed for ACh concentration ac-
cording to the procedure utilized by Damsma et al. (1987), except for the internal
standard (Potter et al., 1983), using high-performance liquid chromatography with
electrochemical detection (for technical details, see De Souza Silva et al. (2000)).
Behavioral analysis.
Open eld. In order to examine spatial novelty induced exploratory activity, be-
havioral habituation to a novel environment after a 24-h interval and recognition of
spatial stimuli after a 72-h retention interval, we exposed the mice repeatedly to an
open eld. The open-eld apparatus was a rectangular chamber (29  29  40 cm)
made of gray Polyvinylchloride. A video camera was mounted 250 cm above the maze.
Diuse white light provided an illumination density of approximately 0.24 lux at the
center of the maze. Masking noise was delivered by an active air conditioning system.
The digitized image of the path taken by each animal was stored and analyzed with a
semiautomated analysis system (EthoVisionﬁ, Noldus, the Netherlands). After each
trial, the apparatus was cleaned with water containing 0.1% acetic acid. We used
a small open 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between learning and stress. Under more aversive conditions, such as a strongly illu-
minated large open space, the decrease in exploratory behaviors, normally observed
during re-exposure to the open eld, might re
ect a memory for the experience of
there being no escape route out of the eld, rather than re
ecting a simple form of
spatial learning.
The behavioral parameters registered during 5-min sessions were (a) rearing { the
number of times an animal was standing on its hind legs with forelegs in the air
or against the wall was recorded manually using counters and (b) locomotion { the
distance in centimeters an animal moved. The animals were given three trials in the
open eld, and the second and third trials were administered 24 and 96 h after the
initial exposure.
Object exploration. Novel object exploration, behavioral habituation to novel ob-
jects and object recognition were evaluated in a familiar open eld (see above). The
mice were rst presented with two identical objects, made of transparent glass with
a height of 12 cm and a base diameter of 4 cm, placed in a balanced fashion in the
corners of the open eld. The mice explored the objects for 2 consecutive days during
5-min sessions. Thereafter, on the third day, one object was replaced by a novel glass
object with a dierent shape, and the animals were allowed to explore the familiar
and novel object for 5 min. The corner in which the novel object was placed was
balanced within the groups. Because the objects were made of the same material,
they could not be distinguished by olfactory cues during the object recognition test.
The objects had sucient weight to ensure that the mice could not displace them.
After each trial, the apparatus and the objects were thoroughly cleaned with water
containing 0.1% acetic acid in order to remove odor cues. The objects had no known
ethological signicance for the mice and had never been paired with a reinforcer. Pi-
lot studies ensured that C57BL/6 mice could discriminate the two objects, and there
was no per se preference for one of these objects. Because the novel object diered
from the familiar object only in shape but not regarding height, material or color,
this novelty discrimination task was assumed to be rather dicult, having a high
sensitivity for detecting promnestic eects. Additionally, we used rather long 24-h re-
tention intervals to further increase the sensitivity of the task to ensure the detection
of promnestic eects in NR2C-2B mice. For each mouse, the time spent exploring the
objects was scored oine from videotapes using stopwatches. The exploration of an
object was assumed when the mouse approached an object and had physical contact
with it, with its vibrissae, snout or forepaws. Vicinity to an object at a distance less
than 2 cm was not considered as exploratory behavior.
Elevated plus maze. In order to probe whether unconditioned fear was aected
by the NR2C-2B subunit exchange, we subjected the animals to the elevated plus
maze. The plus maze consisted of two open arms (29  5 cm) and two walled arms
(29  5  15 cm) with an open roof, arranged around a central platform (5  5 cm),
in a way that the two arms of each type were opposite to each other. The maze was
elevated to a height of 40 cm. The videotaped, digitized tracking, masking noise and124 NR2C-2B subunit exchange alters brain acetylcholine
illumination settings were the same as for the open-eld experiment. After each trial,
the apparatus was swept out with water containing 0.1% acetic acid. The mice were
placed on the central platform of the maze facing one of the walled arms and were
observed for 5 min, during which the number of entries into and time spent in the
open and enclosed arms were measured.
Statistical analysis. Behavioral data were analyzed with repeated measures oneway
ANOVAs and t-tests for dependent and independent samples. Neurochemical data
were analyzed using t-tests for independent samples. All P-values given are two-tailed
and were considered to be signicant when p < 0:05.
7.3 Results
7.3.1 Mutant NR2B gene expression in cholinergic neurons of the nu-
cleus basalis. To our knowledge, the expression of NMDA-R subunits in the nu-
cleus basalis has been investigated neither in rats nor in mice. It is unclear whether
NMDA-R in the nucleus basalis expresses the NR2C and/or the NR2B subunits. Fur-
thermore, it is not known whether these subunits are expressed in cholinergic cells
of the nucleus basalis. We therefore performed double in situ hybridization using

uorescence-labeled probes against ChAT and NR2C or NR2B, respectively, to know
whether (a) these subunits are expressed in the nucleus basalis of wild-type mice and
(b) they are expressed in ChAT-positive cholinergic cells. Indeed, both NR2C and
NR2B proteins are expressed in the nucleus basalis of wild-type mice (Fig. 7.1(a) and
(d)) and are observed in ChAT-positive cells (Fig. 7.1(c) and (f)). Thus, we conrmed
that NMDA-Rs on cholinergic cells of the nucleus basalis express both the NR2C and
NR2B subunits in wild-type mice. In NR2C-2B subunit exchange mice, the coding
region of the NR2C gene was replaced by a cDNA fragment coding for the NR2B
protein, placed directly behind the ATG codon of the NR2C gene. Thus, these mice
no longer express the NR2C protein in the brain. In adult wild-type mice, the highest
level of NR2C protein expression is found in the cerebellum. Previously, we showed
by means of Western blot analysis that the NR2C protein is absent in the cerebellar
tissue of NR2C-2B subunit exchange mice (Schlett et al., 2004). Therefore, one can
be certain that the NR2C protein is also absent in the nucleus basalis of NR2C-2B
subunit exchange mice and that cholinergic cells which express the NR2C protein
in the wild-types are instead expressing the NR2B protein in the NR2C-2B subunit
exchange mice. The coexpression of NR2B together with ChAT in the same cells was
also conrmed for the NR2C-2B subunit exchange mice (Fig. 7.1(g){(i)).
7.3.2 Neurochemistry: brain ACh levels. The in situ hybridization studies
conrmed that murine cholinergic cells in the nucleus basalis express both the NR2C
and NR2B subunits. The nucleus basalis cholinergic cells of NR2C-2B subunit ex-
change mice no longer express the NR2C protein but instead express additional NR2B7.3. Results 125
Figure 7.1: In situ hybridization for NR2C subunit and NR2B subunit mRNA in
cholinergic neurons in the nucleus basalis. (a) NR2C subunit mRNA antisense probe (green)
in nucleus basalis of wild-type mice (100). (b) Choline acetyl transferase (ChAT) mRNA antisense
probe (red) in nucleus basalis of wild-type mice (100). (c) Overlay shows the colocalization of
NR2C subunit with ChAT in cholinergic neurons of nucleus basalis of wild-type mice. (d) NR2B
subunit mRNA antisense probe (green) in nucleus basalis of wild-type mice (100). (e) ChAT
mRNA antisense probe (red) in nucleus basalis of wild-type mice (100). (f) Overlay shows the
colocalization of NR2B subunit with ChAT in cholinergic neurons of nucleus basalis of wild-type
mice. (g) NR2B subunit mRNA antisense probe (green) in nucleus basalis of NR2C-2B mice (100).
(h) ChAT mRNA antisense probe (red) in nucleus basalis of NR2C-2B mice (100). (i) Overlay
shows the colocalization of NR2B subunit with ChAT in cholinergic neurons of nucleus basalis of
NR2C-2B mice.
subunits. We next evaluated whether this subunit exchange of nucleus basalis NMDA-
R has an eect on ACh concentrations in the two main target areas, the frontal cortex
and amygdala, which are innervated by these cholinergic cells (Luiten et al., 1985).
Compared with wild-type littermates, the ACh levels of NR2C-2B mice were elevated
by 27.6{21.8% in the frontal cortex (P = 0:03; Table 7.1, t-test for independent sam-
ples) and by 12.7{11.1% in the amygdala (P = 0:03; Table 7.1, t-test for independent
samples). Our results suggest that the replacement of the NR2C by the NR2B sub-
unit in nucleus basalis cholinergic neurons of NR2C-2B mutant mice increases ACh126 NR2C-2B subunit exchange alters brain acetylcholine
levels in the frontal cortex and amygdala. The hippocampus also receives a dense
cholinergic innervation, which, however, rises from cells located in the medial septum
and the vertical limb of the diagonal band (McKinney et al., 1983). Conversely, the
striatum itself contains intrinsic cholinergic interneurons (Phelps et al., 1985). Both
the hippocampus (Raki et al., 2000) and striatum (Beas-Z arate et al., 2002) express
the NR2C subunit and should be likewise aected by the NR2C-2B subunit exchange
in the mutant mice. We therefore also measured ACh levels in the hippocampus and
striatum. Surprisingly, no statistically relevant changes were found in the hippocam-
pus or in the striatum in the mutant mice compared with the wild-type mice (each
P > 0:1).
7.3.3 Behavioral analysis.
Behavioral habituation to an open eld. Both groups showed behavioral habitua-
tion to the open eld, as indicated by an eect of exposures on rearing activity and
locomotion (NR2C-2B: rearings: F2;18 = 19:132; P < 0:001; wild-type: rearings:
F2;16 = 9911; P = 0:002; NR2C-2B: locomotion: F2;18 = 29:378; P < 0:001; wild-
type: locomotion: F2;16 = 20:098; P < 0:001; repeated measures ANOVA, Fig. 7.2(a)
and (b)). There was no signicant main eect of genotype or genotype  day interac-
tion (both p-values > 0:05).
Behavioral habituation to objects. Across the 2 days, the NR2C-2B mice showed
signicant behavioral habituation to objects as indicated by an eect of exposures
on the time spent exploring two equal objects (F1;9 = 8540; P = 0:017; repeated
measures ANOVA; Fig. 7.2(c), left). Wildtype mice failed to show statistically signif-
icant behavioral habituation to objects (F1;8 = 4311; P = 0:072). However, there was
no signicant main eect of genotype or genotype  day interaction (both p-values
> 0:05).
Object recognition. The NR2C-2B mice spent signicantly more time exploring a
novel object relative to a familiar object, as indicated by an eect of objects (F1;9 =
5:276; P = 0:047; repeated measures ANOVA; Fig. 7.2(c), right). Wildtype mice
failed to prefer the novel to the familiar object (F1;8 = 1:650; P = 0:235). However,
there was no signicant main eect of genotype or genotype  object interaction (both
p-values > 0:05).
Elevated plus maze. Neither the time spent in nor the number of entries into the
open and walled compartments of the maze was statistically dierent between groups
(time spent in open arms: P = 0:26, walled arms: P = 0:90; entries into open arms:
P = 0:48, walled arms: P = 0:2; t-test for independent variables; Fig. 7.2(d) and
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Table 7.1: Mean (SEM) concentration (pmol/mg) of acetylcholine in respective brain areas for
NR2C-2B and wild-type mice
NR2C-2B Wildtype
Frontal cortex 7:625  0:683 5:723  0:292
Ventral striatum 19:668  2:793 19:318  0:859
Neostriatum 20:118  0:499 19:732  0:947
Hippocampus 6:671  0:261 6:738  0:545
Amygdala 12:05  0:465 10:611  0:311
p < 0:05; t-test
7.4 Discussion
To analyze the behavioral and neurochemical eects of perpetuating the NMDA-R
subunit composition in vivo, we generated mutant mice, in which the coding sequence
of the NR2C gene was replaced by that of the NR2B gene, whereas the promoter
sequence of the NR2C gene was kept functional. These mutants express the NR2B
subunit instead of the NR2C subunit throughout the brain. We previously showed
in mature cerebellar granule cells that the NR2C protein is absent in the mutants
and that the subunit exchange yields functional NMDA-R with distinct properties
(Schlett et al., 2004).
Cholinergic neurons in the nucleus basalis, from where cholinergic projections
to the frontal cortex and basolateral amygdala arise, are excited by glutamate and
blocked by NMDA-R antagonists but not a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA-R) antagonists (Fadel et al., 2001; Giovannini et al., 1997). The
infusion of NMDA into the basal forebrain induces cortical ACh release (Fournier
et al., 2004), and ACh-R activation enhances NMDA-mediated responses (Sabatino
et al., 1999). Furthermore, basal forebrain NMDA-Rs contribute to the cortical ACh
release after behavioral stimulation (Fadel et al., 2001). These studies suggest im-
portant functional interactions between glutamatergic and cholinergic systems at the
level of the cholinergic basal forebrain.
Despite this evidence, suggesting a close functional link between glutamatergic and
cholinergic systems, the subunit composition of NMDA-R located on nucleus basalis
cholinergic cells in rodents is still unknown. Furthermore, it is unclear whether the
NR2C or NR2B subunits are expressed in the nucleus basalis and whether these sub-
units are expressed in cholinergic neurons. We here demonstrate for the rst time that
both subunits are expressed in cholinergic cells of the nucleus basalis of mice. In light
of these results, we next asked whether the changed NMDA-R subunit composition in
nucleus basalis cholinergic neurons in NR2C-2B mice might have an impact on ACh
content in the two main target areas of the cholinergic basal forebrain, e.g. the frontal
cortex and amygdala. An HPLC-EC ACh assay revealed that the NR2C-2B mice had
indeed increased ACh levels in the frontal cortex and amygdala. These results suggest128 NR2C-2B subunit exchange alters brain acetylcholine
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Figure 7.2: Behavioral analysis of NR2C-2B mutant and wild-type mice. (a) Open eld.
Bars represent mean (SEM) number of rearings on indicated days during 5-min sessions. (b)
Open eld. Bars represent mean (SEM) locomotion in centimeters on indicated days during 5-
min sessions. (c) Object memory. Eects of the NR2C-2B subunit gene replacement on habituation
to object stimuli (day 2) and object recognition (day 3). Bars represent mean (SEM) time spent
exploring objects on indicated days. (d) Elevated plus maze. Bars represent mean (SEM) time
spent in seconds on indicated arms. (e) Elevated plus maze. Bars represent mean (SEM) number
of entries into indicated arms.7.4. Discussion 129
that the replacement of the NR2C by the NR2B subunit in nucleus basalis cholinergic
neurons of NR2C-2B mutant mice aects cholinergic innervation of the frontal cor-
tex and amygdala. This assumption is in accordance with the projection pattern of
nucleus basalis cholinergic neurons (Luiten et al., 1985). The hippocampal formation
expresses the NR2C subunit (Raki et al., 2000) and receives cholinergic input from
cells located in the medial septum and the vertical limb of the diagonal band (McKin-
ney et al., 1983). The NR2C subunit was also detected in the striatum (Beas-Z arate
et al., 2002), which contains intrinsic cholinergic interneurons (Phelps et al., 1985).
Because the mutant NR2C-2B mice express the NR2B subunit instead of the NR2C
subunit in these structures, it can be assumed that ACh levels in the hippocampus
and striatum should be likewise altered. Surprisingly, mutant mice did not dier from
the wild-type regarding ACh levels in these brain areas. Thus, the subunit exchange
has selectively aected ACh concentrations in the frontal cortex and amygdala.
Because the NR2C-2B subunit exchange is coupled to the developmental expres-
sion prole of NR2C, which is expressed postnatally and reaches adult levels within
the fourth week after birth (Schlett et al., 2004; Sircar et al., 1996), developmen-
tal eects of the gene substitution might not account for these ndings. However,
although such results can be interpreted as an increase in release, synthesis or in-
crease in the number of cholinergic synaptic terminals in these brain areas, it should
be noted that these changes in post-mortem ACh content might also re
ect changes
such as metabolism and re-uptake (Finlay and Zigmond, 1995). Therefore, it remains
to be determined whether the increased frontal cortex and amygdala ACh levels are
associated with changes in basal and novelty-induced ACh release. Furthermore, it
remains to be determined whether NR2C and NR2B are expressed in the same or
separate cholinergic cells. Regarding the rst alternative, it would be also interesting
to know whether these two subunits are found in the same NMDA-Rs or in dierent
NMDAR populations. NMDA-Rs containing both the NR2B and NR2C subunits
have not yet been reported to occur in the rodent brain. The eect of NR2C-NR2B
subunit replacement on NMDA-mediated responses in the nucleus basalis remains to
be examined. Finally, by evaluating ACh levels in the frontal cortex and amygdala
of NR2C-knockout mice (Kadotani et al., 1996), one can decide whether the present
eects are due to the absence of the NR2C subunit or due to NR2B expression from
the mutant NR2C gene locus.
It is known that NMDA-Rs are involved in cortical ACh release in brain struc-
tures relevant for learning and memory performance (Fadel et al., 2001; Fournier
et al., 2004) and that the enhancement of cholinergic transmission in the brain can
have promnestic eects (Sarter and Bruno, 1997). ACh release in the frontal cor-
tex was implicated in novelty-induced arousal, attention and the encoding of novel
stimuli and modulates memory consolidation (Acquas et al., 1998; Sarter and Bruno,
2000). Cortical ACh regulates the gating or excitability of sensory neurons during the
processing of novel stimuli. Increased ACh levels in the frontal cortex and amygdala
might improve learning and memory performance by increasing attention to task-130 NR2C-2B subunit exchange alters brain acetylcholine
relevant stimuli (Cangioli et al., 2002; De Souza Silva et al., 2002; Giovannini et al.,
2001; Pallar es et al., 1998). When rats are exposed to a novel environment, they typ-
ically show exploratory behaviors concomitant with large increases of extracellular
levels of cortical ACh. Both exploratory behaviors and extracellular levels of cortical
ACh progressively decline when the environment becomes more and more familiar
(Giovannini et al., 1998; Inglis et al., 1994). Object exploration and recognition also
depends on an intact cholinergic innervation of cortical areas by the basal forebrain
(Abe and Iwasaki, 2001). It is known that the amygdala modulates the consolidation
of the memories of emotionally arousing experiences (McGaugh, 2004). The activation
of ACh-Rs in the basolateral amygdala plays an important role in memory consolida-
tion (Power et al., 2003). Furthermore, neuronal nicotinic ACh-Rs are permeable to
Ca2+ and may interact with NMDA-R to increase intracellular Ca2+ concentrations
required for cellular memory consolidation (Broide and Leslie, 1999). Therefore, we
subjected NR2C2B mutant and wild-type mice to behavioral tasks related to encoding
and retention of spatial and object novelty.
The decrease in exploratory behaviors over repeated exposures to a novel envi-
ronment re
ects a basic form of spatial learning (Cerbone and Sadile, 1994). We
therefore examined whether the NR2C-2B mice might show changes in behavioral
habituation to novel spatial and object stimuli as well as object recognition after long
retention intervals. However, open-eld behavior of the NR2C-2B mutants was not
signicantly dierent from their wild-type controls.
The object recognition task bases on the principle that rodents spontaneously ex-
plore novel and familiar objects (Ennaceur and Delacour, 1988) and tend to spend
more time exploring a novel object relative to a familiar one. It is also possible to mea-
sure behavioral habituation to novel objects over multiple trials (Dere et al., 2003a).
We used long 24-h retention intervals in order to reveal a possible promnestic eect of
the NR2C-NR2B subunit replacement. However, neither the behavioral habituation
to novel objects (days 1 and 2) nor object recognition performance was signicantly
dierent between genotypes. Nevertheless, within-subject analysis revealed that, in
contrast to mutant mice, the wild-type mice failed to show signicant behavioral
habituation to novel objects and novel object recognition.
It has been argued that spatial or object novelty might represent a stressful condi-
tion and that the cholinergic activation after exposure to novelty is partly attributable
to stress or emotionality. Furthermore, subunits of the NMDA-R have been impli-
cated in unconditioned anxiety. NR2D-knockout mice showed reduced levels of anxi-
ety (Miyamoto et al., 2002). Ifenprodil, a selective antagonist at NMDA-R featuring
the NR2B subunit, has been reported to induce anxiolysis in an elevated plus maze
(Fraser et al., 1996), but not in the graded anxiety test (Dere et al., 2003b). The
elevated plusmaze behavior of NR2C-2B mice was not statistically dierent from the
controls, suggesting that the increased ACh concentrations in the amygdala of mu-
tant mice had no eect on emotional reactivity to novel environments. These results
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amygdala, the NR2C-2B subunit exchange has not aected anxiety-related behavior
and behavioral habituation to spatial and object novelty, as well as object recognition.
Nevertheless, it remains to be determined whether shorter or longer retention inter-
vals and whether running the elevated plus-maze test under more aversive conditions,
such as higher levels of illumination, would yield dierent results. It is also possible
that the failure to observe behavioral eects, related to increased ACh contents in the
frontal cortex and amygdala, might be due to compensatory changes in postsynaptic
muscarinergic and/or nicotinergic ACh-R in terms of quantity and/or sensitivity.
Unlike our mutant mice, those in which the NR2B subunit was overexpressed in
the forebrain displayed improved object recognition after long retention intervals (up
to 3 days). The authors concluded that the increased expression of NR2B subunits
in the hippocampus led to better learning and memory performance because of eased
long-term potentiation (LTP) induction (Tang et al., 1999). It would be interesting to
evaluate these mice in terms of frontal cortex and amygdaloid ACh content in order
to know whether NR2B overexpression in these mice goes along with changes in brain
cholinergic systems.
In conclusion, we showed, for the rst time, that nucleus basalis cholinergic neurons
express the NR2B and NR2C subunits. Furthermore, in NR2C-2B subunit exchange
mice, ACh levels in the frontal cortex and amygdala were increased. It is possible
that the replacement of the NR2C by the NR2B subunit in cholinergic neurons of
the nucleus basalis led to this increased ACh content in two of its main target areas.
However, despite the changes in ACh levels, behavioral habituation to novel envi-
ronments and objects as well as object recognition after long retention intervals was
unchanged after NR2C-2B subunit gene replacement.
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The hypothesis of an immune privileged central nervous system (CNS) dates back
to the beginning of the 20th century when several studies reported potential immune
privileged regions in the brain (Shirai, 1921; Billingham and Boswell, 1953; Medawar,
1948). Immune privilege is dened as an evolutionary adaptation to ensure protec-
tion of vital body regions from the in
ammatory immune response. Nowadays, CNS
immune privilege is considered relative and rather an active than a passive process
(Galea et al., 2007). An example of the in
uence of the immune system on the reg-
ulation of brain neuronal homeostasis is represented by cytokine activity. Cytokines,
such as TNF- are involved in a myriad of cellular responses including in
ammation,
growth, and cellular dierentiation in immune and non-immune cells. Under several
pathological conditions, such as neurodegeneration, cytokine expression was found to
be up-regulated (Fillit et al., 1991).
Neurodegeneration is a detrimental process that results in progressive loss of neu-
ronal function and ultimately in neuronal death. Thus, the investigation of the role of
neuroprotective molecular mechanisms in preventing and treating neurodegenerative
diseases is of great importance. In neurodegenerative diseases glutamate is released
in high quantities and represents the major cause of neuronal death (Olney et al.,
1972).
One model to study in vitro the molecular mechanisms underlying neurodegen-
eration is the glutamate-induced excitotoxicity paradigm, where neurons are treated
with glutamate to induce neuronal death and several substances are tested for their
potency to prevent this neuronal death. Hitherto, a number of studies showed that
the cytokine TNF- is able to promote neuroprotection against glutamate-induced
excitotoxicity in cortical neurons (Barger et al., 1995; Cheng et al., 1994; Fontaine
et al., 2002; Marchetti et al., 2004). Until now, the molecular mechanisms underlying
these benecial eects of TNF- are largely unknown. An initial study showed that
TNF- increases neuronal survival by activating the TNF-R2 pathways (Marchetti
et al., 2004). TNF-R2-associated neuroprotective eects are mediated by the activa-
tion of PKB/Akt (Fontaine et al., 2002) and subsequent sustained NF-B activation
(Marchetti et al., 2004).
In this thesis the underlying molecular mechanism of the neuroprotective TNF-
eect was investigated in more detail. Furthermore, the kinetics of the protective
TNF- signaling, upstream molecules and downstream targets involved in this bene-
cial TNF- eect were studied.
8.1 Long term TNF- treatment changes the neu-
ronal state from a vulnerable to a resistant state
against excitotoxic insults
8.1.1 PKB/Akt and NF-B play a major role in TNF- mediated neuro-
protection signaling.8.1. Long term TNF- treatment changes the neuronal state from a
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Chapters 2 and 4 of this thesis investigate the neuroprotective mechanisms by which
TNF- enhances neuronal resistance against glutamate-induced excitotoxicity. First,
the kinetics of the neuroprotective eect of TNF- in primary cortical neurons was
studied. Short-term exposure of neurons for 2-4 h to TNF- did not rescue neurons
from the glutamate-induced cellular death. However, after 6-8 h or longer of TNF-
treatment neuronal survival was signicantly increased.
Several studies showed the in
uence of TNF- treatment on synaptic transmis-
sion (Beattie et al., 2002; Stellwagen and Malenka, 2006; Stellwagen et al., 2005).
Interestingly, TNF- acting on neuronal TNF-R1 receptors, but not on TNF-R2 re-
ceptors increases surface AMPA receptors expression through a PI3-Kinase-dependent
pathway after 20 to 40 min (Stellwagen et al., 2005). This fast increase of excitatory
synaptic transmission (AMPARs) is concomitant with endocytosis of GABA receptors
that weakens the inhibitory synaptic strength. This TNF- eect could explain why
the rst hours of TNF- treatment were not able to induce neuroprotection against
glutamate excitotoxicity.
It was previously shown that long term (24 h) TNF- treatment causes an increase
of PKB/Akt phosphorylation (Marchetti et al., 2004). PKB/Akt phosphorylation in
cortical neurons is associated with increased cellular survival (Lawlor and Alessi,
2001). Chapter 2 describes the PKB/Akt kinetics upon TNF- treatment. Since
PTEN is the major negative regulator of PKB/Akt activation (Bellacosa et al., 2004)
the PTEN expression upon TNF- treatment was investigated. In previous studies,
an increase of PTEN expression in cortical neurons was shown to induce neuronal
death (Gary and Mattson, 2002). Short term TNF- treatment (2-4 h) induced an
increase of PTEN expression and a decrease of PKB/Akt phosphorylation. However,
long term TNF- treatment (6-8 to 24 h) resulted in a decrease of PTEN expression
and augmented PKB/Akt phosphorylation in a time dependent manner. The fact
that high levels of PTEN coincided with low levels of PKB/Akt phosphorylation and
vice versa is in accordance with the inverse relationship between PTEN and PKB/Akt
activation.
To assess the contribution of both TNF-receptors, TNF-R1 and/or TNF-R2 to
the neuroprotective TNF- mediated pathway, PKB/Akt and PTEN expression in
TNF-R1-/- and TNF-R2-/- neurons was investigated. It appeared that in TNF-R1-/-
neurons, PKB/Akt was phosphorylated after long term TNF- treatment with vis-
ible eects after 6-8 h, while in TNF-R2-/- PKB/Akt phosphorylation was down
regulated in a TNF- treatment dependent manner (Chapter 2). From these data we
conclude that in wild-type neurons the increase of PTEN expression and the decrease
of PKB/Akt phosphorylation observed in the rst hours of TNF- treatment could be
attributed to TNF-R1 signaling, while the later decrease of PTEN levels and increase
of PKB/Akt phosphorylation are due to TNF-R2 signaling (Fig. 8.1).
The increase of PKB/Akt activation can be explained by the low levels of PTEN
expression but the remaining question is how is PTEN expression down regulated after
several hours of TNF- treatment. This may occur through the TNF--mediated NF-140 Summary and general discussion
Figure 8.1: The inverse relationship between PTEN and PKB/Akt activation in neu-
ronal survival mechanisms. A. PTEN expression and B. PKB/Akt phosphorylation in wild-type,
TNF-R1-/- and TNF-R2-/- neurons treated with TNF- for 24 h.
B activation signaling (Kim et al., 2004).
In neurons, activation of NF-B is associated with increased neuronal survival
(Mattson and Camandola, 2001). Evidence for the hypothesis that NF-B might be
involved in PTEN down regulation comes from the fact that in cells that are decient
in NF-B activation, TNF did not repress PTEN (Vasudevan et al., 2004). Indeed, it
was demonstrated that a decrease of PTEN levels by NIK/NF-B results in activation
of the PI3K/Akt pathway and an increase of TNF--induced PI3K/Akt activation.
NF-B-inducing kinase (NIK) participates in the regulation of NF-B pathway by
activating the I(kappa) B kinase (IB) both in vivo and in vitro. IB is a temporal
regulatory switch to turn o NF-B activity. However it is not known how the activity
of NIK is regulated (Xiao and Sun, 2000).
TNF- mediated activation of NF-B via PKB/Akt was shown to be dependent
on the inhibitors of IKK complex (IB- or IB-). Cells with higher IB- tend
to be more responsive to PKB/Akt-induced NF-B activation, whereas cells with
higher IB- tend to be less responsive to TNF/PKB/Akt-induced NF-B activation
(Gustin et al., 2004). These results are in good agreement with our ndings, since
PTEN levels were down regulated after long term TNF- treatment (Chapter 2), a
time frame that coincided well with an increased and persistent NF-B activation
(Marchetti et al., 2004).
Besides PTEN, PKB/Akt signaling is modulated by several other molecules, in-
ter alia by carboxyl-terminal modulator protein (CTMP) through a mechanism that
involves direct protein-protein interaction (Maira et al., 2001) or by a recently dis-
covered PH domain leucine-rich repeat phosphatase (PHLPP) (Gao et al., 2005).
Since PKB/Akt pathway could be regulated by cyclic adenosine monophosphate
(cAMP)-dependent signaling as well, Chapter 3 investigated the eect of two main-
stream pathways initiated by cAMP, cAMP-dependent protein kinase (PKA) and8.1. Long term TNF- treatment changes the neuronal state from a
vulnerable to a resistant state against excitotoxic insults 141
exchange proteins directly activated by cAMP (Epac1 and Epac2) on PKB/Akt
phosphorylation in primary cortical neurons. PKA activation led to a decrease of
PKB/Akt phosphorylation, whereas activation of Epac increased PKB/Akt phospho-
rylation. PKA, PKB/Akt and Epacs were all shown to be complexed with the neu-
ronal A-kinase anchoring protein 150 (AKAP150). Particularly, activation of Epac2
increased phosphorylation of PKB/Akt complexed to AKAP150, whereas silencing
of cellular Epac2 diminished PKB/Akt phosphorylation. From experiments using
PKA binding decient AKAP150 and PKA disrupting anchoring to AKAP150 pep-
tides, AKAP150 was found to act as a key regulator in the two cAMP pathways that
control PKB/Akt phosphorylation (Fig. 8.2).
Several reports showed that PKB/Akt activation is essential for cellular survival
and for TNF- mediated neuroprotective pathway (Marchetti et al. (2004); Lawlor
and Alessi (2001), Chapter 2 of this thesis). The CNS is endowed with three PKB/Akt
isoforms: PKB/Akt1, PKB/Akt2 and PKB
/Akt3, therefore we were interested in
the question which PKB/Akt isoforms are important for TNF- mediated neuropro-
tection. To answer this question we transfected primary cortical neurons with siRNA
probes for individual PKB/Akt isoforms. NR2B/TNF neurons were chosen since they
express constitutively elevated levels of activated PKB/Akt compared with wild-type
neurons. Furthermore, NR2B/TNF neurons express regionally high levels of TNF-
 and are totally resistant to excitotoxic eects induced by glutamate treatment
(Marchetti et al., 2004). In NR2B/TNF mice TNF- is expressed under the con-
trol of the murine NMDAR subunit NR2B promoter. Using this system, PKB/Akt1
and PKB/Akt3 isoforms were found important for TNF- mediated neuroprotection,
while PKB/Akt2 had minimal eects on PKB/Akt phosphorylation (Chapter 2).
Another essential player in TNF- induced neuroprotective signaling is NF-B
(Marchetti et al., 2004). One possible downstream molecule of NF-B activation is
represented by small conductance Ca2+-activated potassium (SK) channel. Recently
two NF-B binding sites were shown to regulate the murine SK2 promoter (Kye et al.,
2007). Therefore, in Chapter 4 it was investigated whether SK channels are possible
downstream targets of TNF- signaling (Chapter 4).
SK channels modulate synaptic excitability and neuronal activity e.g. by con-
tributing to afterhyperpolarization processes. The hypothesis of the neuroprotective
properties of SK channels in cortical neurons originates from the SK channels' capa-
bility to lower the ring frequency of action potentials and to dampen NMDA receptor
activity. Therefore, SK channels may enhance the resistant state of neurons against
glutamate excitotoxicity (Stocker, 2004). The connection between potassium chan-
nels and TNF- mediated neuroprotection was suggested by Houzen and colleagues
(1997) who showed that the TNF- induced neuroprotective eect is dependent on the
increase of outward potassium current (A-current) density in cortical neurons. The
A-current regulates the ring activity of neurons and it reduces the neuronal excitabil-
ity. Interestingly, a specic blocker of A-current inhibits the TNF- neuroprotective142 Summary and general discussion
eect (Houzen et al., 1997).
In the present study, SK2 channel expression is augmented upon TNF- treat-
ment. This increase of SK2 channel expression corresponded with the time point of
increased PKB/Akt phosphorylation and increased cellular survival against glutamate
toxicity (Chapter 2). The neuroprotective function of SK channels was demonstrated
by the nding that the SK channel activators, NS309 and CyPPA, promoted neuro-
protection against glutamate-induced excitotoxicity in primary cortical neurons. In
addition, apamin, a specic antagonist of SK2 channels, partially blocks the pro-
tection mediated by TNF- indicating that SK channel activity may underlie the
TNF--induced neuroprotective mechanisms. The increase of SK2 channel expression
after TNF- treatment was shown to be NF-B-dependent since the NF-B inhibitor
BAY11-7082 blocked the TNF--induced increase in SK2 channel expression.
Although TNF-R2, PKB/Akt and NF-B were suggested to be important in TNF-
 induced neuroprotective mechanisms (Fontaine et al. (2002); Marchetti et al. (2004),
this thesis), data on potential up-stream activators of these signaling pathways were
not available yet. Interestingly, a commercially available drug, lovastatin commonly
used in coronary artery disease was recently discovered to specically enhance TNF-
R2 expression in HUVEC cells (N ubel et al., 2005b). In addition, lovastatin was
proposed as neuroprotective agent for several neurodegenerative disorders. Although
both lovastatin and TNF- were shown to be neuroprotective, so far their signal-
ing pathways had been studied independently. The study described in Chapter 5
shows that lovastatin can induce TNF-R2 expression in primary cortical neurons. It
was demonstrated that NF-B is responsible for the lovastatin-dependent increase of
TNF-R2 expression (Chapter 5). Since in TNF-R1-/- neurons inhibition of PKB/Akt
activity reverted the protective eect induced by lovastatin (Figure 8.2) it was con-
cluded that lovastatin-induced TNF-R2 expression contributes to neuronal survival
through PKB/Akt activation.
The mechanisms through which lovastatin activates the neuroprotective TNF-
R2/PKB/Akt pathway remain elusive (Chapter 5). One possibility is that lovastatin
in
uences TNF-R2 signaling by reducing the cellular cholesterol levels. In endothelial
cells statins induce the recruitment of PKB/Akt to the plasma membrane, which re-
sults in the activation of PKB/Akt. This process could be attributed to the disruption
of cholesterol-rich microdomains of the plasma membrane called lipid rafts (Skaletz-
Rorowski et al., 2003). Statins deplete the lipid rafts and promote receptor clustering
and initiation of TNF-R signaling. Related to this hypothesis, it is still under debate
whether statins are able to reduce cholesterol levels in the brain (Wolozin, 2004). In
cultured cortical neurons it was shown that statins reduce the total pool of cholesterol
(Zacco et al., 2003). However, in the brain, due to tight cholesterol regulation, even
high doses and long-exposure time (3 months) to statins had a minimal eect on brain
cholesterol levels (Johnson-Anuna et al., 2005).8.1. Long term TNF- treatment changes the neuronal state from a
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Another possibility to explain the lovastatin-induced neuroprotective mechanisms
via TNF-R2/PKB/Akt signaling is the recently discovered relationship between Rho-
associated kinase (ROCK) signaling and PTEN. ROCK activates PTEN in HEK cells
and leukocytes through Rho-associated kinase (RhoA). By blocking the isoprenyla-
tion of RhoA and ROCK, statins could inhibit the activation of PTEN, which in
turn would induce PKB/Akt phosphorylation. Interestingly, TNF- activates RhoA
through TNF-R1 signaling. Depletion of cholesterol from lipid rafts caused a redistri-
bution of TNFR1 to non-lipid raft area of the plasma membrane and prevented ligand-
induced RhoA activation (Lotocki et al., 2004). These ndings are in agreement with
the observation that TNF-R1 increases PTEN expression in cortical neurons (Chap-
ter 2). In addition, lovastatin treatment could abolish PTEN activation (Pedrini et
al., 2005), repress TNF-R1-mediated RhoA activation (Lotocki et al., 2004) and in-
crease PKB/Akt phosphorylation via TNF-R2 (Chapter 5). Overall, these ndings
may explain how lovastatin mediates neuroprotection via TNF-R2/PKB/Akt path-
ways (Figure 8.2).
Chapter 6 consolidates the role of PKB/Akt as a downstream molecule in lovastatin-
mediated neuroprotective signaling. Using an in vivo model, in which NMDA was
infused in the nucleus basalis of Meynert (MNB), located in the basal forebrain cholin-
ergic complex, the eect of lovastatin on cortical cholinergic bers was investigated.
Since the basal forebrain provides the major input in cholinergic projections to the
cerebral cortex and hippocampus (Mesulam and Geula, 1988; Gaykema et al., 1990)
the cortical cholinergic target area was quantied to determine the magnitude of
cholinergic ber loss produced by NMDA lesions in MNB. Although brain cholinergic
neurons have dierent sensitivity to pathogenic insults, the basal forebrain cholin-
ergic neurons are particularly susceptible to neuronal death when exposed to toxic
agents, such as glutamate or nitric oxide (Fass et al., 2000; Schliebs and Arendt,
2006). Lovastatin treatment signicantly protected cholinergic neurons and their cor-
tical projections against NMDA induced cell death in MNB. Furthermore, lovastatin-
mediated neuroprotection was shown to be dependent on protein kinase B (PKB)/Akt
signaling since inhibition of PKB/Akt with LY294002 blocked the lovastatin-induced
neuroprotective eect (Chapter 6).
Several studies already provided evidence of a decrease of presynaptic cholinergic
markers in the cerebral cortex of patients with early-onset of AD (Davies and Mal-
oney, 1976; Bowen and Davison, 1980). The decline of cortical cholinergic markers is
highly linked with the memory deciency in AD patients. A correlational study of
the cognitive performance and the cholinergic neurons of the basal forebrain in both
aged human patients and mild cognitive impaired human patients shows that the cog-
nitive decits are detectable when at least 30% of the total cholinergic basal forebrain
neurons are degenerated (Arendt, 1999). Since lovastatin treatment was shown to
prevent cortical cholinergic ber loss produced by NMDA infusion in MNB (Chap-
ter 6) the memory performance was tested in a passive avoidance behavior paradigm144 Summary and general discussion
Figure 8.2: Proposed TNF- mediated neuroprotective mechanisms in primary cortical neurons
and a spontaneous alternation test. Lovastatin treatment improved memory decits
in NMDA-lesioned mice. Several studies showed as well that statins improve the spa-
tial learning and memory decits after hypoxic-ischemic or traumatic brain injuries
in rats (Balduini et al., 2003; Lu et al., 2007); and learning and attention in a mouse
model of neurobromatosis type I (Li et al., 2005). Overall, the study presented in
chapter 6 substantiates the lovastatin-induced increase in learning and memory per-
formance eect.
The presence of distinct NMDA-Rs subunits in the CNS and the fact that these
NMDA-Rs subunits may play dierent roles in the brain suggests a relationship be-8.1. Long term TNF- treatment changes the neuronal state from a
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tween receptor subunit composition and receptor function (Cull-Candy and Leszkiewicz,
2004). The structure and function of NMDA-Rs subunits is altered in several neurode-
generative disorders (Wang et al., 2000). For example in AD NMDA receptor subunits
are selectively and dierentially reduced in the cortex and hippocampus, brain regions
known to be involved in learning and memory (Maragos et al., 1987). Particularly,
the NR2B receptor subunit is signicantly diminished in the hippocampus (40%) and
the entorhinal cortex (31%) when compared with the levels in age-matched control
human patients (Sze et al., 2001; Hynd et al., 2004).
The functional properties of NMDA-Rs are in
uenced mainly by the type of NR2
subunit (Cull-Candy et al., 2001). Several studies showed that NMDA-R featuring
NR2B subunits compared with NMDA-R bearing NR2C subunits, provide special
properties, e.g. a higher Ca2+ conductance, higher Mg2+ sensitivity, higher excitatory
postsynaptic potentials (EPSPs) (Nakanishi and Masu, 1994). Generation of NR2C-
2B mutant mice, in which NR2B cDNA insertion into the gene locus of the NR2C gene,
replaced NR2C by NR2B throughout the whole brain allowed to further investigate the
consequences of this subunit exchange. Alterations in cerebellar morphology together
with motor decits were found in NR2C-2B mutant mice. In addition, the amplitude
of NMDA currents was found increased in cerebellar slices of NR2C-2B mutant mice
compared with wild-type neurons (Schlett et al., 2004).
Since the overexpression of the NR2B subunit in the forebrain improves object
recognition memory (Tang et al., 1999) and increased cortical ACh levels are asso-
ciated with memory performance (Abe and Iwasaki, 2001), NR2C-2B mutant mice
were used to examine whether a subunit exchange in cholinergic neurons would aect
acetylcholine (ACh) content in several brain structures (Chapter 7). Interestingly,
this NR2C-2B receptor subunit exchange induced an increase in the content of ACh
in cholinergic target regions from MNB, such as the frontal cortex and amygdala.
Although brain ACh modulates neuroplasticity and novelty-induced arousal, the be-
havioral analysis in adult mice (novel object recognition) did not indicate any gross
behavioral alteration in the adult mutant mice compared with the adult wild-type
mice (Chapter 7). A follow up study in juvenile mice investigated dopamine, sero-
tonin content in the frontal cortex and in regions related to the defense system, such
as periaqueductal grey matter (De Souza Silva et al., 2007). Furthermore, juvenile
NR2C-2B mice showed increased open arm avoidance in the elevated plus-maze and
increased fear-induced immobility. The increase of serotonin content in the frontal
cortex and the decrease of ACh levels in periaqueductal grey matter was associated
with enhanced anxiety- and fear-related behaviors possibly due to the replacement of
subunit NR2C by NR2B in juvenile mice (De Souza Silva et al., 2007).
Increase of cholinergic transmission in human patients with mild cognitive impair-
ment has been shown to improve hippocampal function (Gr on et al., 2006). Therefore,
it would be interesting to test in future experiments whether the increased level of
ACh in the frontal cortex of NR2C-2B transgenic mice could compensate the memory
decit induced by NMDA lesions in MNB.146 Summary and general discussion
8.2 Degenerative and protective eects of TNF- in
CNS
Several studies investigating the eect of TNF- on cellular survival/death showed
that TNF- could trigger both neuroprotective and neurodegenerative signaling path-
ways.
Excess TNF- causes cell death of human cortical neurons and oligodendrocytes
(Chao and Hu, 1994). Another degenerative TNF- eect was attributed to the so-
called neurotoxic synergy between TNF- and glutamate. For example, in a spinal
cord trauma model, TNF- was shown to exacerbate cellular injury processes through
excitotoxic interactions with glutamate and increased c-Fos expression (Hermann
et al., 2001). In organotypic hippocampal brain slices, TNF- potentiates cellular
death initiated by glutamate through an NMDA receptor-dependent pathway and by
NF-B activation (Zou and Crews, 2005).
On the other hand, accumulating evidence indicates that TNF- contributes to
neuroprotection against glutamate-induced excitotoxicity in cortical neurons (Cheng
et al. (1994); Marchetti et al. (2004), this thesis).
An explanation for this dual eect of TNF- may lie within dierent experimental
protocols (e.g. duration, concentration), cellular types (e.g. neurons, T cell, lympho-
cytes) cellular models or source of TNF- (murine, human). To make things even
more complicated, within CNS some neuronal populations vary in their expression
levels of the endogenous TNF- and TNF-Rs levels in diseased and non-diseased
brain (Fontaine et al., 2002). Several studies faced the diculty of dierentiating the
dual eect of TNF- on cellular viability. Most of the protocols used soluble TNF-
(sTNF-) to investigate TNF- signaling (Shohami et al., 1999). Since sTNF- binds
with a higher anity to TNF-R1 it was for a long time rather impossible to recognize
subtle TNF-R2-mediated eects. The nding that inhibitors of TNF- converting en-
zyme (responsible for cleaving sTNF- from the membrane-bound TNF-) protected
neurons from focal brain ischemia (Wang et al., 2004) indicated a possible involve-
ment of TNF-R2 in the neuroprotective pathways. By using mice lacking TNF-R1,
TNF-R2 or both receptors, it has become much easier to study the contribution of
TNF-Rs to neuroprotective/neurodegenerative pathways.
8.2.1 \Est consensus in rebus" (There is a link between all things).
First of all, \Est modus in rebus" (There is a proper measure in all things) is a quote
that describes well the eect of TNF- doses on neuronal survival. An important ex-
ample related to the eect of dierent concentrations of TNF- on neuronal viability
is represented by the eect of TNF- on dopaminergic neurons. Loss of dopaminer-
gic neuronal function leads to typical symptoms of Parkinson's disease (Rinne et al.,
1987). In experimental animal models for Parkinson's disease 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine or MPTP is widely used to induce Parkinson's-like symp-
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the substantia nigra and subsequently the Parkinson's like symptoms induced by
MPTP treatment are reduced in the absence of TNF- (Ferger et al., 2004). Inter-
esting, though, is the fact that low endogenous levels of TNF- promote neuropro-
tection against 6-hydroxy-dopamine (6-OHDA)-induced lesions in dopaminergic cells
(Pitossi et al., 2003). Overall, these experiments showed that elevated TNF- levels
in dopaminergic neurons of the substantia nigra promote neuronal death, whereas low
levels of TNF- exert neuroprotective functions.
Secondly, duration of TNF- treatment or \Est tempus in rebus" (There is a time
to all things) is crucial in promoting neuroprotective signaling. In primary corti-
cal neurons short-exposure time (2-4 h) to TNF- failed to induce neuroprotection
(Chapter 2), whereas longer exposure time (6-8 h) induced increased cellular survival
against glutamate toxicity.
The inter-connectivity between up-stream molecules and downstream targets of
TNF- plays an important role in TNF- protective mechanisms (\Est consensus in
rebus" (Everything is inter-connected). For example, lovastatin (described as one of
the up-stream molecules of TNF- signaling), PKB/Akt and NF-B activation (as
down-stream targets) are associated to TNF--mediated cellular survival mechanisms
(Chapters 2, 4, 5). Understanding and controlling these neuroprotective pathways
could lead to the development of new treatments for preventing neuronal death that
occurs in several neurodegenerative disorders.
8.2.2 \Est evolvere in rebus"(All things evolve and adapt).
Necrosis is a cellular death process characterized by an increase in cellular entropy
due to the cell's inability to balance internal-external 
ux of ions and to perform
normal functions. In order to prevent the spread of cellular death to other cells,
organisms have evolved over millions of years a form of adaptation, a programmed,
ordered, non-energy dependent mechanism called apoptosis. This \programmed cell-
death" mechanism has several switch-o points. For example, TNF- signaling in
neurons could interfere in the apoptotic pathways and change the balance towards
programmed-cell survival.
Microarray study of approximately 22600 genes attempted to clarify the down-
stream TNF- signaling pathways (Quintana et al., 2007). An important group of
genes involved in the development and cellular survival (heat shock proteins, NF-B,
c-fos) were found down regulated in the cortex of TNF-R2-/- mice. Furthermore, TNF-
R2 depletion decreased the expression level of several genes involved in the modula-
tion of synaptic plasticity (synaptotagmin (syt1), dynamin-1 like (dpl1), SH3-domain
GRB2-like 2 (Sh3gl2), and potassium voltage-gated channel, shaker-related subfam-
ily, beta member 1 (kcnab1)) (Quintana et al., 2007). Analysis of the gene expression
prole of the cortex of TNF-R1-/- mice and of wild-type mice showed lower expression
of the genes involved in pro-in
ammatory response in TNF-R1-/- mice compared with
wild-type mice (e.g. signal transducer, and activator of transcription-3 (stat-3)). This
is in agreement with the overall decreased in
ammatory response of TNF-R1-/- mice148 Summary and general discussion
(Quintana et al., 2005). In addition, lovastatin treatment, which activates TNF-R2
neuroprotective signaling in neurons (Chapter 4) and in endothelial cells (N ubel et al.,
2005b), was shown to enhance the expression of several anti-apoptotic genes (Bcl-2,
c-fos, H1.2, and c-myc) in the mouse cortex (Johnson-Anuna et al., 2005).
Taken together, these results suggest that TNF-R2 signaling could elicit an anti-
in
ammatory and neuroprotective eect under various brain injury conditions (Su-
vannavejh et al., 2000; Quintana et al., 2007).
8.3 Molecular basis for new therapeutics
Cytokine expression is drastically altered in various neurodegenerative conditions,
including AD and Parkinson's disease (Fillit et al., 1991). TNF-R1, TRADD and
TNF- are increased 3- to 10-fold in AD patients as compared to the levels in age-
matched control brains. In contrast, TNF-R2 and Fas-associated death domain-like
interleukin-1-beta-converting enzyme-inhibitory protein (FLIP) (Taouk et al., 2007),
which mediate neuroprotective mechanisms, are decreased in late pathological con-
ditions of AD, at the same time as progressive neuronal injury occurs (Zhao et al.,
2003). The increase of TNF-R1-death receptor expression is rst seen in the en-
torhinal cortex, then in hippocampus and prefrontal cortex, in agreement with the
predicted progression of AD pathology.
Together these observations suggest a strong connection between TNF- and the
initiation and progression of AD disease. Since extensive clinical reports suggest that
statins may protect against AD pathology (Wolozin et al., 2006) and that lovastatin
can increase the expression of TNF-R2 levels, as we demonstrated in this thesis,
one approach to restore the balance in TNF-R1/TNF-R2 expression in AD patients
could be a treatment with statins. Another approach would be anti-TNF- therapy,
by which the expression of TNF- and TNF-R would be down regulated. However,
anti-TNF- therapy in neuroin
ammatory and neurodegenerative disorders has so far
resulted in con
icting outcomes. In clinical trials of rheumatoid arthritis or in
amma-
tory bowel disease, blockade of TNF- produced impressive benecial outcomes for
the majority of patients. In some cases, however, it led to lupus and manifestations of
neuroin
ammatory disease (Feldmann et al., 1996; Sandborn and Hanauer, 1999). In
multiple sclerosis patients, anti-TNF- therapy induced disease exacerbation (Sicotte
and Voskuhl, 2001).
Interestingly, a recent study showed that treatment for 6 months with Etanercept,
(an TNF- scavenger drug) improved learning and memory in AD patients (Tobinick
et al., 2006). In their most recent study, Tobinick and colleagues reported in a one-
case study a tremendous memory improvement within 30-45 minutes after Etanercept
administration (Tobinick and Gross, 2008). Noteworthy is the fact that this patient
received a combination of Etanercept and statins, which could mean that Etanercept
supressed soluble TNF- whereas statins induced TNF-R2 expression and therefore
changed the balance of TNF-R1/TNF-R2 towards neuroprotective TNF-R2 signaling.References 149
In conclusion, our studies suggest potential for therapeutic manipulation of TNF-
signaling in the treatment of neurodegenerative disorders.
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De ziekte van Alzheimer, ziekte van Parkinson en andere neurodegeneratieve aan-
doeningen worden onder andere gekarakteriseerd door een toenemende sterfte van
specieke zenuwcellen. De ontregeling van verscheidene fysiologische processen als
gevolg van deze neuronale sterfte heeft aanzienlijke gevolgen voor hersengebieden die
betrokken zijn bij leer- en geheugenfuncties. Om die reden is het van groot belang
om ernaar te streven het neuronale disfunctioneren in deze hersengebieden te beper-
ken. Het ontwikkelen en toepassen van nieuwe therapieen in klinische trials om sterfte
van hersencellen te beperken is een complexe opgave omdat neurodegeneratieve pro-
cessen het resultaat zijn van ingewikkelde mechanismen van signaaloverdracht. Om
die reden vormt het ontrafelen van de moleculaire processen die ten grondslag liggen
aan neurodegeneratie de basis van mogelijk succesvolle therapeutische benaderingen.
Een experimenteel in vitro model om deze neuronale processen te bestuderen is het
blootstellen van zenuwcellen aan toxische concentraties van de neurotransmitter gluta-
maat, een begrip dat wordt aangeduid met de term excitotoxiciteit. Hiermee kunnen
verschillende potentieel beschermende medicijnen op hun eectiviteit om celsterfte
te voorkomen worden getest. Tot nu toe hebben verschillende onderzoeken aange-
toond dat het cytokine tumor necrose factor (TNF) alfa beschermend kan werken
tegen door glutamaat veroorzaakte excitotoxiciteit. TNF- is een bekend cytokine
dat in toenemende mate tot expressie komt in de hersenen en de cerebrospinale vloei-
stof van mensen die lijden aan een neurodegeneratieve ziekte. Het hoofdthema van
dit proefschrift betreft de moleculaire mechanismen die ten grondslag liggen aan de
beschermende werking van TNF- in de zoogdierhersenen
Hoofdstukken 2 en 4 van dit proefschrift onderzoeken het beschermende mechanis-
me waardoor TNF- de weerstand tegen glutamaat toxiciteit vergroot. In de eerste
plaats werden de kinetische eigenschappen van het neuroprotectieve proces tegen glu-
tamaat onderzocht in celcultures van primaire corticale neuronen. Het blootstellen
van neuronen gedurende 2-4 h aan TNF- leidde niet tot bescherming tegen gluta-
maat veroorzaakte celdood. Opvallend echter bleek dat 6-8 h of langere aanwezigheid
van TNF- wel een signicante redding van de hersencellen teweegbracht.
Uit eerder onderzoek was bekend dat lange termijn behandeling (24 h) met TNF-
 een toename van PKB/Akt fosforylering veroorzaakt. Interessant daarbij is dat
PKB/Akt forforylering in corticale zenuwcellen geassocieerd wordt met een toename
in neuronale overleving. Hoofdstuk 2 beschrijft de kinetiek van PKB/Akt activering
ten gevolge van behandeling met TNF-. Omdat het zg. PTEN de belangrijkste
onderdrukker is van PKB/Akt activering werd de PTEN expressie na TNF bloot-
stelling verder onderzocht. In voorgaande studies werd een toename van PTEN in
corticale neuronen in verband gebracht met een toename in neuronale celsterfte. Een
korte behandeling met TNF gedurende 2-4 h veroorzaakte een toename van PTEN
productie en een afname van PKB/Akt fosforylering. Lange termijn behandeling met
TNF- (6-8 tot 24 h) echter resulteerde in een tijdsafhankelijke afname van PTEN
expressie en een toegnomen PKB/Akt fosforylering. Het feit dat hoge concentraties
van PTEN samengaan met lage nivo's van PKB/Akt fosforylering en omgekeerd komt159
goed overeen met de omgekeerde relatie tussen PTEN en PKB/Akt activering.
Om vast te stellen wat de rol is van de twee TNF receptoren, TNF-R1 en TNF-R2
in het protectieve mechanisme van de TNF- signalen, werden PKB/Akt en PTEN
expressie onderzocht in neuronen van transgene knock-out muizen TNF-R1-/- en TNF-
R2-/-. Hieruit bleek dat in TNF-R1-/- neuronen, PKB/Akt gefosforyleerd werd na
langdurige TNF- behandeling met waarneembare eecten na 6-8 h, terwijl in TNF-
R2-/- neuronen PKB/Akt fosforylering was onderdrukt op een TNF- afhankelijke
wijze (hoofdstuk 2).
Welke PKB/Akt isoform nu precies betrokken is bij de TNF--gemedieerde neu-
roprotectie is niet bekend. In hoofdstuk 2 geven we meer infomatie over de bijdrage
van verschillende PKB/Akt isoforms in het neuroprotectieproces. Gebruik makend
van specieke siRNA technieken die specieke Akt vormen kunnen uitschakelen, heb-
ben we bepaald welke PKB/Akt types betrokken zijn bij de door TNF veroorzaakte
neuroprotectie. Met deze siRNA methode hebben we gevonden dat met name Akt1
en Akt3 betrokken zijn bij neuroprotectie terwijl Akt2 geen rol blijkt te spelen.
Samvattend tonen deze resultaten aan hoe TNF- de beschadigende eecetn van
glutamaat overstimulering bestrijdt d.m.v. PKB/Akt activering.
Omdat bekend is dat de PKB/Akt signaal transductie tevens wordt gereguleerd
door cyclisch adenosine monofosfaat (cAMP)-afhankelijke processen, werden in hoofd-
stuk 3 de eecten van twee hoofdstromen van cAMP signalering onderzocht: cAMP-
afhankelijk protein kinase (PKA) en exchange proteins directly activated by cAMP
(Epac1 en Epac2) op PKB/Akt fosforylering. PKA activering resulteerde in een af-
name van PKB/Akt fosforylering, terwijl activering van Epac PKB/Akt fosforylering
bevorderde. Ook werd aangetoond dat zowel PKA, PKB/Akt als Epac alle gekop-
peld zijn aan het zg. neuronale A-kinase anchoring protein 150 (AKAP150). In het
bijzonder bleek dat Epac2 de fosforylering van PKB/Akt gekoppeld aan AKAP150
bevordert, terwijl inactivering van Ecap2 PKB/Akt fosforylering reduceert. Uit ex-
perimenten waarbij de koppeling van PKA aan AKAP150 wordt onderbroken bleek
dat AKAP150 een sleutelrol speelt in de twee cAMP signaalwegen die PKB/Akt
controleren.
Howel tot nu toe een rol van TNF-R2, PKB/Akt en NF-B werden verondersteld
in het TNF- beschermende mechanisme was er geen informatie beschikbaar over
het preciese verloop van deze signaalweg in de zenuwcel en de doelsystemen die het
fysiologisch mechanisme kunnen verklaren. Daartoe hebben we in hoofdstuk 4 onder-
zocht of SK kanalen een mogelijk doelwit kunnen zijn van TNF signalering, omdat
bekend is dat NF-B de expressie van SK2 kanalen reguleert. SK kanalen kunnen
de synaptische exciteerbaarheid van neuronen veranderen door hun bijdrage aan de
zg. na-hyperpolarisatie. In ons onderzoek hebben we gebruik gemaakt van zeer spe-
cieke agonisten (NS309, CyPPA) en remmers (apamin) van SK kanalen op corticale
neuronen. We vonden hierbij dat NS309 en CyPPA de overleving van neuronen na
glutamaat blootstelling bevorderde, terwijl apamin het protective eect van TNF-
tegenging. Deze uitkomsten tonen een belangrijke rol aan van SK kanalen in het160 Nederlandse samenvatting
fysiologische mechanisme van de TNF- protectieve werking.
Recent werd aangetoond dat een commercieel beschikbaar medicijn, lovastatine,
toegepast om het cholesterolnivo in het bloed te verlagen speciek de expressie van
TNF-R2 kan verhogen in humane endotheelcellen. Lovastatin was al eerder voorge-
steld als een farmacon dat neuroprotectief zou kunnen werken in neurodegneratieve
ziekten. Hoewel lovastatine als TNF- beide neuroprotectieve eigenschappen zijn toe-
bedacht zijn hun signaleringswegen nooit eerder in samenhang onderzocht. In hoofd-
stuk 5 tonen wij aan dat lovastatine de expressie van de neuroprotectieve TNF-R2
in corticale neuronen sterk kan stimuleren. Verder bleek uit dit onderzoek dat NF-
B verantwoordelijk is voor de lovastatin-afhankelijke toename in TNF-R2 expressie.
Omdat in TNF-R1-/- neuronen de remming van PKB/Akt activiteit het protectieve
eect van lovastatin omkeerde werd geconcludeerd dat lovastatin-geinduceerde TNF-
R2 expressie bijdraagt aan neuronale overleven d.m.v. PKB/Akt activering.
Chapter 6 bevestigt de rol van PKB/Akt als een downstream molecuul in lovastatin-
gemedieerde neuroprotectieve signaalwegen. Gebruik makend van een in vivo model,
waarin het glutamaat analogon NMDA werd geinjecteerd in de nucleus basalis van
Meynert (MNB), die deel uitmaakt van het basale voorhersensysteem van cholinerge
neuronen, werd het protectieve eect van lovastatine onderzocht op de overleving van
cholinerge neuronen en hun corticale innervatiepatronen. Omdat de basale voorher-
senneuronen de belangrijkste innervatiebron vormt van cholinerge projecties naar de
schors werd het cholinerge innervatiepatroon gequanticeerd om de neuroprotectie
door lovastatine te meten. Deze experimenten toonden aan dat lovastatine behan-
deling cholinerge neuronen signicant beschermt tegen NMDA geinduceerde celdood
in de NBM. Tevens werd aangetoond dar deze statine neuroprotectie afhankelijk is
van PKB/Akt activering, omdat het beschermend eect geblokkeerd werd door rem-
ming van PKB/Akt door LY294002. De protectie van de cholinerge neuronen door
lovastatine werden vergezeld door een verbetering van de geheugenprestatities in de
geledeerde muizen.
Samenvattend hebben onze studies aangetoond dat therapeutische manipulaties
van het TNF- system potentieel kan bijdragen aan de bescherming van hersenweefsel
bij neurodegeneratieve ziekten.Sumarul tezei162 Sumarul tezei
Moartea neuronilor sau celulelor din sistemul nervos central reprezint a o carac-
teristic a esent ial a ^ n bolile neurodegenerative, cum ar  boala Alzheimer sau Par-
kinson. Reducerea activit at ii neuronilor ^ n zonele creierului implicate ^ n memorie
 si ^ nv at are are consecint e devastatoare la nivel individual  si social. De aceea, pre-
zervarea funct iilor de baz a ale neuronilor este de o important  a vital a. Designul  si
implementarea de noi medicamente ^ n studiile clinice pentru prevenirea  si stoparea
mort ii neuronale reprezint a o provocare ^ n neuro stiint  a, deoarece mecanismele pro-
ceselor degenerative sunt complexe. Studiul acestor procese degenerative ar putea
conduce la terapii mult mai eciente dec^ at cele actuale. Un model de studiu in vitro
al mecanismelor moleculare ale degener arii const a ^ n inducerea toxicit at ii prin tra-
tarea neuronilor cu neurotransmit  atorul L-glutamat. Prin acest model, viabilitatea
neuronilor este testat a  si se^ ncearc a protejarea neuronilor de la moartea celular a prin
tratamentul cu diferite substant e. P^ an a ^ n prezent, studiile efectuate folosind acest
model au ar atat c a o citokin a numit a factorul alfa de necroz a tumoral a (TNF-)
poate proteja neuronii de la moartea celular a indus a de concentrat ii crescute de L-
glutamat. TNF- este o citokin a ce se g ase ste^ n cantit at i ridicate^ n creierul  si 
uidul
cerebrospinal al pacient ilor cu boala Alzheimer. Principalul obiectiv al acestei teze a
fost investigarea mecanismelor moleculare de neuroprotect ie mediate de TNF-.
Capitolele 2  si 4 ale acestei teze investigheaz a mecanismele neuroprotective ale
TNF- prin care se m are ste rezistent a neuronilor la toxicitatea indus a de glutamat.
In primul r^ and, s-a studiat cinetica neuroprotectiv a a efectului indus de TNF-.
Expunerea neuronilor pentru o perioad a scurt a de timp (2-4 ore) la TNF- nu a
atenuat toxicitatea mediat a de glutamat. In schimb, expunerea la TNF- a neuronilor
pentru cel put in 6-8 ore a indus protejarea neuronilor.
Studii recente au ar atat c a tratamentul neuronilor pentru 24 ore cu TNF- a
provocat fosforilarea protein kinazei B (PKB/Akt). In general, fosforilarea PKB/Akt-
ului^ n neuroni este asociat a cu o viabilitate celular a ridicat a. In capitolul 2 se descrie
cinetica activ arii PKB/Akt-ului ^ n urma expunerii neuronilor la TNF-. Deoarece
PTEN este principalul regulator negativ al PKB/Akt-ului, s-a investigat  si expresia
PTEN-ului ^ n timpul tratamentului cu TNF-. Multiple studii au asociat expresia
ridicat a de PTEN cu moartea celular a. In aceast a tez a, se arat a c a tratamentul
neuronilor cu TNF- pentru 2-4 ore induce expresia PTEN-ului  si produce sc aderea
fosforil arii PKB/Akt-ului. In schimb, tratamentul neuronilor pentru o durat a mai
mare de timp (6-24 ore) suprim a expresia PTEN-ului  si induce cre sterea fosforil arii
PKB/Akt-ului.
Pentru a determina contribut ia receptorilor TNF--ului^ n mecanismele de neuro-
protect ie ale TNF-, s-a studiat expresia PKB/Akt-ului  si PTEN-ului ^ n neuronii
knockout pentru TNF-receptor 1 (TNF-R1)  si TNF-receptor 2 (TNF-R2). S-a obser-
vat c a activarea PKB/Akt-ului este detectabil a dup a 6-8 ore de expunere la TNF-
^ n neuronii TNF-R1-/-, de si ^ n neuronii TNF -R2-/- fosforilarea PKB/Akt-ului scade
^ n funct ie de timpul de expunere a neuronilor la TNF-.
PKB/Akt se g ase ste ^ n sistemul nervos central sub form a de 3 izoforme:163
PKB/Akt1, PKB/Akt2  si PKB
/Akt3. P^ an a^ n prezent nu se cunoa ste care dintre
cele trei izoforme ale PKB/Akt este important a pentru mecanismele neuroprotective
mediate de TNF-. In capitolul 2 al acestei teze, folosind probe specice de siRNA
pentru a inhiba expresia PKB/Akt1, PKB/Akt2 sau PKB
/Akt3, s-a constatat c a
PKB/Akt1  si PKB
/Akt3 sunt esent iale pentru neuroprotect ia indus a de TNF-.
Aceste rezultate sugereaz a c a TNF-, prin activarea PKB/Akt, poate minimiza
consecint ele toxice induse de cantit at i ridicate de glutamat.
Activarea mecanismelor induse de PKB/Akt poate  modulat a de cAMP. In capi-
tolul 3 se investigheaz a efectele produse de 2 molecule a c aror activitate este init iat a
de cAMP. Aceste molecule sunt protein kinaza A (PKA)  si proteinele de schimb
activate direct de cAMP (Epac1  si Epac2). In neuroni, activarea PKA conduce la
diminuarea fosforil arii proteinei PKB/Akt, iar activarea proteinelor Epac induce fos-
forilarea proteinelor PKB/Akt. PKA, PKB/Akt  si Epacs s-au g asit complexate cu
kinaza A de ancorare neuronal a (AKAP150). Adit ional, activarea proteinei Epac2
produce fosforilarea proteinei PKB/Akt complexate cu AKAP150.
In aceast a tez a s-a demonstrat implicarea proteinelor TNF-R2, PKB/Akt  si a
factorului nuclear de transcript ie kappa B (NF-B) ^ n mecanismul de neuroprotect ie
indus de TNF-. In capitolul 4 s-a investigat act iunea canalelor de potasiu acti-
vate de Ca2+ intracelular (canalele SK) ca  si potent ial downstream target al TNF-
deoarece NF-B regleaz a activitatea canalelor SK. Aceste canale de potasiu modu-
leaz a excitabilitatea sinaptic a  si activitatea neuronal a. In capitolul 4 s-a ar atat c a
agoni stii specici pentru canalele SK (NS309  si CyPPA) produc protect ie neuronal a
iar antagoni stii canalelor SK inhib a act iunea de protect ie indus a de TNF-.
Recent s-a descoperit c a lovastatina, un medicament folosit pentru reducerea co-
lesterolului  si pentru prevenirea infarctului miocardic, poate induce expresia recepto-
rului TNF-R2 ^ n celulele endoteliale. Lovastatina poate  un agent neuroprotectiv ^ n
diverse boli degenerative. Administrarea prolactic a de statine poate^ mbun at at i me-
moria pacient ilor de Alzheimer a
at i^ n stadiul incipient sau moderat al bolii. De si s-a
studiat independent act iunea neuroprotectiv a a lovastatinei sau a TNF--ului, nu s-a
investigat p^ an a acum dac a exist a puncte commune^ n mecanismele de neuroprotect ie.
In capitolul 5 s-a demonstrat c a lovastatina poate induce expresia receptorului TNF-
R2 ^ n neuroni  si c a NF-B este responsabil pentru acest efect.
Capitolul 6 consolideaz a rolul proteinei PKB/Akt ^ n mecanismele de neuropro-
tect ie ale lovastatinei. Folosind un model in vivo de studiu, NMDA a fost injectat
^ n nucleul bazal al lui Meynert, localizat ^ n complexul cholinergic din forebrain-ul
bazal. NMDA produce moartea neuronilor din nucleul bazal dar  si deterioarea bre-
lor corticale ascendente ce provin din nucleul bazal. Aceste proiect ii includ  si brele
ascendente colinergice cu traseu spre hipocamp (regiune implicat a^ n procesele de me-
morie  si ^ nv atare)  si cortex. S-a investigat act iunea administr arii lovastatinei la nive-
lul brelor colinergice corticale  si s-a constatat c a tratamentul cu lovastatin a induce
protect ia brelor colinergice prin intermediul act iunii proteinei PKB/Akt. Adit ional,
s-a demonstrat c a tratamentul cu lovastatin a a redus decitul de memorie observat164 Sumarul tezei
^ n animalele tratate cu NMDA.
In concluzie, studiile efectuate^ n aceast a tez a sugereaz a potent ialul de manipulare
terapeutic a al mecanismelor TNF--ului ^ n tratarea bolilor degenerative.Acknowledgements166 Acnkowledgements
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